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During the early 1980s, waterborne hepatitis outbreak was reported and later denominated 
as Hepatitis E [1, 2]. Hepatitis E virus (HEV) was first discovered in a feces sample in 1983 [3] 
and molecularly cloned in 1990 [3]. However, due to the lack of culture system, studies of 
HEV life cycle, pathogenesis, genome variability and other molecular characteristics were 
substantial hampered. HEV is a positive-strand RNA virus, its genome contains a 7.2 kb RNA 
that typically contains three open reading frames (ORFs) [4]. The diameter of HEV virions is 
around 27 - 34 nm [4]. 
HEV belongs to the Orthohepevirus genus within the Hepeviridae family [5]. With the 
development of the sequencing technology, genetically different HEV strains were identified, 
the Hepeviridae family can be classified as genera: genus Orthohepevirus (all mammalian 
and avian HEV isolates) and genus Piscihepevirus (cutthroat trout virus) [6, 7]. Within the 
Orthohepevirus species, at least four genotypes (gts) are known have the ability to infect 
humans and all belong to a single serotype. Gt1 HEV mainly causes large outbreaks in Asia. 
Gt2 can also cause large outbreaks and is mainly restricted in Mexico and some African 
countries [7]. Gt3 HEV infection can cause chronic hepatitis in specific population such as 
immunocompromised patients in industrialized countries [8, 9]. Gt4 HEV infection is mainly 
prevalent in China and Japan [10-12]. Both gt3 and gt4 HEV are zoonotically transmitted and 
animal reservoirs play important roles during transmission and epidemiology [7]. 
Course of HEV infection 
Acute infection 
Gt1 and gt2 HEV are the main HEV genotypes that could cause the waterborne outbreak of 
acute HEV infection in developing countries [13-15]. Therefore, to control the HEV infection, 
basic sanitation is thought to be the first strategy against HEV infection. Both gt1 and gt2 
HEV are strictly restricted to humans. Importantly, gt1 infection is particularly dangerous for 
pregnant women: infected expecting mothers display severe symptoms and an extremely 
high mortality, up to 25% [16-18]. Currently, in Nepal and China, large-scale randomized, 
double-blind studies are performed based on a recombinant-produced vaccine against gt1 
HEV [19-21]. However, only one vaccine named Hecolin has been licensed in China since 2012. 
Gt3 and gt4 HEV have a broad host range including wild animals and domestic 
animals. Pigs and game are thought to be the main reservoirs. Zoonotic foodborne 
transmission is the most common route of sporadic infection [13]. However, other 
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transmission routes can not be ruled out. The detection of HEV RNA in milk from infected 
cows provides us new clue that how the zoonotic transmission occurred [11]. The 
seroprevalence rate of HEV in developed countries is diverse, ranging from 5% to 20% and 
the highest seropositive rate has been reported in southwest France [22]. In the Netherlands, 
the HEV seropositive rate in general population is around 30% and the prevalence increase 
with age [23, 24]. A small group of study among hospital-associated patients indicates that HEV 
also plays an important role in causing acute hepatitis in this specific population in the 
Netherlands as well [25].  
Chronic infection 
Chronic HEV infection is mainly caused by gt3 HEV [4]. In European countries, chronic HEV 
infections are mainly found in immunocompromised patients, for example in transplantation 
recipients, HIV patients and patients under chemotherapy [8, 9, 26-28]. Chronic HEV infection 
confers a high risk for developing into to cirrhosis and in transplantation patients also 
causing graft loss, eventually leading to a requirement for new transplantation [4, 8, 9]. 
Interestingly, most of the chronic infections in organ transplant recipients were reported in 
European countries, whereas only a limited number of cases have been reported from the 
North America. This may probably due to the lack of standard diagnostic test approved for 
clinical use in this region. 
Anti-HEV treatment 
Usually, acute HEV infection is a self-limiting disease and the antiviral treatment is not 
necessary. In some cases, such as in pregnant women and immunocompromised patients, 
antiviral therapies are required. Pegylated (PegIFN-α) or ribavirin monotherapy or a 
combination have been used in this respect [29-32]. Although both antiviral treatments have 
strong antiviral potential, as evident from in vitro study [33-35], ribavirin as monotherapy has 
been more widely used recently. The reason is that most chronic infections HEV occurred in 
organ transplantation patients and thereby the use of IFN-α is associated with side effects 
that sometimes lead to graft rejections. Therefore, ribavirin has become the best choice in 
this respect and its efficacy has been proven [36]. Meanwhile, ribavirin also shows its clinical 
effectiveness when treating severe acute HEV infection [37, 38]. 
Although ribavirin is effective in most acute and chronic patients, there were cases 
had been reported that recurrence was found during or after ribavirin treatment [39]. A 
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sequencing study found a G1634R mutation in the HEV RdRp domain (Fig. 1) may associate 
with the treatment failure [39]. A similar mutation was also observed in a different study [40]. 
Interestingly, both studies showed that this mutation did not alter the sensitivity towards 
ribavirin treatment [39, 40]. Instead, the replication fitness of HEV was improved when 
introducing this G1634R mutation into the wide-type virus. Recently, more mutations were 
identified to be associated with the ribavirin resistance. For instance, Y1320H, G1634R 
mutations and an insertion in the hypervariable region were found to be related to the 
increase replication of HEV, while the K1383N mutation was found related to decrease 
replication and conferred enhanced sensitivity to ribavirin [41]. A recent study found that the 
1634R variant has lower prevalence in patients that achieve sustained virological response 
(SVR) as compared to patients with treatment failure [42]. However, even in the presence of 
this 1634R mutation, a second ribavirin treatment still has therapeutic effects [42]. Therefore, 
whether there is clinical potential to use this mutation as a biomarker to predict the ribavirin 
treatment outcome still needs further exploration [42]. 
The combination of ribavirin related viral resistance and IFN-α related severe side 
effect create an urgency to develop new antiviral therapies. Sofosbuvir, an HCV polymerase 
inhibitor, was shown has the ability to inhibit gt3 HEV replication in vitro [43], but some 
inconsistent results have also been reported [44]. Interestingly, this drug failed in clearing HEV 
viremia in a patient that was co-infection with both HCV and HEV [45]. Thus, more studied are 
required to evaluate the anti-HEV potential of this drug. In our recent study, we have found 
that the activation of protein kinase C alpha (PKCα) and its downstream pathway strongly 
inhibits HEV replication [46]. In addition, the nucleotides synthesis pathway also constitutes a 
potential anti-HEV target. We have proven that the inhibition of the pyrimidine pathway 
exerted strong anti-HEV effect [47]. Interestingly, we observed that the gene expression of 
many ISGs is up-regulated when this pathway is blocked and importantly, this happens in an 
IFN-JAK-STAT axis independent manner. However, whether this up-regulation of ISG 
expression contributes to the antiviral ability of these nucleotide synthesis inhibitors is still 
unclear [47]. Taken together, all these studies provide new ideas to develop novel antiviral 
drugs against HEV infection and encourage investigation in this respect.  
Most chronic HEV infection happens in immunocompromised patients, therefore, it is 
important to assess the effect of different immunosuppressive drugs [48]. In vitro studies 
from our group have shown that mTOR inhibitors (rapamycin, everolimus) and calcineurin 
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inhibitors (cyclosporin A, tacrolimus) enhance HEV replication in cell culture models [49, 50]. In 
contrast, mycophenolic acid (MPA) effectively suppresses HEV replication [50]. Although 
these important findings give some clues that different immunosuppressive drugs may affect 
the propagation of HEV, there are only limited studies available reporting the effect of these 
drugs in patients. A recently study showed that patients received mTOR inhibitor treatment 
have higher HEV RNA levels as compared to those had calcineurin inhibitors treatment [51], 
whereas the treatment of mycophenolic acid had no influence on the effect of ribavirin [51]. 
In toto, a picture emerges in which different type of immunosuppressive interacts with the 
HEV infectious process. Studies focus on the interaction details shall be continued. 
Molecular organization of HEV 
The HEV genomic RNA is 7-methylguanylate (m7G) capped at the 5’ end and has a poly-A tail 
at the 3’ end [4]. It is generally believed that the HEV RNA contains three open reading 
frames (ORFs) [4, 13, 52]. ORF1 encodes a nonstructural protein is essential for RNA replication 
[53]. ORF2 protein is the viral capsid protein [4]. ORF3 is a small protein that may play a poorly 
defined role during the viral secretion step [4]. Recently, a novel ORF4 was defined in gt1 HEV 
[54]. Usually, two different HEV RNAs are produced during the HEV life cycle, a 7.2 kb full-
length RNA and a 2.2 kb subgenomic RNA (Fig. 1).  
ORF1 is the largest ORF in HEV genome which constitutes almost 70% of the genomic 
length [4]. ORF1 translates into a polyprotein [4]. Employing computer-assisted alignments, in 
ORF1, eight putative domains are discerned based on the similarity with other viruses [55]. 
The main functional domains including an RNA-dependent RNA polymerase (RdRp) domain, 
a Y domain (Y), a methyltransferase (MeT), a macro, a papain-like cysteine protease (PCP) 
and an RNA helicase (Hel) domain (Fig. 1) [56]. The function of each domain still needs further 
investigations. 
The putative PCP domain of ORF1 has some homology with the protease of Rubella 
virus [55]. However, the function of the PCP during HEV replication is still controversial. 
Generally, positive-strand RNA virus expresses proteases for processing viral polyproteins or 
host proteins to foster the infectious process. Many studies support the idea that HEV PCP 
also processes the ORF1 polyprotein [57-62]. However, the absence of processing activity by 
ORF1 PCP has also been reported [63-65]. Further studies should continue to address this issue 
since a clear understanding of this question and this will open novel avenues for developing 
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new anti-HEV drugs that directly target this protein. Such studies would also extend our 
knowledge on the HEV life cycle and pathogenesis in general.  
Hel domain exerts NTPase and RNA unwinding activities [66]. Meanwhile, Hel also 
plays important roles during cap formation [67]. Thus, HEV may employ this protein to initiate 
the synthesis of 5’ cap RNA [67]. Therefore, HEV helicase may exert two functions in one 
protein, a strategy common to viruses, which are under evolutionary pressure to encode 
multiple viral proteins in a relatively small genome.  
The Met domain is at the N-terminus of the ORF1 polyprotein. Computer-assisted 
sequence analysis revealed AA (amino acids) residues 56-240 was predicted as the putative 
Met domain [55]. The RdRp domain is located at the end of HEV ORF1 [4]. RdRp is a viral 
protein that is required for all positive-stranded RNA viruses and plays an essential role 
during RNA replication. Purified recombinant HEV RdRp protein has the ability to bind to the 
3' end of viral RNA, which is a potential location for a replication start site [68]. The expression 
of GFP-tagged RdRp protein demonstrates that it locates to the endoplasmic reticulum, 
where it might be colocalized with the negative-stranded RNA synthesis [69]. Importantly, the 
recently reported above-mentioned ribavirin-related HEV mutations mainly emerge in this 
domain [39, 41, 42, 70, 71]. 
The ORF2 encodes capsid is a 72 KD protein constituting of 660 AA (Fig. 1). It can be 
glycosylated at Asn 132, Asn 310 and Asn 562 sites [72-74]. However, it is not clear whether 
these glycosylation sites exert any biological function for HEV infection since it is not 
common for the non-enveloped viruses to have their capsid proteins glycosylated. 
Mutagenesis studies revealed that the elimination of potential glycosylation sites will lead to 
the loss of infectious ability of the virus particles [75]. HEV that derived from cell culture 
medium has a lipid envelope [76] and the non-enveloped and quasi-enveloped HEV have a 
distinct entry mechanism [77]. However, whether there is any relation between the 
glycosylation of ORF2 and the lipid envelope still requires further study. The HEV capsid 
protein contains three linear domains named as S domain (AA 129-319), M domain (AA 320-
455) and P domain (AA 456-606) that constitute a neutralizing epitope [78-81]. With the 3.5-A 
resolution crystal structure of HEV VPL (viral-like particles), it showed that the HEV VPL 
structure is consistent by 60 subunits capsid protein [81]. Meanwhile, a mutation study 
showed that the P domain plays important roles with regard to the binding to the host cells, 
and that, as said, it contains some epitopes for antibody-mediated neutralization [81].  
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The ORF3 partially overlaps with ORF2 and it is the smallest ORF of HEV. The ORF3 
protein encodes a product of 13 KD (VP13) and constitutes of 113 AA (gt3) or 114 AA (gt1, 2 
and 4) [4]. It contains a phosphorylation site (Ser71) that can be phosphorylated by MAPK 
(mitogen-activated protein kinase) [82]. Based on a hybridization study, ORF3 was suggested 
to may play a regulatory in the signal transduction pathway [83]. An early study showed that 
the ORF3 protein associates with cytoskeletal fraction via its hydrophobic N-terminal domain 
[82]. In a subsequent study, GFP-tagged ORF3 was shown to interact with microtubules and to 
have the ability to modulate its dynamics [84]. In a recent in vivo study, the ORF3 protein was 
found to be mainly located near to the apical membrane and within the bile canaliculi, which 
suggests that this protein plays some roles during HEV egress and viral secretion into the bile 
[85]. In vitro studies also demonstrated that ORF3 is required for the egress of HEV [86, 87]. 
Apart from these cellular functions, the ORF3 protein was also reported to interact with HEV 
viral proteins such as Hel, PCP and Met, suggesting it plays important roles during HEV 
replication as well [88]. However, the exact function and structure of HEV ORF3 protein still 
need further investigations.  
 
Figure 1. Molecular organization of HEV RNA. 
The HEV genome is a 7.2 kb, single-stranded positive RNA. It has a 7-methylguanylate (m7G) at the 5’ 
end and a poly-A tail at the 3’ end. Usually, it has three open reading frames (ORFs). It is generally 
believed that two HEV RNA are produced during replication, a 7.2 kb full-length RNA and a 2.2 kb 
subgenomic RNA. ORF1 is a polyprotein translated from the 7.2 kb full-length RNA. It has several 
domains including methyltransferase (Met), Y domain (Y), papain-like cysteine protease (PCP), 
hypervariable region (HVR), Macro, RNA helicase (Hel), RNA-dependent RNA polymerase (RdRp). 
ORF2 is the capsid protein and ORF3 partially overlaps with ORF2. Both of them are translated from 
the 2.2 kb subgenomic RNA. An insertion of human sequences (S17) into the HVR domain increases 
cell culture adaptation.  
Recently, a novel viral protein ORF4 was identified in gt1 HEV [54]. Interestingly, unlike 
other HEV viral proteins, it is a protein that induced by endoplasmic reticulum (ER) stress via 
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the internal initiation mediated translation to promote gt1 HEV infection [54]. This unique 
protein interacts with multiple viral and cellular proteins [54]. Together with host eEF1α1 
(eukaryotic elongation factor 1 isoform-1), ORF4 increases HEV RdRp activity to enhance 
viral replication and an ORF4 stably expressed human hepatoma cells have higher HEV 
replication level [54]. This novel ORF4 protein was only found in gt1 HEV [54]. Whether this 
protein is related to the higher pathogenicity of gt1 HEV is still unclear and needs further 
investigation.  
HEV cell culture models 
Since the discovery of HEV virus, great efforts have been taken to propagate this virus in cell 
culture systems. However, such cell culture mediated production is still relatively inefficient 
and seems ineffective. With regard to producing infectious virus, as a surrogate, a virus that 
is also a member of Hepeviridae family, Cutthroat trout virus (CTV) is developed as an 
alternative virus model to study the replication cycle of HEV [89]. Gt3 and gt4 HEV have been 
successfully cultured under laboratory conditions. However, until now, there is only one 
study that reported a successful culture of patient serum-derived gt1 HEV without 
transfection RNA directly into host cells [90]. An attempt to infect swine kidney cells with gt1 
HEV revealed that the HEV infectivity was inhibited at multiple steps [91].  
For single-stranded positive RNA viruses, the direct transfection of RNA into host cells 
is a commonly used strategy, in which the thus-delivered RNA is able to start the translation 
of viral protein just after transfection. In vitro transfection of plasmid-derived capped HEV 
RNA in two different cell lines, PLC/PRF/5 and Huh7 cells were shown to support HEV 
replication and the production of infectious virions [92]. A better replication result of gt1 HEV 
(Sar55) was observed in a subclone of the Huh7 cell, S10-3 cell [93]. Nevertheless, all these 
studies required the delivery of HEV RNA into the host cell that may not totally recapitulate 
the real infection progress and thus, the host response.  
Gt3 HEV from an acute hepatitis patient can be cultured in PLC/PRF/5 cells [94] and 
A549 cells [95]. Interestingly, a gt3 HEV strain named Kernow-C1 was isolated from a chronic 
patient and had the ability to infect different human and animal cell lines such as pig and 
deer cells [93]. They also observed an insertion of human sequences into the HEV viral 
genome (ORF1, HRV) (Fig. 1) [93]. Since this insertion was noticed after six passages, this 
strain was denominated as Kernow-C1 p6. The following study demonstrated that this 171-
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nucleotide insertion is important for the enhanced replication ability of this p6 strain [96]. The 
gt3 HEV Kernow-C1 p6 is a widely used cell culture system by different research groups [39, 41, 
96-98]. In the present thesis, I also used this gt3 Kernow-C1 p6 strain. The observation that gt3 
HEV has the ability to the complete life cycle in pluripotent stem cell (PSC)-derived 
hepatocytes may provide new ideas for developing novel HEV cell culture system [99]. Gt4 
HEV from the feces of experimentally infected monkeys can be effectively cultured in the 
PLC/PRF/5 and the replication of this strain was inhibited by IFN-α [100].  
Animal models 
Rabbits are used as a model to recapitulate HEV infection and to evaluate vaccine efficacy 
[101]. For certain HEV strains, acute infection can even develop to chronic infection in rabbit 
models [102, 103]. Another widely used experimental model to investigate HEV infection is pigs 
[104, 105]. Other animals like rat [106] and Mongolian gerbils [107] are also reported to support 
infection by certain strains of HEV.  
Recently, three different groups reported that the human liver chimeric mice could 
be used for modeling chronic HEV infection [85, 108, 109]. Stool-derived HEV gt1 and gt3 have 
the ability to establish a long-term HEV infection in the UPA/SCID/beige chimeric mice that 
have humanized liver [85]. Interestingly, a gt1 HEV-infected mouse can infect naïve 
humanized mice when they stay in the same cage, indicating that gt1 HEV infection can be 
transmitted fecal-orally or through direct physical contact route [85]. However, feeding of 
these mice with HEV contaminated food was not able to create a robust infection. Therefore, 
the direct physical contact route or the blood route via micro-injuries cannot be ruled out. 
Of note, compared to gt1 infection, gt3 infection showed a more slow progression and 
displayed lower viral titers with respect to the latter strain [85]. This appears consistent with 
the clinical observation that gt1 HEV mainly leads to acute infection, whereas gt3 mainly 
leads to chronic infection. Importantly, neither gt1 nor gt3 infection induces any liver 
damage [85]. The commonly used anti-HEV drug ribavirin has convincing antiviral ability in 
these models against gt1 HEV infection. Nevertheless, the antiviral potential of ribavirin and 
another commonly used anti-HEV drug, IFN-α should also be evaluated regarding gt3 HEV 
infection [85].  
In another study, in such animals it was demonstrated that cell cultured-derived HEV 
did not result in a detectable HEV infection, but when the supernatant was treated with 
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sodium deoxycholic acid and trypsin, the HEV RNA can be detected in some mice, albeit not 
in all mice. Chimpanzee-derived HEV can infect humanized mice. Stool suspension from gt1 
(Sar55) HEV infected chimpanzees was intrasplenically injected and led to robust infection. 
Viral titer was 10- to 100- fold higher in stool than in plasma. Patient-derived gt3 HEV could 
also infect this humanized mice model, consistent with the above-mentioned study [85]. It 
was also observed that a relatively low viral titer was reached in gt3 infection mice as 
compared to gt1 HEV-infected mice. Gt1 HEV-infected mice display a small up-regulation of 
host ISG expression, while a large subset of ISG is intact during infection [108]. 
In a third study, immunocompromised patient-derived gt3 HEV was used to infect 
chimeric mice that have a humanized with human liver [109]. Interestingly, they also found 
human feces- or liver-derived HEV has the ability to establish a chronic infection in this mice 
model. HEV RNA can be detected in all infected mouse livers [109]. It was also noticed that 
HEV from cell culture medium or patient plasma failed to infect these chimeric mice [109]. In 
summary, all three studies used humanized chimeric mouse to model chronic HEV infection, 
feces-derived HEV superior with respect to infection in these models. All these chimeric 
humanized mouse models provide valuable tools to study the acute and chronic infection of 
HEV. However, further studies that use these models to evaluate the new anti-HEV therapy 
should be conducted.  
Host response and IFN pathway 
Usually, viral infection induces an innate immune response by producing interferons (IFNs), 
especially the production of type I IFNs [110]. Human type I IFNs is a group of antiviral 
cytokines than can be divided into many subtypes including IFN-α and IFN-β [111]. This type of 
IFNs plays essential roles in defending viral infection and human with defected IFN 
production or receptors are more sensitive to viral infections [112-114]. After viral infection, the 
production of type I IFNs is mainly triggered via the detection of pathogens by pattern 
recognition receptors (PRRs) [110]. Viral nucleic acids are important PAMPs that can be sensed 
by different kinds of PRRs. For example, Toll-like receptor 3 (TLR3) have the ability to 
recognize ds-RNA (double-stranded RNA ) and retinoic acid-inducible gene 1 (RIG-I) detect 
viral RNA with unique signatures in the cytoplasm [115]. Meanwhile, melanoma 
differentiation associated protein 5 (MDA5) is also a cellular RNA sensor that has the ability 
to sense the present of viral RNA in the cytoplasm [116]. For DNA viruses, its nucleic acids 
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could be detected by DNA sensor, cyclic GMP-AMP synthase (cGAS) [117]. Upon the detection 
of virus by these PRRs, the downstream pathways will be activated which eventually leading 
to the production of anti-viral cytokines, especially type I IFNs [110]. More specifically, RIG-I 
and MDA5 converge on the mitochondrial antiviral signaling protein (MAVS) which located in 
mitochondrial membrane while cGAS could activate the stimulator of IFN genes (STING) 
which mainly distributed in the endoplasmic reticulum (ER) [110]. After the stimulation of 
MAVS and STING, interferon regulatory factor 3 and 7 (IRF3 and IRF7) will be phosphorylated 
[110] and transported into the nucleus. Meanwhile, the NF-κB pathway will be also activated 
by IRF3 and 7 [110]. Next, all these transcription factors including IRF3, 7 and NF-κB bind to 
the promotor region of antiviral cytokines like type I IFNs (Fig. 2) [110]. The binding leads to 
the gene expression of IFNs genes and eventually protein productions. 
Once the IFNs have been produced and secreted, the IFN proteins bind to the cell 
surface receptors complex such as IFN-α receptor 1 (IFNAR1) and 2 (IFNAR2) [111]. The 
binding of IFN proteins and receptor chains leads to the activation of STAT (signal 
transducers and activators of transcription) 1 and 2 via the phosphorylation of JAK1 and 
TYK2 (Janus kinase 1 and Tyrosine kinase 2) [110]. The phosphorylated STAT1, STAT2 together 
with IRF9 will form a complex named IFN-stimulated gene factor 3 (ISGF3). This complex will 
be transported into the nucleus and bind to a unique element named IFN-stimulated 
response elements (ISRE) and finally leading to the transcriptional regulation of more than 
300 IFN-stimulated genes (ISGs) [110]. The products of these genes are thought to be the 
ultimate effectors of IFN [110, 118, 119]. It has been shown that many of the ISGs exert their 
antiviral function at different steps of viral life cycles [110, 118, 119]. For instance, IFITM3 and 
MX2 inhibit viral entry [120-123], IFIT1 inhibits viral protein translation [124], Viperin (also known 
as RSAD2) inhibits virus at the egress stage [125]. Meanwhile, a large number of ISGs play 
regulatory roles in pathogen recognition and cellular signaling pathways. Many ISGs are 
induced by IFNs but also involved in signal transduction such as IRF9 and STAT1, which have 
the ability to rapidly amplify the IFN-initiated cell cascade [110]. Interestingly, many of the 
PRRs are also ISGs that constitutively expressed at host cell. After viral infection, these PRRs 
such as MDA5, RIG-I and cGAS were induced by IFNs, which eventually scaling up the IFN 
productions [110, 118, 119, 126]. Finally, some ISGs such as SOCS are negative regulators that 
prevent the excessive expression of IFNs and ISGs, which have pathological outcomes for the 
host cells [110]. They also help the activated cells back to homeostasis status [110]. Taken 
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together, the host response to viral infection by producing antiviral IFNs, the IFN establish an 
antiviral status by the transcriptional regulation of a large number of ISGs. These ISGs form a 
complicated web that eventually eradicates virus invasion.  
Host response to HEV infection 
Until now, there are limited studies about the cellular immune response after HEV infection. 
An RNA-Seq based transcriptome analysis of Huh7 cells infected by gt1 HEV demonstrated 
that totally 306 genes were affected. Most of the genes were related to immune response 
and signal transaction [127]. SIRP-α (signal regulator protein α) was strongly stimulated while 
pIRF3 was down regulated by gt4 HEV infection, which eventually leading to the negative 
regulation of IFN-β and the host innate immune system [128]. Gt4 HEV infection in A549 cells 
affects the protein expression of totally 31 proteins, as revealed by a proteomics analysis [100]. 
Among these 31 proteins, 10 proteins were up-regulated while the rest were down-
regulated [100]. In a PLC/PRF/5 cells based monkey feces-derived gt4 HEV cell culture model, 
HEV infection leads to the up-regulation of many ISGs including IFI27, IFI6, MX1, and CMPK2 
[129]. 
As combat strategies, HEV developed different tools to manipulate the host immune 
response. HEV was found have the ability to suppress poly (I:C)-initiated immune response 
and the product of HEV ORF1 was the antagonist [130]. By screening each domain of the ORF1, 
the author revealed that the PCP domain inhibits IFN-β expression by deubiquitinating RIG-I 
and TBK-1, which are key components involved to type I IFN expression. Meanwhile, they 
identified the X domain (macro domain) also play some roles in the suppression of IFN-β 
expression [130]. In another study done by the same author, ORF3 was found to stimulate 
poly (I·C)-initiated immune response through the interaction of one important PRR for type I 
IFN expression, RIG-I [131]. HEV ORF3 protein stimulates RIG-I controlled IFN-β expression by 
activating RIG-I expression and function [131]. Interestingly, these two studies showed that 
one virus has different effects on the same host cellular response. What is the exact role of 
this difference in establishing an infection is still unclear and needs further investigation. In 
another study, they showed that the IFN-α induced STAT1 phosphorylation and ISG 
expression were inhibited by HEV infection [132]. They further identified ORF3 alone have the 
ability to complete this inhibition effect [132]. Similarly, the IFN-initiated ISG expression was 
suppressed in HEV infected cell. In line with this, in Chapter 4, we also observed the similar 
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results. We demonstrated that the IFN-initiated ISG expression was inhibited by HEV 
infection [35]. 
Beside IFN pathway, other cellular pathways were also influenced by the HEV 
infection. For instance, the transfection of HEV ORF2, but not ORF3 in human hepatoma cells 
inhibits NF-κB signaling activity by the disruption of IκBα ubiquitination [133]. Meanwhile, an 
ORF3 protein from a gt1 strain was also reported has the ability to inhibit TNF-α induced NF-
κB pathway activation [134]. Furthermore, the ORF3 protein was also reported to regulate the 
transportation of STAT3, which may affect regulation of the inflammatory response [135]. 
Altogether, the difference of HEV viral proteins in modulating innate immune response 
suggests further investigations are required.  
Although the cell culture system could reflect the host response after HEV infection, 
it cannot totally capture the in vivo infection course and immune response. Therefore, many 
studies were performed in animal models and in patients. In a chimpanzees model that 
infection with gt1 HEV, 58 ISGs were up-regulated in acute HEV infection. However, the 
induction level was much lower compared to HCV infection, which had a stronger induction 
of ISG expression [136]. In a study performed in whole blood from patients with chronic HEV 
infection, they found a total number of 30 genes were stimulated compare to health 
patients [137]. Interestingly, 25 out of these 30 genes were ISGs and the expression of some 
ISGs was correlated with HEV persistence [137]. Since HEV infection is more severe in 
pregnant patients, a study was focused on the relation between cytokines and HEV infection 
outcomes [14]. They showed that the expression level of many cytokines was much higher in 
HEV infected women [14]. This suggested the high mortality of HEV infection in pregnant 
women might due to the high level of cytokine productions [14, 16-18]. Interestingly, the 
cytokines such as TLR3 and IFN-γ were reported to have a beneficial role during HEV 
infection [138]. Patients with higher expression levels of TLR3 and IFN-γ are pro to eradicate 
infection and get full recover [138]. In Chapter 7, we revealed that the antiviral ability of IFN-α 
against HEV and HCV can be enhanced by one important cytokine, TNF-α. We showed that 
the downstream of TNF-α, NF-κB can directly bind to the ISRE motif in the ISG promoter to 
drive the transcription of antiviral ISGs [139]. However, the in vivo roles of TNF-α are still 
unclear. It was reported that the polymorphisms of TNF-α are related to HEV infection 
outcomes, for example, the genotype -308AA was more common found in gt1 HEV infected 
patients [140]. Taken together, cytokines, especially IFNs play important roles during HEV 
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infection. Meanwhile, HEV also develops different strategies to combat the host immune 
response. However, there are limited studies currently about the virus-host interactions, 
especially the interaction between HEV infection and innate immunity. Further 
investigations should focus on this field.  
Scope of this thesis  
As discussed above, IFN-α and ribavirin were used to treat chronic HEV patients [29-32]. 
However, failures of ribavirin treatment were observed [39, 42, 71] and thereby new antiviral 
treatments are urgently required. The IFN pathway plays an important role in defending viral 
infection through the expression of ISGs [110, 118], but little is known about the relation 
between HEV infection and IFN/ISG pathway. In this thesis, we aimed to investigate anti-HEV 
activities of IFN pathway and its mechanism-of-action. We first studied the anti-HEV 
potential of IFNs against HEV in cell culture models. Next, we mainly focused on the anti-HEV 
ability of many important ISGs and the mechanism-of-action of some key anti-HEV ISGs. 
Meanwhile, some novel mechanisms that regulate ISG transcription and their role in 
controlling HEV were also investigated. 
Outline of this thesis 
IFN-initiated cell signaling is the most important antiviral pathways against viral infection [110]. 
ISGs are the ultimate antiviral effectors and different cell pathways precisely controlled their 
expressions. In Chapter 2, we comprehensively reviewed the regulation of ISG transcription, 
including the canonical and non-canonical mechanisms. As mentioned above, many ISGs, 
especially some IRFs and PRRs were thought to exert their function through the induction of 
IFNs. In Chapter 3, we discussed the IFN-independent antiviral mechanisms of these ISGs in 
defending viral infections.  
In Chapter 4, we characterize the antiviral potential of a panel of cytokines against 
HEV infection and identified IFN-α exert strong antiviral ability. We further comprehensively 
investigated the antiviral potential different type of IFNs against HEV replication in 
comparison with HCV. Given the fact that ISGs are ultimate effectors of IFN, in Chapter 5, by 
using an overexpression approach, we screened the anti-HEV potential of many important 
human ISGs. We identified RIG-I, MDA5 and IRF1 as the potent anti-HEV ISGs. In Chapter 5, 
we mainly focus on the mechanism-of-action of RIG-I. This extends our knowledge about the 
anti-HEV mechanism of IFNs and paves the avenues for developing new anti-HEV strategies. 
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In Chapter 6, we further investigated the antiviral mechanism of IRF1, which is an important 
ISG that have broad antiviral activities. The anti-HEV mechanism of IRF1 was investigated in 
multiple cell lines and the interaction with ribavirin was evaluated. In Chapter 7, we focus on 
another important antiviral cytokine, TNF-α. The antiviral ability of TNF-α and its novel 
mechanism that involved in the regulation of ISG transcription were investigated. In Chapter 
8, we explore the mechanisms that allow antiviral ISGs constitutively expressed without IFN 
treatment. The antiviral potential of these basally expressed ISGs against HEV and HCV 
replication was evaluated. Since the virus totally relies on the host machinery to complete 
viral life cycles but little is known upon HEV infection. In Chapter 9, we focus on the role of 
host translation complex played during HEV replication. In Chapter 10, we studied whether 
HEV replication can be influenced by the host protein degradation system. The novel 
findings of this thesis were summarized and discussed in Chapter 11. This may provide a 
better understanding of the virus-host interaction during HEV infection and may open the 
gate to develop new antiviral therapies.  
 
Figure 2. The interferon (IFN) pathway and HEV infection.  
The binding of IFN and cell surface receptors leads to the phosphorylation of STAT 1 and 2. 
Phosphorylated STAT1, STAT2 together with IRF9 form the ISGF3 (IFN-stimulated gene factor 3) 
complex. This complex binds to ISRE (IFN-stimulated response elements) and then activates the 
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expression of ISGs (IFN-stimulated genes). HEV ORF1 was reported to inhibit poly (I:C)-initiated IFN 
expression by deubiquitinating RIG-I and TBK-1 (TANK Binding Kinase 1). Meanwhile, HEV ORF3 was 
reported to enhance innate immune response by direct interaction with RIG-I. At the same time, 
ORF3 also binds to STAT1 to prevent its phosphorylation and thereby inhibit IFN-initiated signaling 
cascades. In Chapter 4, we showed IFN-α exert strong anti-HEV ability. In Chapter 5, we studied the 
anti-HEV activity of each individual ISG. RIG-I, MDA5 and IRF1 were identified as the potent anti-HEV 
ISGs. We further showed RIG-I inhibits HEV replication independent of its IFN production ability, but 
partially through the phosphorylation of STAT1. In Chapter 6, we showed IRF1 inhibits HEV via the 
activation of the JAK-STAT pathway. In Chapter 7, we found TNF-α inhibits HEV replication through 
the activation of ISG expression. We further revealed that NF-κB, the downstream of TNF-α, have the 
ability to directly bind to the promoter region of many ISGs. In Chapter 8, we reported a novel 
mechanism that the unphosphorylated ISGF3 (U-ISGF3) complex drives the constitutive expression of 
ISGs in homeostatic condition. This novel U-ISGF3 complex consists by unphosphorylated STAT1 and 
STAT2 together with IRF9.   
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Abstract 
Interferon-stimulated genes (ISGs) are a group of gene products that coordinately combat 
pathogen invasions, in particular viral infections. Transcription of ISGs rapidly occurs upon 
pathogen invasion, and this is classically provoked via activation of the Janus kinase/signal 
transducer and activator of transcription (JAK-STAT) pathway, mainly by interferons (IFNs). 
However, plethoras of recent studies have reported a variety of non-canonical mechanisms 
regulating ISG transcription. These new studies are extremely important for understanding 
the quantitative and temporal differences in ISG transcription under specific circumstances. 
Because these canonical and non-canonical regulatory mechanisms are essential for defining 
the nature of host defense and associated detrimental pro-inflammatory effects, we 
comprehensively review the state of this rapidly evolving field and the clinical implications of 
recently acquired knowledge in this respect. 
Keywords: IFN; ISG; transcription 
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Outstanding Questions 
• Although signaling through the same receptor, there are many type I IFNs in the 
genome. How the cells dynamically control the production of the particular members 
of these type I IFNs? 
• Upon IFNλ binding, which types of modification (e.g. phosphorylation, acetylation) 
happened to IFNλRs to kick off ISG transcription? 
• Generally, HAT activity transforms chromatin into a more relaxed structure, while 
HDAC activity organizes chromatin into higher order nucleosomes. Counterintuitively, 
HDAC activity has been reported to be required for ISG transcription. How this 
mechanistically works? 
• How exactly the nucleotide synthesis pathways mediate ISG transcription? 
• Will ISG-based antiviral strategy circumvent the issue of side effects caused by IFN 
treatment, but retain the therapeutic potency in patients?  
Trends Box 
• Transcriptional regulation of interferon-stimulated genes (ISGs) defines the state of 
host anti-pathogen defense. 
• In light of the recently identified regulatory elements and mechanisms of the IFN-
JAK-STAT pathway, new insights have been gained into this classical cascade in 
regulating ISG transcription. 
• A variety of non-canonical mechanisms have been recently revealed that 
coordinately regulate ISG transcription. 
• With regards to the adverse effects of IFNs in clinic, ISG-based antiviral strategy could 
be the next promising frontier in drug discovery. 
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Host antiviral defense 
IFN-mediated innate immune response forms a forward line of cell-autonomous defense 
against pathogens. Virus invasion (e.g. the presence of single-stranded RNA in endosomes or 
cytosolic double-stranded RNA) triggers the host cells to recognize the infection through 
pattern recognition receptors, that in turn mediates production of IFNs [1]. The thus-released 
IFN molecules bind to cell surface receptors and initiate signal transduction prominently 
involving the Janus kinase signal transducer and activator of transcription (JAK-STAT) 
pathway. This activates the transcription of hundreds of so-called IFN-stimulated genes (ISGs) 
that are the effectors of cell-autonomous antiviral defense. The representative well-studied 
ISG members in this respect with specific or broad antiviral activities include RIG-I, MDA5, 
MX2, IRF1, IRF3, IRF7, IRF9, IFITM3, ISG15 and OASL [2]. ISGs act at different stages of the 
viral life cycle, from entry, replication, assembly to release. This leads to a remarkable 
antiviral state that provides adequate cellular immunity against positive-, negative-, and 
double-stranded RNA viruses, DNA viruses, and even intracellular bacteria and parasites. 
Although the JAK-STAT pathway plays key roles in regulating ISG transcription, a far 
more complex cell signaling network with both canonical and non-canonical mechanisms is 
involved [3]. The signaling strength, kinetics and specificity of regulatory pathways on ISG 
transcription are modulated at various levels by distinct mechanisms in conjunction. 
Understanding the different mechanisms of ISG transcription and how their mode-of-action 
relates to clinically used antiviral medications will reveal new insights of virus-host 
interactions and provide novel avenues for antiviral drug development. Therefore, we aim to 
comprehensively review the classical and non-classical mechanisms in regulating ISG 
transcription and to emphasize their clinical implications.  
Classical mechanisms of regulating ISG transcription: the IFN-JAK-
STAT pathway 
Upon IFN binding to its cognate cell surface receptors, a signal is transmitted through the 
membrane into the cell via the JAK-STAT pathway, leading to rapid transcriptional activation 
of ISGs [4]. Decades of dedicated efforts have elucidated this classical regulatory network, as 
we have outlined here (Figure 1). 
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Figure 1. The classical IFN signaling pathways in regulating ISG transcription.  
The three different classes of IFNs signal through their corresponding receptor complexes, leading to 
the phosphorylation of preassociated Janus kinases. For type I and III IFNs, the phosphorylated Janus 
kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) in turn phosphorylate the receptors at specific 
intracellular tyrosine residues. This leads to the recruitment and phosphorylation of signal 
transducers and activators of transcription 1 and 2 (STAT1 and STAT2) at specific tyrosine residues. 
Then, STAT1 and 2 recruits IRF9 to form the IFN-stimulated gene factor 3 (ISGF3). For type II IFNs, the 
phosphorylated JAK1 and JAK2 tyrosine kinases phosphorylate the receptor chains, leading to 
tyrosine phosphorylation and homodimerization of STAT1. Both ISGF3 and STAT1 homodimer 
translocate to the nucleus to get further phosphorylation at specific serine residues of STAT1, 
achieving fully activation. Consequently, IFN-stimulated genes (ISGs) are transcriptionally activated 
upon the binding of ISGF3 and STAT1 homodimer to IFN-stimulated response elements (ISRE) and 
gamma-activated sequence (GAS) promoter elements, respectively. Conversely, the specific 
phosphatases in the nucleus dephosphorylate STAT1 and STAT2 to avoid excessive and detrimental 
responses. 
IFNs and their receptors-dependent regulation  
Genes encoding IFNs and their receptors have been duplicated extensively throughout 
vertebrate evolution, indicating substantial evolutionary pressure on this system in 
combating pathogens [5]. Up to now, more than twenty distinct IFN genes/proteins have 
been identified. Based on the type of receptor through which they signal, the multitude of 
different IFNs in mammalian genome are classified into three major types: Type I, II and III. 
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In humans, type I IFNs include IFN-α (which can be further subdivided into 13 different 
subtypes), IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-ζ and IFN-ω1-3. All type I IFNs bind to a common 
cell-surface receptor, the type I IFN heterodimeric receptor complexes comprising two 
subunits: IFN-α receptor 1 (IFNAR1) and IFN-α receptor 2 (IFNAR2). Unlike type I IFNs, there 
is only one type II IFN, IFN-γ. It has no marked structural homology with type I IFNs. IFN-γ 
binds to a different cell surface receptor comprised of two subunits: IFNGR1 and IFNGR2. 
Type III IFN family is composed of four genes: IFNλ1 (IL29), IFNλ2 (IL28A), IFNλ3 (IL28B) and 
IFNλ4 (frameshift variant of IL28B). They signal through the IFNλ receptor (IFNλR) which is 
composed of two subunits: IFNλR1 (IL28Rα) and IL10Rβ.  
Type II IFN signaling leads to STAT1 phosphorylation, followed by homodimerization, 
nuclear translocation, and DNA binding at gamma-activated sequence (GAS) elements 
located within promoter regions of IFN-γ-induced genes. While both type I and III IFN 
signaling activate similar intracellular JAK-STAT pathway forming the transcription complex, 
ISGF3, to transcribe ISGs, although they utilize distinct receptor complexes for signaling [6]. 
However, IFNAR is ubiquitously expressed in all nucleated cells; whereas IFNλR1 is only 
expressed on specific tissues/cells of epithelial origin [7], suggesting a selectivity of type III 
IFNs compared with type I IFNs.  
For optimal activation, signaling through the IFN receptor complex depends on 
tyrosine phosphorylation, serine phosphorylation and acetylation on IFN receptors (Table 1) 
[8-10]. Nevertheless, negative regulation is also essential for balancing its beneficial antiviral 
versus detrimental pro-inflammatory effects. Primarily, this is achieved by (i) 
phosphorylation induced IFN receptor ubiquitination and degradation [11]; (ii) blocking the 
interaction between IFNAR and downstream signaling elements, such as the function of 
USP18, ISG15 and SOCS1 [12-16]; (iii) receptor-mediated ligand internalization/degradation [17]; 
and (iv) modulating cell surface IFN receptor level [18, 19].  
JAK kinases (JAKs)-dependent regulation  
The JAKs comprises 4 members, three of them (JAK1, JAK2 and TYK2) function in IFN 
signaling and are ubiquitously expressed [20]. They are pre-associated with the corresponding 
IFN receptor. Upon IFN binding to receptor, they become activated through close proximity 
trans-phosphorylation (JAK1: Tyr1022,1023, JAK2: Tyr1007,1008 and TYK2: Tyr1054,1055). 
Subsequently, activated JAKs phosphorylate the cytoplasmic regions of the receptor, 
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generating docking sites for SH2-domain containing proteins, in particular STAT1 and STAT2 
[21]. Activation of JAK enzymatic activity also triggers negative feedback on antiviral immunity. 
Phosphatases, including T cell protein tyrosine phosphatase (TCPTP), protein tyrosine 
phosphatases (PTP) 1B and CD45, are the most important negative regulators [22-25]. The 
SOCS-1 protein also negatively regulates this process through phosphorylation mediated 
proteasomal degradation of JAK [26]. The critical function of JAKs in cell signaling has made 
them ideal targets for controlling a range of autoimmune diseases. Several JAK inhibitors 
have been approved by the FDA or are in clinical trials for the treatment of rheumatoid 
arthritis, psoriasis, inflammatory bowel disease and ankylosing spondylitis [27].  
Table 1. Classical modification of the IFN-JAK-STAT pathway 
 Modification site Modification typea Signal transduction References 
IFNAR1 Tyr466 Phosphorylation Activation [28] 
IFNAR1 Tyr512 and Tyr337 Phosphorylation Activation [29] 
IFNAR1 Ser535, Ser539 Phosphorylation Inactivation [11] 
IFNAR1 Lys501, Lys525 and 
Lys526 
Ubiquitination Inactivation [11] 
IFNAR2 Ser364, Ser384 Phosphorylation Activation [9] 
IFNAR2 Lys399 Acetylation Activation [9] 
IFNGR1 Pro267 ND Activation [30] 
IFNGR1 Tyr440 Phosphorylation Activation [31] 
IFNGR1 270LI271 ND Inactivation [17] 
IFNGR1 Tyr441 Phosphorylation Inactivation [16, 31] 
IFNGR2 263PPSIP267 and 
270IEEYL274 
ND Activation [10] 
JAK1 Tyr1022,1023 Phosphorylation Activation [21] 
JAK2 Tyr1007,1008 Phosphorylation Activation [21] 
TYK2 Tyr1054,1055 Phosphorylation Activation [21] 
STAT1 Tyr701 Phosphorylation Activation [32] 
STAT1 Ser727 Phosphorylation Activation [32] 
STAT1 Ser708 Phosphorylation Activation [33] 
STAT1 Lys703 SUMO-1 Binding Inactivation [34] 
STAT2 Tys690 Phosphorylation Activation [35] 
STAT2 Ser287 Phosphorylation Inactivation [35] 
aND, not determined. 
STAT-dependent regulation 
There are seven STAT members in mammals, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b 
and STAT6. STAT1 and STAT2 are the most important STATs with respect to IFN signaling [2]. 
In response to IFNs, STAT1 is phosphorylated on Tyr701, Ser708 and Ser727. These sites are all 
Chapter 2 
33 | P a g e  
 
positively related to signaling transduction [33, 36]. STAT2 acquires transcriptional activation 
upon tyrosine phosphorylation (Tyr690). Conversely, serine phosphorylation (Ser287) in STAT2 
negatively regulates IFN response [21, 35]. Although JAKs play key role in STAT1 
phosphorylation and activation, nevertheless, other cellular factors are also required. 
Tyrosine kinase non-receptor 1 (TNK1) and retinoic acid-inducible gene I (RIG-I) potentiate 
dual phosphorylation of STAT1 at Tyr701 and Ser727 positions [37-39]; Nuclear cyclin-dependent 
kinase 8 (CDK8) phosphorylates Ser727 of STAT1 [40, 41]. Protein kinase C family members, PKC-
δ or PKC-ε mediates phosphorylation of STAT1 on Ser727 (no effect on STAT1 tyrosine 
phosphorylation) via its upstream phosphatidylinositol 3-kinase (PI3K)-AKT pathway [42-45]. 
Interestingly, stress signals can also induce phosphorylation of STAT1 (Ser727) via the p38-
MAPK pathway [46]. As p38-MAP kinase inhibitors are well tolerated and safe for humans, it is 
thus tempting to speculate that such inhibitors may be used to mitigate pro-inflammatory 
effects following IFN-γ-therapy [47].  
Evidently, phosphatase-dependent STAT1 dephosphorylation constitutes an 
important negative-regulatory event that is central in titrating the IFN response. The 
functional phosphatases include SHP-2 [48, 49], the nuclear isoform of TCPTP, TC45 [50] and 
SHPTP1 [51]. Phosphatase dysregulation has been reported in cancers and autoimmune 
disorders, thus representing potential therapeutic targets [52]. A small ubiquitin-related 
modifier 1 (SUMO-1) was also reported to conjugate at Lys703 of STAT1 to inhibit signaling 
transduction [34]. Thus, a plethora of molecular mechanisms can balance the IFN response 
through acting on STAT1. 
IRF9 is a main DNA binding component of the ISGF3 complex. IRF9 alone binds to 
DNA and recognizes the specific promotor elements denoted as interferon-stimulated 
response elements (ISRE), but has no transcriptional activity. Upon its DNA binding, IRF9 
provides specific protein-DNA interaction sites for STAT1 and STAT2. Activated STAT1 and 
STAT2 bind to the ISRE region together with IRF9 to exert strong pro-transcriptional activity 
[53 ]. Theoretically, IRF9 (as part of the ISGF3 complex) only involves in type I and III IFN 
signaling to regulate ISG transcription. However, IFNγ induced ISG activation and antiviral 
state were severely impaired in the absence of IRF9, indicating that IRF9 may also be 
involved in type II IFN signaling [54, 55]. More interestingly, IFNγ pretreatment induces high 
levels of IRF9, which serves as an important subunit of latent precursor to ISGF3. In this way, 
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IFN-α and IFN-γ synergize to induce the formation of ISGF3 complex, leading to much 
stronger ISG transcription [56].  
Regulation of ISGs at the transcriptional level 
In the case of type I and III IFNs, ISGF3 works as the predominant transcriptional factor 
binding to ISREs within the promoter region of ISGs; whereas for type II IFN, the homodimers 
or heterodimers of STATs are the determinant binding to GAS elements. However, this is a 
simplified model and other regulatory elements are also involved (Figure 2).  
Chromatin modulators. 
Histone octamers bind to DNA and organize chromatin into higher order nucleosomes, 
prohibiting transcription factor binding and gene expression [57]. As a consequence, the 
induction of ISGs by IFNs requires chromatin remodeling. The condensed chromatin needs to 
be transformed into a more relaxed structure. In humans, the nucleosome remodeling 
complex BAF and PBAF prime ISG promoters by utilizing ATP-derived energy to maintain 
chromatin in a constitutively open conformation, allowing fast and potent induction of ISGs 
after IFN exposure [58-61]. Histone acetylation and deacetylation are also essential in 
chromatin modulation. These reactions are typically catalyzed by enzymes with histone 
acetyltransferase (HAT) or histone deacetylase (HDAC) activity. HAT activity transforms 
chromatin into a more relaxed structure, while HDAC activity organizes chromatin into 
higher order nucleosomes. Therefore, the HAT family members, including p300/CBP and 
GCN5, are essential for transcriptional activation of ISGs [62, 63]. HATs are positive regulators 
of transcription in general. However, HDAC activity is also essential for transcriptional 
induction of ISGs [64-69]. HDAC activity has been reported to be required for recruiting RNA 
polymerase II to the promoters of ISGs [70], although how HDACs regulate transcriptional 
activation of ISG remains unclear. In addition, FOXO3 and PI3K/AKT pathway coordinate in 
chromatin modulation. FOXO3 together with the nuclear co-repressor 2 (NCOR2) and HDAC3 
forms a ternary complex to facilitate a closed chromatin structure to limit ISG transcription 
under basal conditions. However, type I IFN can activate the PI3K/AKT pathway, which in 
turn leads to FOXO3 degradation and ISG transcription [71]. 
Co-activators and co-repressors. 
Particular co-activators or co-repressors mediate the transcription of ISGs via the interaction 
with ISGF3 or STAT1 homodimers. The co-activators, such as MCM5 (minichromosome 
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maintenance) and MCM3 protein complex [72, 73], N-Myc interactor (NMi) [74] and DRIP150 [75], 
facilitate the transcriptional activation of ISGs. Conversely, co-repressors, such as TAF-1 [76] 
and the protein inhibitor of activated STAT proteins (PIAS1 and PIASγ [77, 78], negatively 
suppress the formation of transcription complex on the ISG promoter to limit transcription. 
Recently, four previously unrecognized regulatory factors (ETV6, ATF3, LYN and TBK1) of ISG 
transcription have been identified [79]. These efforts have led to a more comprehensive 
understanding of ISG transcription. 
 
Figure 2. The transcriptional regulation of IFN-stimulated genes (ISGs) involves chromatin 
remodeling and various co-activators and co-repressors.  
Upon IFN stimulation, the IFN-stimulated gene factor 3 (ISGF3) or STAT1 homodimer binds to ISG 
promoter regions, recruiting various chromatin remodeling factors and transcriptional co-activators. 
These factors include the nucleosome remodeling complex BAF and PBAF, p300/CBP and GCN5 
histone acetyltransferase (HAT), histone deacetylase (HDAC), minichromosome maintenance 3 and 5 
(MCM3 and MCM5), N-Myc interactor (NMi), DRIP150 (a subunit of the multimeric mediator 
coactivator complex). Consequently, the condensed chromatin transforms into a more relaxed 
structure to facilitate the transcription of ISGs. Conversely, the co-repressor factors could inhibit ISG 
transcription either via the facilitation of a closed chromatin or interference with the recruitment of 
STAT1 or ISGF3 to the ISG promoter. 
Non-canonical regulation of ISG transcription  
All three types of IFNs signal through the JAK-STAT pathway to elicit antiviral activity. Yet, 
type II IFN is thought to do so only through STAT1 homodimers; whereas type I and III IFNs 
activate both STAT1 and STAT2 to form ISGF3 together with IRF9. However, accumulating 
evidence highlights a far more complex process of activation and function beyond this 
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classical theory. The heterogeneity of the regulatory mechanisms of ISG transcription has 
been recently highlighted. A substantial fraction of these cascades have little or no link to 
STAT1/2 and ISGF3, paralleling the existence of non-canonical mechanisms outside of the 
JAK-STAT axis [79]. Here, we review both JAK-STAT axis dependent and independent non-
canonical mechanisms of ISG transcription (Figure 3). 
 
Figure 3. Non-canonical mechanisms in regulating ISG transcription.  
Non-canonical mechanisms both within and outside of the IFN-JAK-STAT axis were summarized. 
Together with canonical mechanisms, they coordinately regulate ISG transcription, thus defining the 
cellular defense status against pathogen invasion. 
Non-canonical ISGF3 complex. 
Up to date, three different forms of non-canonical ISGF3 complexes have been identified, 
including ISGF3II, the STAT2-IRF9 complex and unphosphorylated ISGF3 (U-ISGF3). IFN-γ 
treatment has been reported to induce the formation of a new manifestation of ISGF3 
(ISGF3II) containing phosphorylated STAT1, unphosphorylated STAT2 and IRF9 [80]. In the 
Chapter 2 
37 | P a g e  
 
absence of STAT1, STAT2 was found to interact with IRF9 to form an ISGF3-like complex to 
mediate specific ISG transcription [81]. Finally, continuous exposure to a low level of 
exogenous IFNs, U-ISGF3 formed by IFN induced IRF9 and unphosphorylated STAT1 and 
STAT2, can lead to increased expression of a subset of ISGs [82, 83].  
STAT5-CrkL complex.  
Apart from STAT1 and STAT2, STAT5 is also involved in type I IFN induced ISG transcription. 
STAT5 interacts constitutively with IFN receptor-associated TYK-2. Upon type I IFN 
stimulation, STAT5 is phosphorylated on both tyrosine and serine sites, thus acting as a 
docking site for the SH2 domain of CrkL. CrkL and STAT5 then form a complex that 
translocates to the nucleus and binds to GAS elements to activate type I IFN-dependent gene 
transcription [3, 84].  
IRFs. 
IRF1 has been shown to function as a transcription factor. The DNA sequences (IRF-E site) 
recognized by IRF1 overlap with the ISRE, and in this way IRF1 induces a subset of ISGs. IRF1 
can also enhance the levels of both total and phosphorylated STAT1 to amplify ISG 
transcription via JAK-STAT pathway [85]. Conversely, IRF2 binds to the same IRF-E site to 
repress IRF1 induced transcription [86, 87]. Upon virus infection, IRF3 is activated and 
cooperates with NF-κB and ATF-2/c-Jun to form a transcriptionally active enhanceosome 
complex on the IFN-β promoter. Newly synthesized IFN binds to cognate receptors to 
activate ISG transcription via the JAK-STAT pathway. Importantly, IRF3 was also been 
reported to directly induce a subset of ISGs in an IFN-independent manner through the ISREs 
element on their promoters [88, 89]. 
Cross-regulation between TNF and IFN signaling.  
It is well documented that when combined with TNF-α, type I or II IFN works cooperatively 
on antiviral ISG induction and exerts synergistic antiviral effects [90-93]. TNF-α has been 
reported to inhibit hepatitis C virus (HCV) infection-caused degradation of IFNAR2, thus 
maintaining IFN signaling and ISG expression [93]. TNF-α alone can already moderately induce 
the transcription of a subset of ISGs [90, 91]. This is mainly through NF-κB protein complex, a 
key downstream element of the TNF-α signaling. This may explain the antiviral activity of 
TNF-α on different virus as documented [92, 94-96]. 
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Rac1/p38 pathway.  
Rac1/p38 Map kinase signaling regulates IFN induced ISG transcription. Type I IFN treatment 
results in activation of Rac1 and its downstream effectors including MAP kinase kinase 3 
(MKK3), MAP kinase kinase 6 (MKK6) [97, 98] and cytosolic phospholipase A2 [99, 100]. In turn, 
these events provoke phosphorylation and activation of the p38 MAP kinase, an important 
mediator of the inflammatory response [101]. p38 MAP kinase activation leads to downstream 
MapKapK-2 and MapKapK-3 activation, contributing to type I IFN-dependent transcriptional 
regulation of ISGs. However, Rac1/p38 Map kinase signaling is not required for IFN-
dependent phosphorylation of STAT1 on both sites (Ser727 and Tyr701) and has no impact on 
the formation of ISGF3 complex [102, 103]. Histone phosphorylation and chromatin remodeling 
are possible mechanisms employed by this cascade [102]. Many immune-relevant gene 
products are subject to post-transcriptional regulation by this signaling [104], but ISGs have 
not been investigated in this respect. 
IFN-γ-activated response element (GATE).  
In response to IFN-γ, two factors bind to a unique IFN-γ-activated response element called 
GATE, the CCAAT/enhancer binding protein C/EBP-β and the GATE binding factor GBF-1. 
MEK1, ERK1 and ERK2 are the upstream kinases needed to activate C/EBP-β in response to 
IFN-γ [105]. This novel IFN-γ-activated pathway promotes ISG expression in STAT1-, but not 
JAK1-dependent manner.  
Nucleotide synthesis inhibitor.  
Purine and pyrimidine nucleotides are the major cellular energy carriers and constitute 
subunits of nucleic acids. Nucleotides can be synthesized de novo through a series of 
enzymatic reactions or recycled through salvage pathways. Interestingly, purine and 
pyrimidine synthesis inhibitors (such as ribavirin, mycophenolic acid and brequinar) can 
efficiently induce ISG expression and exert strong and broad antiviral responses [106-108]. 
However, this process is independent of the classical JAK-STAT cascade, suggesting a non-
canonical mechanism that is independent of IFNs [109]. Ribavirin, an inhibitor of the IMPDH 
enzyme, was shown to reset a subset of ISG promoters to a “ready to be activated” status, 
thus potentiating ISG activation [110]. However, the crosstalk of nucleotide synthesis and 
innate immune response remains to be further elucidated. 
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Retinoic acid.  
Retinoic acid (RA) is a metabolite of vitamin A that mediates the functions of vitamin A 
required for growth and development. RA activates transcriptional status via retinoic acid 
receptors (RAR) and retinoid X receptors (RXR) heterodimer, which binds to regions in 
promoters called retinoic acid response elements (RAREs). Numerous studies have reported 
antiviral activities of RA against a variety of pathogens [111, 112]. Interestingly, intracellular RA 
increases ISG expression at basal levels and augments ISG induction in response to IFNs [113]. 
This is consistent with the clinical observation that RA enhances the response to IFN-based 
antiviral therapy [112, 114]. Strikingly, a bioinformatics study showed that most ISGs regulatory 
regions contain RARE sequence [113]. This indicates that RA can induce transcriptional 
activation of these ISGs containing RAREs, facilitating the binding of additional transcription 
factors to the promoters of these ISGs. Consequently, RA initiates and works synergistically 
with IFNs to induce ISG expression.  
IFNs and ISGs: clinical implications and future perspective 
IFNs have been used in various clinical settings to counteract pathogen-related diseases. 
Because of its robust and broad antiviral activity, IFN-α represents the standard treatment 
for chronic hepatitis B virus (HBV) or HCV infections for decades. Its application also extends 
to other virus infections as off-label treatment, e.g. hepatitis E virus [115] and severe acute 
respiratory syndrome [116]. IFN-λ has been shown to play a crucial role in cancer, 
autoimmune disease and viral infections [117]. The antitumor and anti-infection activities of 
IFN-γ have been comprehensively evaluated and used in a variety of clinical indications. It 
has been approved by FDA to treat chronic granulomatous disease and osteopetrosis and is 
experimentally used for the treatment of idiopathic pulmonary fibrosis and Friedreich's 
ataxia [118]. But it is unsuccessful for treating viral infections [119, 120]. IFN-λ has been shown 
specific antiviral activity in both chronic HBV and HCV patients, not superior as compared to 
IFN-α therapy but with limited side effects [121, 122]. This is because of the fact that IFNλR1 has 
a more restricted tissue-specific pattern of expression. IFN-λ has also been shown to 
determine the intestinal epithelial antiviral host defense against rotavirus infection. It acts 
synergistically with IL-22 for the induction of ISGs and eventually controls rotavirus infection 
in animal models [123, 124]. Thus, IFN-λ might be an attractive option for the treatment of 
many viral infections. Although the clinical application of IFNs, in particular for HCV, will be 
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limited because of the recent launch of direct-acting antiviral agents, it may extend to other 
devastating viral diseases such as Ebola, Zika or Dengue virus infections.  
Mechanistically, for all three different types of IFNs, ISGs are the ultimate antiviral 
effectors. Recent studies on the function of individual ISG indicate that different viruses are 
targeted by unique sets of ISGs. Some ISGs possess broad antiviral but others have specific 
antiviral effects [125]. Thus, characterization of individual ISG with respect to their antiviral 
spectrum or specificity provides new avenues for improving current antiviral therapies. 
Interestingly, several ISGs have been reported to paradoxically enhance the replication of 
certain viruses, illustrating the complexity of the network of mutual interaction between 
ISGs and viruses [125]. In pre-clinical or clinical studies, the expression pattern of some 
specific ISGs have been identified as bio-makers to predict treatment responses, disease 
progression or outcomes in both infectious (e.g. HCV and HIV infections) [126-128] and non-
infectious human diseases (e.g. Aicardi-Goutieres syndrome and systemic lupus 
erythematosus) [129, 130]. Some ISGs (e.g. TLR3, TLR7, RIG-I and MDA5) belong to pattern 
recognition receptors (PRRs). Attributing to their key roles in innate immune responses, 
there is a growing interest in targeting PRRs for the prevention and treatment of cancer, 
autoimmune diseases and infections. Their specific activators are now undergoing preclinical 
and clinical evaluation for safety and efficacy [131]. With regards to the adverse effects of IFNs 
in clinic, ISG-based antiviral strategies could be the next promising frontier in drug discovery. 
Concluding Remarks  
Decades of research has shaped up a picture of the complex network in regulating ISG 
transcription. This includes both canonical and non-canonical mechanisms within and 
outside of the IFN-JAK-STAT axis, coordinately defining the cellular defense status against 
pathogen invasion. We expect that the spectrum of new elements involved in both canonical 
and non-canonical regulation of ISG transcription will continue to grow and their 
mechanism-of-actions will be further clarified (see Outstanding Questions). Because of their 
importance in clinical implication, this knowledge is highly relevant in guiding the 
development of new therapies that promote the eradication of severe pathogen infections, 
but avoiding autoimmune diseases and toxic effects to the host. 
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Type I interferons (IFNs) have broad antiviral activities through the induction of interferon-
stimulated genes (ISGs). It is considered to constitute the first line of antiviral defense, but 
excessive exposure to IFNs provokes tissue damage and other pathological events. In 
addition to type I IFNs, however, the body has other innate antiviral defenses as well, which 
were commandingly reviewed by dr. Paludan in a recent issue of Trends in Immunology [1]. 
The article highlights that type I IFN-independent antiviral mechanisms, including alternative 
antiviral cytokines (e.g. IFN-λ or interleukin 22), or the basal expression of particular ISGs 
that all can mediate early antiviral defenses without evoking the inflammatory damage 
associated with production of type I IFNs. However, we feel that, while the constitutively 
expressed IFN regulatory factors (IRFs) and pattern recognition receptors (PRRs) have been 
largely examined in the context of the scaling of IFN responses, they also mediate important 
antiviral mechanisms that are independent of IFN induction and, thus, should also be 
emphasized.  
There are hundreds of ISGs that are usually induced by IFNs. Although they are 
thought to be the ultimate antiviral effectors, only a small subset of ISGs actually have 
potent antiviral activity as recently demonstrated by a screening of over 380 human ISGs for 
their antiviral effects [2, 3]. Some ISGs appear to act on specific viruses; whereas others have 
potent antiviral activity against a broad spectrum of viruses, especially IRFs (e.g. IRF1 and 
IRF2) and PRRs (e.g. cGAS, RIG-I and MDA5) [2, 3]. Classically, the induction or/and activation 
of these broad antiviral ISGs by viruses or IFNs are thought to enhance further IFN 
production, in turn inducing strong and broad induction of ISGs capable of combating viral 
infection through positive feedback loop. However, constitutive expression of particular ISGs 
may provide necessary antiviral defense without the need for IFN production. Especially the 
observation that, several ISGs have general antiviral effects in human STAT1 deficient 
fibroblasts, which are deficient in IFN signal transduction, in our view strongly supports this 
notion [2]. 
IRFs are transcription factors that indeed can bind to promoter regions of specific IFN 
genes to drive their transcription. PRRs can recognize specific components of the viral 
nucleic acid and trigger IFN production through downstream elements including IRF3 and 
IRF7 [4]. Thus, IFNs are important mediators of their antiviral action. However, accumulating 
evidence suggest that these broad antiviral ISGs simultaneously function through IFN-
independent pathways, as they are capable of inducing transcription of many ISGs 
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independent of IFN production or signaling [2]. For instance, IRF1 inhibits hepatitis E virus 
infection through activation of STAT1 transcription and phosphorylation without 
concomitant IFN production [5]. cGAS can induce a large number of ISGs via a STING-
dependent, IRF3-mediated process but functions independent of the canonical IFN signaling 
[3]. RIG-I has also been demonstrated to induce ISGs by augmenting STAT1 activation but 
independent of the classical IFN pathway [6]. It has been reported to strengthen STAT1 
activation by disruption of the binding of STAT1 to its negative regulator SHP1 [7].  
We feel that this idea is further bolstered by the definition of at least some of the 
other molecular mechanisms that execute type I IFN-independent antiviral defense. RIG-I 
can directly inhibit viral replication by blocking the binding of viral polymerase to viral RNA [8, 
9]. During hepatitis B virus (HBV) infection, RIG-I recognizes and binds the 5’-ε region of the 
pregenomic viral RNA (pgRNA). It thus prevents the interaction of HBV polymerase with this 
5’-ε region, leading to suppression of HBV replication [8]. During influenza A virus infection, 
RIG-I binds to the nucleocapsids of cytoplasm-invading viruses, resulting in destabilization of 
the nucleocapsids that hampers viral propagation [9]. Furthermore, RIG-I and MDA5 exert 
their direct antiviral functions that require intact ATPase activity and involves displacing viral 
proteins from their pre-bound positions on dsRNA [10]. In response, viruses have also 
developed sophisticated strategies to counteract host antiviral defense. For instance, 
herpesvirus can hijack activated RIG-I to avoid antiviral cytokine production [11]. Hepatitis C 
virus can prevent physical interaction between viral RNA and host PRRs like RIG-I and MDA5 
[12]. Nevertheless, constitutive expression of RIG-I and MDA5 can be expected to provide 
protection against a variety of viruses. 
In line with the review by Paludan highlighting the essential role of IFN-independent 
antiviral response, we now have extended and emphasized the importance of possible IFN-
independent mechanisms of these broad antiviral ISGs. However, these non-canonical 
antiviral mechanisms are largely elusive, thus deserving further investigation, although the 
IFN-dependent mechanisms also require further clarification (Figure 1). We would thus call 
upon the scientific community to devote more attention to this under-investigated subject 
as it appears to constitute a vital component of the defense of the body against viral 
challenges. 
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Figure 1. Interferon (IFN)-Dependent and Independent Antiviral Mechanisms of IFN-Stimulated 
Genes (ISGs).  
Classically, Type I IFN induces gene expression via the Janus kinase-signal transducer and activator of 
transcription (JAK-STAT) pathway, resulting in expression of a range of ISGs that can be mainly 
divided into antiviral effectors and positive regulators. Some positive regulators, such as retinoic-acid 
inducible gene I (RIG-I), melanoma differentiation associated protein 5 (MDA5), and cyclic GMP-AMP 
synthase (cGAS), can recognize viral nucleic acid, triggering expression of IFNs through the IFN 
regulatory factors IRF3 and IRF7. Many of these positive regulators can activate the transcription of 
ISGs independently of IFN production. In particular, cGAS can induce ISG expression via a stimulator 
of IFN genes (STING)-dependent, IRF3-mediated process. RIG-I can induce ISG expression by 
augmenting STAT1 activation. IRF1 can activate ISG expression via STAT1 activation. Of note, RIG-I 
and MDA5 also directly inhibit viral propagation. Abbreviations: IFNAR1/2, IFN-α receptor 1/2; ISRE, 
IFN-stimulated response element. The red line with a blunt end indicates antiviral activity. 
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Abstract 
Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. 
Although there is no proven medication for hepatitis E, pegylated Interferon-α (IFN-α) has 
been used as off-label drug for treating HEV. However, the efficacy and molecular 
mechanisms of how IFN signaling interacts with HEV remain undefined. As IFN-α has been 
approved for treating chronic hepatitis C for decades and the role of interferon signaling has 
been well studied in hepatitis C virus (HCV) infection, this study aimed to comprehensively 
investigate virus-host interactions in HEV infection with focusing on the IFN signaling, in 
comparison to HCV infection. A comprehensive screen of human cytokines and chemokines 
revealed that IFN-α was the sole humoral factor inhibiting HEV replication. IFN-α treatment 
exerted a rapid and potent antiviral activity against HCV; whereas it had moderate and 
delayed anti-HEV effects in vitro and in patients. Surprisingly, blocking the basal IFN pathway 
by inhibiting JAK1 to phosphorylate STAT1 has resulted in drastic facilitation of HEV, but not 
HCV infection. Gene silencing of the key components of JAK-STAT cascade of the IFN 
signaling, including JAK1, STAT1 and interferon regulatory factor 9 (IRF9) stimulated HEV 
infection. In conclusion, compared to HCV, HEV is less sensitive to IFN treatment. In contrast, 
the basal IFN cascade could effectively restrict HEV infection. This bears significant 
implications in management of HEV patients and future therapeutic development. 
Keyword: Hepatitis E virus; interferon; interferon-stimulated genes; JAK-STAT cascades 
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Introduction  
As an emerging infectious pathogen, hepatitis E virus (HEV) represents the most common 
cause of acute viral hepatitis [1]. Outbreaks of hepatitis E occur periodically throughout the 
developing world, which often cause fulminant hepatitis with high mortality (reaching 25%) 
in the case of pregnant women [2]. In the industrialized countries, HEV usually only causes an 
acute and self-limiting infection, it however bears a high risk of developing chronic hepatitis 
in immunocompromised patients with substantial mortality rates [3]. Thus, it is important to 
understand the underlying mechanisms of the distinct infection courses of different 
populations upon exposure to HEV. For severely affected patients, there is an urgent need 
for developing optimal therapies, because no proven antiviral medication is available for 
hepatitis E. 
Cytokines induced by viral infection play a key role in host defense against the 
infection [4], but their roles in anti-HEV immunity remain largely obscure. HEV provokes the 
production of a panel of inflammatory cytokines and chemokines with considerable higher 
levels in experimental models and in patients [4-7]. However, the action of these HEV-induced 
cytokines on the life-cycle and pathogenesis of HEV infection remain unknown. Interferons 
(IFNs), pleiotropic cytokines, are of vital importance for the innate defense against viral 
infection [8]. They are grouped into three classes including type I, II and III, which bind to 
distinct receptors to stimulate their antiviral responses in host cells [9]. Pegylated IFN-α in 
combination with ribavirin was considered the standard antiviral therapy for chronic 
hepatitis C virus (HCV) infection [10]. In addition, type III IFN-lambdas (IFN-λs), which appear 
to have less side effects than IFN-α, are currently clinically evaluated for the treatment of 
chronic hepatitis C [11, 12]. Although Pegylated IFN-α, ribavirin or the combination have 
already been used to treat individual cases or small case series of HEV infection as off-label 
drugs [13-15], their mechanism-of-actions in the setting of HEV remain poorly investigated. 
Intriguingly, basal JAK-STAT signaling in the absence of exogenous IFN stimulation 
could already serve as a first line of intracellular antiviral defense [16]. In fact, the 
seroprevalence of HEV is substantially high in both developing and developed countries; 
whereas majority healthy people have only asymptomatic or self-limiting acute infection. 
Thus, humans clearly have powerful defense mechanisms against HEV. It is of an intriguing 
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question whether basal IFN signaling plays a crucial role in the process of HEV resistance or 
self-limiting.  
The absence of robust cell culture models has hampered fundamental and 
translational research of HEV. Fortunately, subgenomic and infectious models for HEV 
infection have come available [17] and such models were recently used in studying the 
infection biology and assessing potential antivirals [18-20]. In this study, we comprehensively 
characterized the role of cytokines in regulating HEV infection. IFN-α was found the sole 
humoral factor provoking inhibition of HEV replication. Further investigation identified the 
essential role of basal IFN signaling and the key components of JAK-STAT cascades in 
protecting against HEV replication. These results revealed distinct mode-of-actions of basal 
and treatment activated IFN signaling in controlling HEV infection. 
Materials and Methods 
Patients  
Chronic HEV patients treated with pegylated IFN-α monotherapy at CHU Rangueil, Toulouse, 
France were selected and 4 cases were identified. Patient 1, 2 and 3 were 
immunocompromised patients with liver transplantation and patient 4 had hematologic 
disease. HEV viral kinetics was analyzed in these four patients by retrieving HEV RNA titters 
(log copies/mL) at day 0, 1, 3, 7, 15, 21 and 30 post-treatment. The study was approved by 
the institutional review boards of Toulouse Hospital, and all of the patients presented their 
written informed consent to participate in this study. 
Reagents  
Cytokines and chemokines (PeproTech or R&D Systems) were used for screening. Human 
IFNs (Thermo Scientific, Netherlands) were dissolved in culture medium. Stocks of Jak 
inhibitor I (Santa Cruz Biotech, Santa Cruz, CA) was dissolved in DMSO (Sigma-Aldrich, St 
Louis, MO) with a final concentration of 5 mg/mL. Stocks of AG-490 and CP 690,550 were 
dissolved in DMSO with a final concentration of 10 mg/mL. Antibodies including phospho-
STAT1, total STAT1, phospho-JAK1, Interferon stimulated factor 9 (IRF9) (Cell Signaling 
Technology, Netherlands) and β-actin (Santa Cruz Biotech, Santa Cruz, CA); anti-rabbit or 
anti-mouse IRDye-conjugated secondary antibodies (Stressgen, Glandford Ave, Victoria, BC, 
Canada) were also used. 
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Cell culture models 
HEV genomic RNA was generated from a plasmid construct containing the full-length HEV 
genome (Kernow-C1 p6 clone, GenBank Accession Number JQ679013) or a construct 
containing subgenomic HEV sequence coupled with a Gaussia luciferase reporter gene (p6-
Luc), using the Ambion MESSAGE MACHINE in vitro RNA transcription Kit (Life Technologies 
Corporation) [17, 21]. The human hepatoma 7 (Huh7) cells were collected and centrifuged for 5 
min, 1500 rpm, 4 °C. Supernatant was removed and washed with 4 mL Opti-MEM by 
centrifuging for 5 min, 1500 rpm, 4 °C. The cell pellet was re-suspended in 100 μL Opti-MEM 
and mixed with p6 full-length HEV RNA or p6-Luc subgenomic RNA. Electroporation was 
performed with the Bio-Rad’s electroporation systems using the protocol of a designed 
program (240 volts, pulse length 0.5, number 1 and cuvette 4 mm) [17]. Huh7-ET replicon was 
based on Huh7 cells containing a subgenomic HCV bicistronic replicon (1389/NS3-
3V/LucUbiNeo-ET) and maintained with 250 µg/mL G418. Huh7 cells harboring the full-
length JFH1-derived genome was used as an infectious HCV model [22].  
Gene knockdown and overexpression by lentiviral vector 
Lentiviral vectors (Sigma-Aldrich) targeting JAK1, STAT1, IRF9 or GFP control were obtained 
from the Erasmus Center for Biomics and produced in HEK 293T cells as previously described 
[23]. After a pilot study, the shRNA vectors exerting optimal gene knockdown were selected. 
To generate gene knockdown or overexpression cells, Huh7 cells were transduced with 
lentiviral vectors. Since the knockdown vectors also express a puromycin resistance gene, 
transduced cells were subsequently selected by adding 2.5 μg/mL puromycin (Sigma) to the 
cell culture medium.  
Measurement of luciferase activity 
For Gaussia luciferase, the activity of secreted luciferase in the cell culture medium was 
measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). For firefly 
luciferase, luciferin potassium salt (100 mM; Sigma) was added to cells and incubated for 30 
min at 37 °C. Both Gaussia and firefly Luciferase activity was quantified with a LumiStar 
Optima luminescence counter (BMG LabTech, Offenburg, Germany). 
MTT assay 
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10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to cells seeded in 96-well plate and the cells were grew at 37 °C with 5% CO2 for 3 hrs. 
The medium was removed and 100 μL of DMSO was added to each well. The absorbance of 
each well was read on the microplate absorbance readers (BIO-RAD) at wavelength of 490 
nm. All measurements were performed in triplicates. 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-Nucleo Spin RNA II kit (Bioke, Leiden, Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total 
RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA was quantified with a SYBR 
Green-based real-time PCR (MJ Research Opticon, Hercules, CA, USA) according to the 
manufacturer’s instructions. GAPDH was considered as reference gene to normalize gene 
expression. 
Western blot assay 
Proteins in cell lysates were heated 5 min at 95 °C followed by loading onto sodium dodecyl 
sulphate-polyacrylamide gel (SDS-PAGE) and separated by electrophoresis. Proteins were 
electrophoretically transferred onto PVDF membrane (Invitrogen) for 1.5 hrs with an electric 
current of 250 mA. Subsequently, the membrane was blocked with blocking buffer. It was 
followed by incubation with rabbit p-JAK1, p-STAT1, t-STAT1, IRF9 (1: 1000) antibodies 
overnight at 4 °C. The membrane was washed 3 times and incubated for 1 hrs with anti-
rabbit or anti-mouse IRDye-conjugated secondary antibodies (1: 5000) at room temperature. 
Blots were scanned and quantified by Odyssey infrared imaging (Li-COR Biosciences, Lincoln, 
NE, USA). Results were visualized and quantitated with Odyssey 3.0 software. 
Statistical analysis 
All results were presented as mean ± SEM. Comparisons between groups were performed 
with Mann-Whitney test. Differences were considered significant at a p value less than 0.05 
*or 0.01 **. 
Results 
HEV replication is insensitive to the regulation of cytokines and chemokines 
Viral infections often induce various cytokines and chemokines that in turn modulate the 
infection course [24]. We thus investigated the effects of a panel of cytokines and chemokines 
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on host susceptibility to HEV infection. To this end, we employed cell culture model of 
human hepatoma cells (Huh7 cell line) transfected with subgenomic construct of HEV coding 
sequence in which the 5’ portion of ORF2 was replaced with the in-frame Gaussia luciferase 
reporter (p6-Luc) [17]. In parallel, Huh7 cells constitutively expressing a non-secreted firefly 
luciferase are used for normalization of non-specific effects on luciferase signals [18, 20].  
 
Figure 1. HEV replication was insensitive to the regulation of cytokines and chemokines.  
Huh7-p6-Luc cells were treated with cytokines at 100 ng/mL (except for IFN-α and IFN-β at 100 IU 
/mL) for 24 (A), 48 (B) and 72 hrs (C), and then luciferase activity was measured. (Mean ± SEM, n = 4). 
** P < 0.01. 
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Exploiting this experimental system, 36 cytokines and chemokines, including type I, II 
and III IFNs, interleukins and others, were examined in the HEV replicon, culture medium 
served as control. MTT assay has shown that these cytokines/chemokines in general did not 
exert cytotoxicity to host cells (Supplementary Figure 1). However, except for some forms of 
IFNs, other cytokines and chemokines had no significant effects on HEV replication (Figure 1). 
Hence, HEV replication is in general insensitive to the regulation of cytokines and 
chemokines, except for type I interferons, suggesting that antiviral immunity to HEV is 
mediated through a very specific branch of our immune system. 
HEV, compared to HCV, is less sensitive to IFN-α treatment  
Based on the results of our profiling of humoral factors involved in anti-HEV immunity, we 
further investigated the action of IFN-α, the archetypical type I IFN that has been 
successfully used to treat chronic HCV in the clinic for decades [25]. As expected, treatment of 
IFN-α resulted in robust inhibition of HCV replication in the Huh7-based subgenomic replicon 
containing a luciferase reporter (Figure 2A), suggesting that our model system can reflect 
clinically relevant processes. High dose of IFN-α (10-1000 IU/mL) almost completely 
suppressed HCV replication as early as after 24 hrs treatment. In contrast, the action of IFN-
α, although evidently present, was much less effective in suppressing HEV replication in a  
similar subgenomic replicon that also contains a luciferase reporter. Moderate inhibitory 
effects were observed only after 72 hrs treatment with relatively high concentrations (100 
IU/mL: 31% ± 8, mean ± SEM, n = 3 independent experiments with each 2 - 3 replicates, P < 
0.01; 1000 IU/mL: 41% ± 3, mean ± SEM, n = 3 independent experiments with each 2 - 3 
replicates, P < 0.01) (Figure 2B). Consistently, in the full-length HCV and HEV infectious 
models, IFN-α had significantly more potent antiviral effects against HCV than HEV (Figure 
2C). In apparent agreement, whereas it is well-known that chronic HCV patients who 
respond to IFN-α therapy often experience a rapid and sharp reduction of viral load within 
the first few days upon treatment [26, 27], we observed that three out of four chronic HEV 
patients had only minor fluctuation of viral load within first two weeks of pegylated IFN-α 
treatment, although all the patients eventually cleared the virus (Figure 2D). These results 
indicate that IFN-α exerts a moderate and delayed antiviral activity against HEV, in contrast 
to the rapid and potent effect of this cytokine against HCV, which suggests that their 
underlying antiviral mechanisms differ. 
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Figure 2. IFN-α exerted moderate but delayed antiviral activity against HEV.  
(A) In the Huh7 cell-based subgenomic HCV replicon, treatment with IFN-α dose-dependently 
decreased viral replication-related luciferase activity. (Mean ± SEM, n = 3 independent experiments 
with each 2 - 3 replicates). (B) In the Huh7 cell-based subgenomic HEV replicon, treatment with IFN-α 
moderately inhibited viral replication-related luciferase activity (Mean ± SEM, n = 3 independent 
experiments with each 2 - 3 replicates). (C) In the full-length HEV and HCV infectious model, IFN-α 
significantly decreased cellular viral RNA at 48 hrs determined by qRT-PCR (Mean ± SEM, n = 5). 
Significant differences between level of INF-α antiviral effects were observed. (D) Four chronic HEV 
patients were treated with monotherapy of INF-α and the viral load was analyzed within 30 days. 
Treatment time was indicated as 24, 48 or 72 hrs * or + P < 0.05; ** or ++ P < 0.01. 
The notion that anti-viral activity of IFN-α towards HEV is mechanistically different 
from that against HCV was further supported by experiments in which the anti-viral effect of 
alternative member of the family of type I, II and III IFNs were investigated. IFN-β and IFN-γ 
effectively inhibits HCV replication in the replicon model, but did not exert a significant 
effect on HEV replication (Figure 3A and 3B). IFN-λ is currently under clinical investigation for 
treating chronic HCV patients and has been shown to possess good anti-HCV antiviral activity 
but with fewer adverse events as compared to IFN-α [12]. In HCV replicon, IFN-λ1, IFN-λ2 and 
IFN-λ3 showed significant inhibition on viral replication. Unexpectedly, high dose of IFN-λ1, 
IFN-λ2 and IFN-λ3 even significantly enhanced viral replication in the HEV replicon after 24 
hrs treatment, although the effects were mild (Figure 3C-E). Thus, the anti-HEV activity of 
type I, II and III IFNs appears mechanistically distinct from that against HCV (Supplementary 
Figure 2). 
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HEV replication is sensitive to basal IFN signaling  
Although humoral factors do not confer protection action against HEV replication, the only 
partial exception being IFN-α (Figure 2 and 3), humans appear to have powerful defense 
mechanisms combating HEV [18], raising questions as to the nature of these mechanisms. The 
partial activity of IFN-α against HEV replication led us hypotheses that signaling elements, in 
particular JAK-STAT cascades, involved in IFN-α signal transduction might contribute to anti-
HEV defense. Constitutive JAK-STAT signaling is an essential part of the innate immunity for 
host defense against viruses [16]. To investigate how the endogenous JAK-STAT signaling 
affects HEV replication, JAK inhibitor I that is known to predominantly inhibit JAK1 (but may 
also inhibit JAK2 and JAK3) was first tested. As expected, it can effectively inhibit its 
downstream target, the phosphorylation of STAT1, induced by treatment of IFN-α or IFN-λ 
(Supplementary Figure 3A). Consistently, it significantly inhibited the stimulation of the IFN 
response reporter, IFN-stimulated response elements (ISRE)-luciferase transcription reporter 
(Supplementary Figure 3B). Accordingly, IFN-α triggered induction of ISGs, as represented by 
four important members RSAD2, ISG15, OAS1 and PKR, were blocked by this inhibitor 
(Supplementary Figure 3C).  
Importantly, treatment of JAK inhibitor I dramatically elevated HEV replication in 
both subgenomic replicon (Figure 4A) and the infectious model (Figure 4B). Treatment with 
10 µM for 72 hrs, increased HEV replication-related luciferase activity by 3.02 ± 0.50-fold 
(mean ± SEM, n = 3 independent experiments with each 3 replicates, P < 0.01) in the replicon 
(Figure 4A). Similarly, treatment with 10 µM for 48 hrs, it increased viral RNA by 4.78 ± 1.13-
fold (mean ± SEM, n = 3, P < 0.05) in the infectious model (Figure 4B). In contrast, JAK 
inhibitor I had only minor effect on HCV replication (Figure 4C). To investigate whether JAK2 
(associated with type II IFN) and JAK3 (activated by cytokines with receptors containing the 
common gamma chain) are also involved, their corresponding inhibitors AG-490 and CP-
690550 were tested in both HEV and HCV replicon. As shown in Figure 4D and 4E, both 
inhibitors had no clear effects on both HEV and HCV replication. Of note, all three inhibitors 
did have notable effects on cell growth determined by MTT assay (Supplementary Figure 3D). 
Thus, the basal JAK-STAT pathway could effectively limit HEV infection, although exogenous 
IFN is ineffective, whereas it is vice versa for HCV.  
 
Chapter 4 
64 | P a g e  
 
 
Figure 3. IFN-β, γ and λs had no significant antiviral activity against HEV infection. 
In the Huh7 cell-based subgenomic HCV and HEV replicon, viral replication-related luciferase activity 
determined after dose-dependently treatments with IFN-β (A), IFN-γ (B), IFN-λ1 (C), IFN-λ2 (D) and 
IFN-λ3 (E) (Mean ± SEM, n = 3 independent experiments with each 3 - 4 replicates). Treatment time 
was indicated as 24, 48 or 72 hrs. * P < 0.05; ** P < 0.01. 
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Figure 4. Pharmacological inhibition of JAK1 dramatically stimulated HEV replication. 
(A) In the Huh7 cell-based subgenomic HEV replicon, treatment with Jak inhibitor I dose-dependently 
increased viral replication-related luciferase activity (Mean ± SEM, n = 3 independent experiments 
with each 3 replicates). (B) In the full-length HEV infectious model, 10 µM Jak inhibitor I significantly 
increased cellular viral RNA at 48 hrs determined by qRT-PCR (Mean ± SEM, n = 3). (C) In the Huh7 
cell-based subgenomic HCV replicon, treatment with Jak inhibitor I did not effectively affect viral 
replication-related luciferase activity (Mean ± SEM, n = 3 independent experiments with each 3 
replicates). (D) AG-490 is an inhibitor of JAK2 signaling and in the Huh7 cell-based subgenomic HEV 
and HCV replicon, treatment with AG-490 did not affect viral replication-related luciferase activity 
(Mean ± SEM, n = 3). (E) CP 690550 is an inhibitor of JAK3 signaling and in the Huh7 cell-based 
subgenomic HEV and HCV replicon, treatment with CP 690550 did not affect viral replication-related 
luciferase activity (Mean ± SEM, n = 3). Treatment time was indicated as 24, 48 or 72 hrs. * P < 0.05; 
** P < 0.01. 
Key components of JAK-STAT cascades restrict HEV infection 
Upon binding of IFN-α to its receptor, JAK1 is stimulated, resulting in tyrosine 
phosphorylation of STAT1 and STAT2. This is followed by the formation and nuclear 
translocation of the STAT1-STAT2-IRF9, a transcription factor complex known as IFN-
stimulated gene factor 3 (ISGF3), which in turn combines to the ISREs in the genome DNA 
and subsequently drives transcription of ISGs to establish an antiviral status (Figure 5A) [28]. 
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Specific inhibition of the JAK/STAT signaling pathway has been reported to modulate HCV 
replication [29]. 
 
Figure 5. Key components of JAK-STAT cascades restrict HEV infection. 
(A) Key components in interferon JAK-STAT signaling. (B) Knockdown of JAK1 by lentiviral shRNA 
vectors. Compared with the control vector transduced cells, the shJAK1 clone 1 and 2 expert potent 
silencing capability shown at mRNA level (Mean ± SEM, n = 4). Correspondingly, knockdown of JAK1 
of clone 2 resulted in significant increase of cellular HEV RNA level (Mean ± SEM, n = 4). (C) 
Knockdown of STAT1 by lentiviral shRNA vectors. Western blot assay presented a potent decrease of 
total STAT1 protein level, correspondingly, silencing of STAT1 led to significant increase of cellular 
HEV RNA level (Mean ± SEM, n = 4). (D) Knockdown of IRF9 by lentiviral shRNA vectors. Western blot 
assay presented a potent decrease of total IRF9 protein level, similarly, silencing of IRF9 led to 
significant increase of cellular HEV RNA level (Mean ± SEM, n = 4). Treatment time was indicated as 
24, 48 or 72 hrs. * P < 0.05; ** P < 0.01. 
To evaluate the direct effects of the key components of JAK-STAT pathway including 
JAK1, STAT1 and IFR9 on HEV infection, Huh7 cells were transduced with integrating 
lentiviral vectors expressing shRNA specifically targeting JAK1, STAT1, IRF9 or GFP as a 
control. For JAK1 knockdown cells, two of the tested three shRNA vectors targeting JAK1 
exert potent gene silencing capacity, resulted in a profound down-regulation of JAK1 mRNA 
level (Figure 5B). Correspondingly, JAK1 silencing led to significant increase of cellular HEV 
RNA level, which was measured by qRT-PCR after inoculation of HEV particles for 72 hrs. For 
instance, knockdown of shRNA clone 2 in JAK1 led to 2.47 ± 0.66-fold increase of HEV viral 
RNA (mean ± SEM, n = 4, P < 0.05) (Figure 5B). Furthermore, STAT1, which is phosphorylated 
by JAK1, was successfully silenced by shRNA targeting STAT1 in Huh7 cells with a potent 
reduction in protein level in shSTAT1 cells (Figure 5C). Consistently, STAT1 silencing could 
also significantly potentiated cellular HEV RNA level to 1.6 ± 0.13-fold (mean ± SEM, n = 3, P 
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< 0.05) (Figure 5C). To further determine whether event downstream of JAK-STAT cascades 
influences HEV replication, IRF9 was silenced with a profound down-regulation of total IRF9 
protein level (Figure 5D). Similarly, silencing of IRF9 resulted in 3.70 ± 1.07-fold (mean ± 
SEM, n = 4, P < 0.05) elevation of cellular HEV RNA level. Therefore, key constituents of JAK-
STAT cascades including JAK1, STAT1 and IRF9 play an intrinsic role in restricting HEV 
infection. 
Discussion 
Cytokines and chemokines are important components of the immune response for 
countering invading viruses [30]. With this group of mediators, especially IFNs play a cardinal 
role, exerting a wide range of pleiotropic effects [25]. Accordingly, IFN-α has become the 
mainstay for the treatment of chronic HCV and HBV infection, despite the considerable 
systemic side effects. Whereas IFN-λ shows a potent anti-viral activity as well in phase III 
clinical trial for treating HCV patients with much less reverse side effects, owing to the 
tissue-restricted expression of type III IFN receptor [31]. Hitherto, there is no approved 
medication for hepatitis E. Lessons have learned from standard therapy of chronic hepatitis 
C that IFN-α, ribavirin, or a combination as off-label drugs have been used to treat individual 
HEV cases or small case series [3]. As shown in this study (Figure 2D), four chronic hepatitis E 
patients all eventually cleared the virus after monotherapy of pegylated IFN-α. However, the 
viral kinetics in responding to IFN-α is very different between chronic hepatitis C and E. In 
chronic HCV, patients who respond to the therapy often experience a rapid and sharp 
reduction of viral load within the first few days upon initiation of IFN-α therapy [26, 27, 32]. In 
contrast, only one out of four chronic HEV patients had a rapid decline of viral load; whereas 
others had rather minor changes in the first two weeks of treatment. This is in line with our 
experimental results that HEV has a moderate and delayed responsiveness to IFN-α, 
compared with HCV in cell culture models. The HEV subgenomic model only mimics viral 
replication; whereas the HEV infectious cell culture system models the complete life cycle of 
HEV infection. IFN-α probably interferes HEV infection at various steps. Thus, the infectious 
clone appears more sensitive to IFN-α compared to the subgenomic replicon (Figure 2A-C). 
Other types of IFNs, including IFN-λ, did not shown any notable antiviral activity against HEV 
(Figure 3). 
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Previous studies have provided evidence of counteracting IFN response by HEV [33]. In 
our study, we also observed that HEV inoculation could indeed inhibit IFN-α induced 
phosphorylation of STAT1 and attenuate the induction of ISGs in Huh7 cells (Supplementary 
Figure 4C and 4D). Nevertheless, this inhibitory effect was rather minor, which may only 
partially contribute to the resistance of HEV to interferon treatment. Thus, the insensitivity 
and resistance of HEV to IFN treatments may be because of the intrinsic characteristics and 
pathogenesis of HEV itself. Therefore, the scenario of developing IFN-based treatment 
against HEV shall be carefully re-considered. Interestingly, a recent large retrospective, 
multicenter study showed that ribavirin as monotherapy could be very effective for treating 
chronic HEV infection that viral clearance was observed in the majority of patients [34]. In 
contrast, ribavirin monotherapy hardly has detectable effect on HCV viral load reduction[35, 
36]. Only when combined with IFN-α, it doubles the response rate, compared with IFN-α 
alone [37]. 
Despite the inferiority of HEV in responding to exogenous IFN treatment, we in fact 
demonstrated a superior function of the basal interferon signaling, which mediates IFN-α, γ 
and λ signaling transduction, in protecting against HEV infection. Pharmacological inhibition 
of JAK1, the key upstream kinase controlling JAK-STAT cascades of the IFN pathway, has 
resulted in drastic facilitation of HEV but not HCV infection in cell culture models (Figure 4A-
C). Consistently, by gene silencing of JAK1, STAT1 and IRF9, key factors of JAK-STAT cascades, 
HEV replication was efficiently potentiated (Figure 5B-D). These results highlighted the 
importance and mechanisms of basal IFN signaling in protecting HEV infection. 
This probably at least partially explains the distinct incidence of chronic development 
upon exposure to HEV or HCV. In general population, HEV is mostly acute and self-limiting, 
except in very young children, pregnant women and immunocompromised patients that 
could cause severe diseases [1]. Chronic hepatitis E has so far only been reported in 
immunocompromised patients who are lacking of adequate immune defense power[20, 38]. 
However, 55% to 85% individuals infected with HCV are not able to clear the virus, but 
develop chronic hepatitis C [39]. Even an activated endogenous IFN response is ineffective in 
eradicating HCV, once chronic infection is established [40]. The only option to cure chronic 
HCV is antiviral treatment, including IFN-based therapies. The fact that one-third of organ 
transplantation patients with chronic HEV could achieve virus clearance even without any 
treatment, but with dose reduction of immunosuppressant [38], suggests the indispensable 
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role of endogenous innate immunity in HEV recovery. In addition, during the early stage of 
HEV infection, patients always remain subclinical and represent no apparent symptom at all. 
This rapidly turn to a self-limiting illness with spontaneously cleaning of HEV and need no 
specific treatment [41]. The phenomenon of quick clearance of HEV infection by body itself 
without any treatment may be associated to the critical role of defense mechanism of basal 
IFN signaling in combating HEV infection. Therefore, the data in current study delineate that 
endogenous JAK-STAT signaling exerts much potency in protecting against HEV than HCV 
infection. The different sensitivities between HCV and HEV to endogenous IFN signaling may 
also determine the distinct clinical course and outcome between hepatitis C and hepatitis E 
patients. 
In conclusion, we revealed that HEV is in general insensitive to the regulation of 
cytokines and chemokines. IFN-α treatment exerts moderate but delayed antiviral activity 
against HEV infection in experimental models and in patients, which suggested the 
ineffectiveness of interferon-based monotherapy in treating chronic hepatitis E. 
Interestingly, blocking the basal IFN pathway resulted in drastic facilitation of HEV infection, 
suggesting that basal IFN pathway can effectively protect against HEV infection. Thus, this 
study has shed new light on the molecular insight of HEV-host interaction, in particular the 
role of therapeutically activated and the basal IFN signaling. This bears significant 
implications in management of HEV patients and future therapeutic development. 
Supplementary Figures 
 
Supplementary Figure 1.  
Cytokines/chemokines did not affect cell proliferation at 72 hrs determined by MTT assay (OD490 
value) (Mean ± SD, n = 4). 
Chapter 4 
70 | P a g e  
 
 
Supplementary Figure 2. 
(A) IFN-α, (B) IFN-β, (C) IFN-γ, (D) IFN-λ1, (E) IFN-λ2 and (F) IFN-λ3 had significantly more potent 
antiviral effects against HCV than HEV in the subgenomic replication models. Treatment time was 
indicated as 24, 48 or 72 hrs. * P < 0.05; ** P < 0.01.  
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Supplementary Figure 3. 
(A) Western blot showed treatment of Jak inhibitor I for 48 hrs effectively inhibited downstream 
target of JAK1, the phosphorylation of STAT1, induced by treatment of IFN-α or IFN-λ for 30 min. β-
actin served as an internal reference. (B) Jak inhibitor I significantly inhibited the stimulation of the 
IFN response reporter, the ISRE-luciferase transcription reporter by IFN-α or IFN-λ for 30 min. (Mean 
± SD, n = 4). (C) Jak inhibitor I blocked the induction ISGs of RSAD2, ISG15, OAS1 and PKR triggered by 
IFN-α. (D) Jak inhibitor I, AG-490 and CP 690550 did not affect cell proliferation determined by MTT 
assay (OD490 value) (Mean ± SD, n = 3). Treatment time was indicated as 24, 48 or 72 hrs. * P < 0.05; 
** P < 0.01. 
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Supplementary Figure 4.  
(A) The basal expression of 
16 ISGs was determined in 
naïve Huh7 cells by qRT-PCR. 
(B) The expression of 16 ISGs 
were significantly stimulated 
by treatment of 1000 IU/mL 
IFN-α for 24 hrs (Mean ± SD, 
n = 4). (C) Western blot assay 
showed that the elevation of 
p-STAT1 level was 
significantly attenuated 
upon 1000 IU/mL IFN-α in 
HEV infected compared to 
naïve Huh7 cells for 48 hrs. 
β-actin served as an internal 
reference. (Mean ± SD, n = 
3). (D) Inoculation of HEV 
moderately inhibited the 
stimulation of most of 16 
tested IGSs upon treatment 
with 1000 IU/mL IFN-α for 24 
hrs (Mean ± SD, n = 4-6). * P 
< 0.05; ** P < 0.01. 
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Abstract 
Interferons (IFNs) are broad antiviral cytokines that exert their function by inducing the 
transcription of hundreds of IFN-stimulated genes (ISGs). However, little is known about the 
antiviral potential of these cellular effectors on hepatitis E virus (HEV) infection, the leading 
cause of acute hepatitis globally. In this study, we profiled the antiviral potential of a panel 
of important human ISGs on HEV replication in cell culture models by overexpression of an 
individual ISG. The mechanism of action of the key anti-HEV ISG was further studied. We 
identified retinoic acid–inducible gene I (RIG-I), melanoma differentiation–associated protein 
5, and IFN regulatory factor 1 (IRF1) as the key anti-HEV ISGs. We found that basal 
expression of RIG-I restricts HEV infection. Pharmacological activation of the RIG-I pathway 
by its natural ligand 5’-triphosphate RNA potently inhibits HEV replication. Overexpression of 
RIG-I activates the transcription of a wide range of ISGs. RIG-I also mediates but does not 
overlap with IFN-a-initiated ISG transcription. Although it is classically recognized that RIG-I 
exerts antiviral activity through the induction of IFN production by IRF3 and IRF7, we reveal 
an IFNindependent antiviral mechanism of RIG-I in combating HEV infection. We found that 
activation of RIG-I stimulates an antiviral response independent of IRF3 and IRF7 and 
regardless of IFN production. However, it is partially through activation of the Janus kinase 
(JAK)–signal transducer and activator of transcription (STAT) cascade of IFN signaling. RIG-I 
activated two distinct categories of ISGs, one class of JAK-STAT-dependent and the other of 
JAK-STAT-independent, which coordinately contribute to the anti-HEV activity. Conclusion: 
We identified RIG-I as an important anti-HEV ISG that can be pharmacologically activated; 
activation of RIG-I stimulates the cellular innate immunity against HEV regardless of IFN 
production but partially through the JAK-STAT cascade of IFN signaling. 
Keyword: HEV; ISG; Retinoic acid-inducible gene I; JAK-STAT pathway 
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Introduction 
Hepatitis E virus (HEV) infection is the most common cause of acute viral hepatitis worldwide 
[1]. As a single-strand RNA virus, HEV has been divided into 4 genotypes (gt) [1]. Although 
acute HEV infections are mostly self-limiting, gt1 HEV infection during pregnancy may lead to 
high mortality up to 30% [2]. In immunosuppressed patients, such as organ transplant 
recipients, gt3 HEV infection can cause chronic hepatitis [2]. For those chronic patients, 
monotherapy or the combination of ribavirin or/and pegylated Interferon-α (PegIFN-α) have 
been used as off-label treatment [1]. The observation that different populations with 
different status of their immune system have distinct outcomes of HEV infection highlights 
the importance of studying HEV-host interactions. 
The innate immune response plays an essential role in defending viral infections. 
Patients with genetic deficiencies in the innate immune system are often pro to viral 
infection and develop more severe symptoms [3, 4]. In response to viral infection, host cells 
produce virus-induced cytokines including interferons (IFNs), particularly type I IFN (IFN-α 
and -β), which have potent antiviral activity against a broad spectrum of viruses [5]. Type I 
IFNs promote an antiviral state in an autocrine or paracrine manner by transcriptional 
induction of hundreds of interferon-stimulated genes (ISGs) [6]. However, excessive 
accumulation of type I IFNs may evoke pathological effects to the organism [7]. Recently, 
emerging studies have described the type I IFNs independent innate antiviral defense [8, 9]. 
These IFN-independent antiviral mechanisms including the production of alternative antiviral 
cytokines (e.g. IFN-λ or interleukin 22) and the basal expression of direct antiviral ISGs [9]. 
The basal expression of these ISGs may be attributed to tonic IFN signaling and this 
establishes a cell-autonomous antiviral status of the host, but independent of virus-triggered 
IFN production. Therefore, ISGs play important roles in both IFN-dependent and -
independent antiviral mechanisms. 
As the ultimate antiviral effectors, ISGs are transcriptionally induced through the 
Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway by tonic 
or exogenous IFNs. In previous studies, more than 380 individual human ISGs have been 
tested for their antiviral effects on a wide species of viruses including many important 
human and animal viruses [10, 11]. Surprisingly, only small subsets of ISGs exert antiviral 
activities against either a specific or broad spectrum of viruses. Unexpectedly, a few ISGs 
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even promote the replication of certain viruses [10, 11]. Given the fact that IFN-α has anti-HEV 
activity in vitro and is probably also effective in chronic patients [12-14], this strongly suggests 
that ISGs may play a vital role in IFN-mediated HEV clearance. Furthermore, a genome-wide 
transcriptome profiling has identified the up-regulation of 30 genes in blood cells of chronic 
HEV patients, of which 25 are ISGs [15].  
Because the function of ISGs during HEV infection remains largely elusive, we have 
profiled the effects of a panel of ISGs that are known to have anti- or pro-viral effects on 
certain viruses [10, 11]. We found most of these ISGs only have minor but some have potent 
anti-HEV effects. Among those ISGs, RIG-I is a key member that effectively restricts HEV 
replication. Furthermore, biological or pharmacological activation of RIG-I exerts potent anti-
HEV effects. Mechanistically, it robustly activates the innate cellular antiviral response, 
unexpectedly dispensable of IFN production, but requiring the key elements of the JAK-STAT 
signaling. 
Materials and Methods 
HEV cell culture models 
Multiple cell lines were used for supporting HEV replication, including Huh7.5 cells: a RIG-I 
defective hepatoma cell line that derived from Huh7 cells; A549 cells: a human lung 
epithelial carcinoma cell line that widely used for supporting HEV replication [16]. HepaRG 
cells: a hepatic cell line which retains many characteristics of primary human hepatocytes 
that also permissive for HEV replication. For the full-length HEV model, a plasmid construct 
containing the full-length HEV genome (Kernow-C1 p6 clone, GenBank Accession Number: 
JQ679013) was linearized at a 3’ terminal MluI. Capped HEV viral RNA transcripts were 
generated by the Ambion mMESSAGE mMACHINE® in vitro RNA transcription Kit (Thermo 
Fisher Scientific Life Sciences) [16]. Huh7.5 cells, A549 cells and HepaRG cells were 
electroporated using the Bio-Rad’s electroporation systems (240 V, pulse length 0.5, number 
1 and cuvette 4 mm) with full-length HEV viral RNA to generate consecutive HEV-infected 
cell models, Huh7.5-p6, A549-p6 and HepaRG-p6. Briefly, cells were collected and washed 
with 5 mL Opti-MEM (Thermo Fisher Scientific Life Sciences) for three times. The cell pellet 
was resuspended with 100 µL Opti-MEM and mixed with 10 µg p6 full-length HEV RNA and 
then subjected to electroporation. To generate the subgenomic (p6-Luc) HEV model, a 
construct containing subgenomic HEV was also used. This plasmid has an HEV sequence in 
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which the 5’ portion of HEV ORF2 was replaced with the in-frame Gaussia princeps luciferase 
reporter gene to generate subgenomic (p6-Luc) [16]. The luciferase has a signal sequence that 
let it secreted into medium, and therefore, measurement of secreted luciferase activity 
represents HEV replication levels. Huh7.5 cells were electroporated as described above with 
HEV subgenomic RNA to generate subgenomic HEV replication model, Huh7.5-p6-Luc.  
HEV reinfection assays 
Supernatant that contains HEV viral particles were collected from the full-length HEV 
infectious cells (Huh7.5-p6) that cultured for 96 h. The supernatant was filtered by 0.45 μm 
filter to get rid of dead cell and then was centrifuged for 30 min (10 000 rpm) to remove cell 
debris. Next, 2 h ultracentrifugation (22 000 rpm) was used to purify and concentrate HEV 
virus particles (SW28 rotor; Beckman Coulter, Brea CA, USA). Subsequently, the collected 
pellet was resuspended and was diluted to 1 × 107 HEV viral RNA copies/mL and then stored 
at -80 °C as described previously [17]. For HEV infection assay, Huh7.5 and A549 cells were 
seeded into 12-well plates at a density of 7 × 104 cells per well. The next day, for each well, 
400 µL HEV stock that contains 1 × 107 viral RNA copies/mL HEV was incubated with target 
cells at 37 °C for 6 h. Next, the HEV inoculum was removed and cell layers were washed 3 
times with 1 mL PBS followed by adding 1 mL fresh medium to each well. For 6-well plates, 
cells were seeded at a density of 1.4 × 105 per well. The next day, for each well, target cells 
were incubated with 800 µL HEV stock at 37 °C for 6 h. Then, the HEV inoculum was 
removed and washed as usual and then added 2 mL fresh medium. 
Lentivirus production and transduction assays 
pTRIP.CMV.IVSb.ISG.ires.TagRFP based ISG overexpression vectors were kind gifts from Prof. 
Charles M. Rice (the Rockefeller University) [10]. Two vectors expressing Photinus pyralis 
luciferase (Fluc) or GFP as reporter genes were used as a control. Lentiviral pseudoparticles 
were generated in 293T cells by co-transfection of ISG expression plasmid 
(pTRIP.CMV.IVSb.ISG.ires.TagRFP), HIV gag-pol and VSV-G in a ratio of 1: 0.8: 0.2 as 
described and lentiviral stocks were stored at -80 °C [10]. For transduction assays, cells were 
seeded into 24-well plates at a density of 5 × 104 cells per well and transduced with lentiviral 
pseudoparticles at 37 °C. pLKO.1 based shRNA lentiviral vectors (Biomics Center in Erasmus 
Medical Center) targeting RIG-I was used to knockdown RIG-I gene expression and 
scrambled control vector (shSCR) was used as a control. Lentiviral pseudoparticles were 
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generated as described previously [17]. To obtain stable gene knockdown cell line, cells were 
transduced with shRNA lentiviral particles for 3 days and selected by puromycin (Sigma-
Aldrich, Zwijndrecht, the Netherlands) at a concentration of 2.5 μg/mL. After selection, 
optimal knockdown cell lines were chosen. The shRNA sequences are listed in Table S1 in 
Supporting Information. 
Statistical analysis 
GraphPad Prism 5 software was used for data analysis using a Mann-Whitney test. All results 
were presented as mean ± standard errors of the means (SEM). P values of less than 0.05 
(single asterisks in figures) were considered statistically significant; whereas P values less 
than 0.01 (double asterisks) and 0.001 (triple asterisks) were considered highly significant. 
Further details are provided in the Supporting Information. 
Results 
Identification of antiviral ISGs against HEV replication 
To identify key ISGs that regulate HEV replication, 25 important human ISGs which are 
known to have anti- or pro-viral effects on certain viruses [10] were tested in two Huh7.5 cells 
based HEV models (Huh7.5-p6-Luc and Huh7.5-p6). Huh7.5 is an RIG-I defective hepatoma 
cell line derived from Huh7 cells, which was widely used for supporting viral infections 
(Supporting Fig. S1A) [18]. These ISGs include MAP3K14, IFI44L, RIG-I (also known as DDX58), 
HPSE, RTP4, NAMPT (also known as PBEF1), IRF1, IFITM1, IFITM2, IFITM3, C6orf150 (also 
known as cGAS), UNC84B (also known as SUN2), IRF2, IRF7, IRF9, IFI6, OASL, DDX60, MOV10, 
TREX1, MDA5 (also known as IFIH1), ADAR, FAM46C, LY6E and MCOLN2 [10].  
Ectopic overexpression of each ISG was delivered by a bicistronic lentiviral vector co-
expressing the ISG and a red fluorescent protein (TagRFP). Two vectors that express a 
Photinus pyralis luciferase (Fluc) gene or a green fluorescent protein (GFP) gene were used 
as controls [10]. The successful overexpression of each ISG was confirmed by flow cytometry 
analysis to measure the expression of TagRFP (Supporting Fig. S1B-S1F). Transient 
transfection was used to overexpression ISG when lentiviral stocks failed to achieve high-
level transduction [10]. Before profiling on HEV, each ISG was first tested for the ability to 
inhibit HCV replication in Huh7.5 cell-based HCV luciferase replicon model [10]. Similar to the 
previous study, most ISGs inhibit HCV replication to some extent; whereas several genes 
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(IRF1, IRF2 and RIG-I) have strong anti-HCV effects (Supporting Fig. S1G). Next, all ISGs were 
tested for their anti-HEV ability in a subgenomic HEV model (Huh7.5-p6-Luc). At 24 h after 
lentivirus transduction, most genes inhibited HEV-related luciferase activity to some extent 
(Fig. 1A). One gene named RIG-I was found to have strong anti-HEV activity at 48 h post 
transduction (Fig. 1B). More anti-HEV ISGs were identified 72 h after transduction, including 
IRF1, MDA5 and RIG-I (Fig. 1C). These genes could inhibit HEV-related luciferase activity by 
almost 50% compared to control. To further validate the antiviral ability, those ISGs were 
also tested in the full-length infectious HEV model (Huh7.5-p6). A similar inhibition pattern 
was obtained in this model (Fig. 1D). At 48 h after transduction, IRF1, MDA5 and RIG-I 
potently decreased HEV viral RNA level; whereas most of the other genes showed minor 
effects.  
 
FIG. 1. Identification of ISGs that inhibit HEV replication. 
Luciferase activity analysis of HEV-related Gaussia luciferase activity in Huh7.5-p6-Luc cells 
transduced with ISG overexpression or Fluc vector for 24 h (A), 48 h (C) or 72 h (C) (n = 4 independent 
experiments with each of 2 replicates). RLU: relative luciferase unit. (D) qRT-PCR analysis of HEV viral 
RNA level in Huh7.5-p6 cells transduced with ISG overexpression or Fluc vector for 48 h (n = 4). Data 
were normalized to the Fluc control (set as 1) and presented in dot plots. 
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RIG-I is a key anti-HEV ISG 
Among these three potent anti-HEV ISGs, we have previously demonstrated that IRF1 
inhibits HEV replication by stimulating antiviral ISG expressions [17]. Both RIG-I and MDA5 are 
pattern recognition receptors (PRRs) that sense viral RNA in the cytoplasm [19]. In this study, 
we mainly focused on the antiviral potential of RIG-I. To validate the anti-HEV activity of RIG-
I, we performed additional independent experiments in two Huh7.5-based HEV models 
(Huh7.5-p6 and Huh7.5-p6-Luc). Lentiviral transduced RIG-I overexpression was confirmed in 
Huh7.5-p6 cells by qRT-PCR and immunoblotting (Fig. 2A). In both models, RIG-I 
overexpression inhibited HEV replication to an extent similar to a high dose of IFN-α 
treatment (Fig. 2B). Next, we confirmed the anti-HEV ability of RIG-I in different cell models: 
a human lung epithelial cell line A549 that is widely used for HEV propagation and a human 
hepatic progenitor cell-derived cell line HepaRG. Both of them are capable of supporting 
long-term HEV replication (A549-p6 and HepaRG-p6) [17]. As shown in Fig. 2C and 2D, RIG-I 
overexpression also significantly inhibited HEV replication in both HepaRG and A549 based 
HEV models. 
To further explore the role of basal RIG-I in constraining HEV infection, RNAi 
approach was used to silence RIG-I gene expression. HEV RNA level was significantly 
increased in RIG-I silenced A549 cells (Fig. 2E and 2F). As expected, in RIG-I defective Huh7.5 
cells, RIG-I knockdown did not affect HEV infection (Supporting Fig. S2A and S2B) and we 
indeed observed that RIG-I defected Huh7.5 cell are more permissive for supporting HEV 
infection (Supporting Fig. S2C). These results have demonstrated that RIG-I has potent anti-
HEV ability and the basal expression of RIG-I plays important role in defending HEV infection. 
Pharmacological activation of RIG-I stimulates an antiviral response that 
inhibits HEV replication 
To explore the antiviral response induced by RIG-I pathway, the natural ligand of RIG-I 
5’pppRNA was used to activate the RIG-I signaling [20]. Different concentrations of RIG-I 
agonist were used to induce an antiviral response in A549 cells, a model with functional RIG-
I expression (Supporting Fig. S1A). As shown in Fig. 3A, gene expression of type I IFN (IFN-β) 
and type III IFN (IFN-λ) was significantly induced by RIG-I agonist 48 h or 72 h after treatment. 
Concurrently, the expression of many ISGs including STAT1, IFIH1, PKR, TRAIL, RANTES and 
RIG-I were also significantly induced by 5’pppRNA treatment (Fig. 3A). 
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FIG. 2. RIG-I inhibits HEV replication in multiple cell models. 
qRT-PCR analysis and immunoblot analysis of RIG-I expression in Huh7.5-p6 cells (A), A549-p6 cells 
(C) and HepaRG-p6 cells (D) transduced with RIG-I, Fluc vector or treated with IFN-α (1000 IU/mL) for 
48 h (qRT-PCR: n = 4). (B) Analysis of HEV-related Gaussia luciferase activity in Huh7.5-p6-Luc cells 
transduced with RIG-I, Fluc vector or treated with IFN-α (1000 IU/mL) for 24 h, 48 h or 72 h (n = 4 
independent experiments with each of 3 - 4 replicates) and qRT-PCR analysis of HEV viral RNA level in 
Huh7.5-p6 cells transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) for 48 h (qRT-PCR: n 
= 8). RLU: relative luciferase unit. qRT-PCR analysis of HEV viral RNA level in A549-p6 cells (C) and 
HepaRG-p6 cells (D) transduced with RIG-I, Fluc vector or treated with IFN-α (1000 IU/mL) for 48 h (n 
= 4). (E) Immunoblot analysis of RIG-I expression in A549 cells transduced with lentiviral shRNA 
vector targeting RIG-I (shRIG-I(1) and shRIG-I(2)) or scrambled control (shSCR). Stable RIG-I 
knockdown or shSCR control A549 cells were infected with HEV. RIG-I expression level and HEV viral 
RNA level (F) were analyzed by qRT-PCR 72 h after HEV infection. Data were normalized to the Fluc 
control (CTR, set as 1, A-D) or to the scrambled control (shSCR, set as 1, F). Data are means ± SEM. *P 
< 0.05; **P < 0.01; ***P < 0.001; NS, not significant. For immunoblot results (A, C, D and E), band 
intensity of each lane was quantified by Odyssey Software. Immunoblot quantification results were 
normalized to β-actin expression and control was set as 1.  
Correspondingly, treatment with RIG-I agonist has resulted in a significant reduction 
of HEV replication in A549-p6 cells. With 1000 ng/mL 5’pppRNA treatment, the HEV viral 
RNA were inhibited by 67.8% ± 8.1% (mean ± SEM) (n = 7; P < .01), 90.0% ± 8.6% (n = 6; P 
< .01) at 48 h and 72 h after treatment, respectively (Fig. 3B). Since Huh7.5 cells are RIG-I 
defected cells (Supporting Fig. S1A), RIG-I agonist was unable to induce any antiviral 
response as expected (Supporting Fig. S2D).  
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FIG. 3. 5’pppRNA stimulates an antiviral response that inhibits HEV.  
A549-p6 cells were transfected with various concentrations of 5’pppRNA (10 ng/mL, 100 ng/mL and 
1000 ng/mL), IFN gene mRNA levels, ISG mRNA levels (A) and HEV viral RNA level (B) were analyzed 
by real-time qRT-PCR 48 h or 72 h after transfection (A: n = 3-5; B: n = 6-8). Data were normalized to 
a control that was transfected with PEI-Mix but without 5’pppRNA at each time point (48 h and 72 h, 
both set as 1), respectively. Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant. 
To clarify whether the antiviral activity of 5’pppRNA exclusively relies on RIG-I 
pathway, we employed wild-type mouse embryonic fibroblasts (MEF) cells (WT, RIG-I+/+) and 
RIG-I deficient MEF cells (RIG-I−/−). These two MEF cell lines were transfected with different 
concentrations of 5’pppRNA. 1000 ng/mL 5’pppRNA treatment induced mouse IFN genes 
(mouse IFN-β, mIFN-β; mouse IFN-λ, mIFN-λ) more than 1000-fold at 24 h after stimulation 
(Supporting Fig. S3A). In contrast, no IFN gene was induced in RIG-I−/− MEF, indicating that 
this is exclusively dependent on the RIG-I signaling (Supporting Fig. S3A). Meanwhile, 
5’pppRNA activated the expression of many mouse ISGs, including mMX1, mIRF9, mIFIH1, 
mSTAT1, mIRF1, mPML, mXAF, mIRF7, mISG15 and mRIG-I in RIG-I+/+ MEF cells (Supporting 
Fig. S3A). After 48 h treatment, IFN gene and ISG expression was significantly induced by 
5’pppRNA, although, to a less extent compared to 24 h after treatment (Supporting Fig. S3B). 
Hence, the anti-HEV activity of 5’pppRNA was specifically via RIG-I. We now demonstrated 
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that pharmacological activation of RIG-I stimulates an antiviral response that inhibits HEV 
replication specifically via RIG-I. 
RIG-I activates the transcription of a wide range of ISGs 
RIG-I has been shown to trigger STAT1 activation and ISG expression [21]. In general, the 
activation of STAT1 leads to the formation and nuclear translocation of IFN-stimulated gene 
factor 3 (ISGF3). This complex further binds to the IFN-stimulated response element (ISRE) 
motifs in the genome DNA and drives the transcription of ISGs. A recent study has reported 
that RIG-I overexpression stimulates ISRE promoter activity [22]. Thus, we employed a 
transcriptional reporter system that mimics IFN response with a reporter luciferase gene 
that was driven by multiple ISREs (ISRE-Luc). As shown in Fig. 4A, RIG-I significantly increased 
the ISRE-related luciferase activity. The activation of ISRE element usually leads to the 
transcription of ISGs that contain this element in their promoter regions. Therefore, we 
measured gene expression of a wide range of important antiviral ISGs. As shown in Fig. 4B-
4D, RIG-I overexpression stimulated the expression of a large number of ISGs in Huh7.5, 
A549 and HepaRG cells. Interestingly, the ISG expression pattern induced by RIG-I was 
different from IFN-α treatment (Supporting Fig. S4A-S4C). The induction of some important 
ISGs was further confirmed by immunoblotting at protein levels (Fig. 4E and 4F).  
RIG-I mediates IFN-α-induced antiviral ISG transcription 
Gene expression profile analysis in the previous study revealed that 5’pppRNA treatment 
induced a distinct transcriptome compared to IFN-α treatment [20]. Besides, as a nucleic acid 
sensor, RIG-I is also an ISG that can be induced by IFN-α treatment and we already 
demonstrated that RIG-I activates the expression of many ISGs (Fig. 4). Therefore, we 
hypothesized that RIG-I may reinforce the IFN-α initiated ISG induction. We thus 
investigated the association of RIG-I expression with the response to IFN-α treatment. 
Indeed, in RIG-I overexpressed Huh7.5 cells, IFN-α induced ISG expression was significantly 
enhanced (Fig. 5A). Similarly, IFN-α induced ISG expression was also enhanced in RIG-I 
transduced A549 cells (Fig. 5B).  
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FIG. 4. RIG-I activates the transcription of a wide range of ISGs. 
(A) Analysis of ISRE related firefly luciferase activity in Huh7-ISRE-Luc cells transduced with RIG-I 
vector or treated with IFN-α (1000 IU/mL) for 48 h (n = 3 independent experiments with each of 1-2 
replicates). qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells (B), A549-p6 cells (C) and 
HepaRG-p6 cells (D) transduced with RIG-I or Fluc vector for 48 h (n = 6). Immunoblot analysis of ISG 
protein levels in Huh7.5-p6 cells (E) and A549-p6 cells (F) transduced with RIG-I or Fluc vector for 48 
h or 72 h. Date in (A) were normalized to the untreated Fluc control (CTR, set as 1). Data in (B-D) 
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were normalized to the Fluc control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; 
***P < 0.001; NS, not significant. For immunoblot results (E and F), band intensity of each lane was 
quantified by Odyssey Software. Immunoblot quantification results were normalized to β-actin 
expression and control was set as 1. 
To further determine the role of RIG-I in IFN-α-activated cell signaling, the RIG-I 
knockdown A549 cell line and RIG-I deficient MEF cell line (RIG-I-/-) were employed. In A549 
cells, RIG-I deficiency significantly attenuated the ISG induction ability of IFN-α (Fig. 5C). 
Consistently, in RIG-I deficient MEF cells (RIG-I-/-), the ISG induction ability of mIFN-α (mouse 
IFN-α) was also significantly reduced (Fig. 5D). In contrast, the ISG induction ability of mIFN-α 
was not affected in IRF3/7-/- or NFκB-/- MEF cells (Supporting Fig. S5A and S5B). Taken 
together, these results demonstrated that RIG-I functionally contributes to the antiviral ISG 
induction ability of IFN-α. 
RIG-I activates the innate anti-HEV immune response dispensable of 
interferon production 
RIG-I is a cytosolic nucleic acid sensor and the binding of viral RNA to RIG-I leads to the 
activation of downstream pathways that eventually triggers IFN gene expression via IRF3 and 
IRF7 [19]. In turn, the secreted IFNs establish antiviral response in infected and surrounding 
cells by stimulating the expression of ISGs. To further study the ISG induction ability of RIG-I 
pathways, the activator of RIG-I 5’pppRNA were transfected in IRF3/7 double knockout MEF 
cells (IRF3/7-/-). Indeed, 5’pppRNA failed to induce IFN-β expression in the IRF3/7-/- cells (Fig. 
6A). Strikingly, 5’pppRNA is still capable of inducing ISGs in the absent of IRF3/7 and IFN-β 
expression (Fig. 6B). These results indicate RIG-I could also stimulate ISG transcription in IFN- 
independent manners. Next, we determined the mRNA expression levels of IFN genes in RIG-
I overexpressed Huh7.5 cell line, a cell line that unable to produce any IFNs [23]. We found 
that the mRNA expression level of IFN genes was very low and no IFN gene (IFN-α, -β and -λ) 
was induced by RIG-I overexpression in Huh7.5-p6 cells (Fig. 6C, Supporting Fig. S6A). 
Furthermore, no IFN gene was up-regulated in HepaRG-p6 cells by RIG-I overexpression 
(Supporting Fig. S6B-S6C). To confirm the lack of IFN production in these RIG-I overexpressed 
cells, conditioned medium (supernatant) from the RIG-I transduced Huh7.5-p6 cells was 
collected (Fig. 6D). Two IFN sensitive assays were performed: an IFN functional assay and an 
HCV replicon-based bioassay. The IFN functional assay was based on a transcriptional 
reporter system that mimics IFN response as used above (Fig. 4A). As shown in Fig. 6E, 
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FIG. 5. RIG-I mediates IFN-
α-induced antiviral ISG 
transcription. 
qRT-PCR analysis of ISG 
mRNA expression levels. 
Huh7.5 cells were 
transduced with RIG-I or 
Fluc vector, at 48 h post-
transduction cells were 
treated with IFN-α (1000 
IU/mL) for 3 h or 6 h (A) (n = 
4). A549 cells were 
transduced with RIG-I or 
Fluc vector, at 48 h post- 
transduction cells were 
treated with IFN-α (1000 
IU/mL) for 3 h or 6 h (B) (n = 
4). Data in (A and B) were 
normalized to untreated the 
Fluc control (CTR, set as 1). 
A549 cells were transduced 
with lentiviral shRNA vectors 
targeting RIG-I or scrambled 
control (shSCR). The stable 
RIG-I knockdown and 
control A549 cells were 
treated with IFN-α (1000 
IU/mL) for 3 h or 6 h (C). ISG 
mRNA levels were analyzed 
by qRT-PCR (n = 6). qRT-PCR 
analysis of mouse ISG mRNA 
levels in WT and RIG-I-/- MEF 
cells treated with mouse 
IFN-α (mIFN-α, 1000 IU/mL) 
for 3 h or 6 h (D) (n = 6). 
Data in (C) were normalized 
to the untreated scrambled 
control (shSCR CTR, set as 
1). Data in (D) were 
normalized to untreated WT 
MEF cells (WT CTR, set as 1). 
Data are means ± SEM. *P < 
0.05; **P < 0.01; ***P < 
0.001; NS, not significant. 
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conditioned 
medium collected 
from RIG-I 
overexpressed 
Huh7.5-p6 cells 
was not able to 
induce ISRE 
activation. 
Furthermore, this 
conditioned 
medium did not 
affect HCV-related 
luciferase activity 
(Fig. 6F). Similarly, 
conditioned 
medium collected 
from HepaRG cells 
also failed to 
activate ISRE-
related luciferase 
activity 
(Supporting Fig. 
S6D). These results 
suggest that 
ectopic 
overexpression of 
RIG-I did not 
trigger IFN 
expression and 
production. Thus, 
we demonstrated that RIG-I could activate innate immune response dispensable of IFN 
production. 
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FIG. 6. RIG-I activates an immune response dispensable of interferon production. 
WT and IRF3 and IRF7 double deficient (IRF3/7-/-) mouse embryonic fibroblasts (MEF) cells were 
transfected with various concentrations of 5’pppRNA (100 ng/mL and 1000 ng/mL), mouse IFN-β 
(mIFN-β) (A) and mouse ISG (B) mRNA levels were analyzed by qRT-PCR 24 h after transfection (n = 
6). (C) qRT-PCR analysis of IFN gene mRNA levels in Huh7.5-p6 cells transduced with RIG-I or Fluc 
vector for 48 h (n = 4). (D) Production of conditioned medium (supernatant). Cells were transduced 
with RIG-I or GFP (CTR) vector for 72 h and then the cells were washed 5 times and medium was 
refreshed. Cells were cultured for another 72 h and supernatant was collected as conditioned 
medium. Analysis of ISRE-related firefly luciferase activity in Huh7-ISRE-Luc cells (E) or HCV-related 
firefly luciferase activity in Huh7.5-ET-Luc cells (F) that treated with conditioned medium from 
Huh7.5 cells or various concentrations of IFN-α for 48 h (n = 3 independent experiments with each of 
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3 - 4 replicates). Data in (A) and (B) were normalized to a control that transfected with PEI-Mix but 
without 5’pppRNA in each cell line (WT and IRF3/7-/-, both set as 1), respectively. Data in (C) was 
normalized to the Fluc control (CTR, set as 1). Data in (E) and (F) were normalized to the untreated 
GFP control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant. 
RIG-I mediated ISG transcription and anti-HEV activity partially through 
activation of JAK-STAT pathway. 
The previous study has demonstrated that RIG-I can augment STAT1 activation, which is a 
key element of JAK-STAT cascade within the IFN pathway [21]. Consistent with these results, 
we also observed that RIG-I overexpression induced the phosphorylation of STAT1 at 701 
site in Huh7.5-p6 cells, which is an indispensable marker of JAK-STAT pathway activation (Fig. 
7A).  
To elucidate whether the ISG induction and anti-HEV abilities of RIG-I are through the 
activation of STAT1, we used a JAK inhibitor named CP-690550 (Tofacitinib) to 
pharmacologically block the JAK-STAT pathway. In Huh7.5-p6 cells, RIG-I and IFN-α induced 
STAT1 phosphorylation were totally blocked by CP-690550 (Fig. 7B). Meanwhile, lentiviral-
delivered RIG-I overexpression was not affected by this inhibitor (Fig. 7B and 7C). 
Surprisingly, we found that RIG-I-induced ISRE activation was not totally diminished by this 
inhibitor; whereas IFN-α triggered ISRE activation was totally blocked (Fig. 7C). These results 
suggest that RIG-I-induced ISRE activation partially independent of its STAT1 
phosphorylation ability. Next, we tested the mRNA expression level of 23 RIG-I inducible 
ISGs in RIG-I overexpressed Huh7.5-p6 cells treated with JAK inhibitor CP-690550. 
Surprisingly, among these 23 tested RIG-I inducible ISGs, only 10 genes were affected by CP-
690550 treatment, but the others were not affected at all (Fig. 7D and 7E). As a positive 
control, the expression level of all these 23 genes that induced by IFN-α was totally 
diminished by this inhibitor (Supporting Fig. S7A and S7B). Consequently, the anti-HEV ability 
of RIG-I was only partially blocked by CP-690550; whereas the anti-HEV effects of IFN-α were 
totally abolished (Fig. 7F). To further confirm these results, another JAK inhibitor named JAK 
inhibitor 1 was used to treat RIG-I transduced Huh7.5-p6 cells. As expected, similar results 
were obtained (Supporting Fig. S8). To explore whether this is a common mechanism in 
different cell lines, we also used this JAK inhibitors 1 to treat RIG-I overexpressed HepaRG-p6 
cells and similar results were obtained (Supporting Fig. S9). 
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FIG. 7. JAK inhibitor CP-690550 partially diminishes RIG-I-induced ISG transcription and anti-HEV 
activity. 
(A) Immunoblot analysis of p-STAT1 (Tyr701) expression in Huh7.5 cells transduced with RIG-I vector 
or treated with IFN-α (1000 IU/mL) for 48 h or 72 h. (B) Immunoblot analysis of ISG protein levels in 
Huh7.5 cells transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) or CP-690550 (1000 
ng/mL) for 48 h. qRT-PCR analysis of RIG-I mRNA level in Huh7.5-p6 cells and analysis of ISRE-related 
firefly luciferase activity in Huh7-ISRE-Luc cells (C) transduced with RIG-I vector or treated with IFN-α 
(1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h (qRT-PCR: n = 4; ISRE: n = 3 independent 
experiments with each of 2 replicates). (D and E) qRT-PCR analysis of ISG mRNA levels in Huh7.5 cells 
transduced with RIG-I vector or treated with CP-690550 (1000 ng/mL) for 48 h (n =5-6). (F) Analysis 
of HEV related Gaussia luciferase activity in Huh7-p6-Luc cells transduced with RIG-I vector or treated 
with IFN-α (1000 IU/mL) or CP-690550 (1000 ng/mL) for 72 h. (n = 4 independent experiments with 
each of 3 - 4 replicates). For immunoblot results (A and B), band intensity of each lane was quantified 
by Odyssey Software. Immunoblot quantification results were normalized to β-actin expression and 
control was set as 1. Data in (C left panel, D and E) were normalized to the untreated Fluc control 
(CTR, set as 1). Date in (C right panel and F) were normalized to the untreated GFP control (CTR, set 
as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
To further confirm the ISG induction ability of RIG-I is not totally dependent on the 
JAK-STAT pathway, we overexpressed RIG-I in STAT1 deficient human (STAT1-/-) fibrosarcoma 
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cells [24]. In STAT1-/- cell, RIG-I failed to induce STAT1 phosphorylation (Fig. 8A). A similar ISG 
induction pattern was also observed in RIG-I overexpressed STAT1-/- cells. Some genes such 
as STAT1, IRF9 and IFI6 can only be induced in WT cell but not in STAT1-/- cells by RIG-I, 
although RIG-I overexpression level was similar in both cell lines (Fig. 8B and 8C). Meanwhile, 
another group includes genes that can be activated in both WT and STAT1-/- cells such as 
IFIT1, RANTES and CXCL10 (Fig. 8D). As a control, IFN-α induced ISG transcription was totally 
abolished in STAT1-/- cells (Supporting Fig. S10A). Together, these results demonstrated that 
RIG-I activates ISG transcription and exerts its anti-HEV activity partially through the 
activation of the JAK-STAT pathway. 
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FIG. 8. The ISG induction ability of RIG-I is partially diminished in STAT1 deficient cells. 
(A) Immunoblot analysis of ISG protein levels in WT and STAT1 deficient (STAT1-/-) fibrosarcoma cells 
transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) for 48 h. (B) qRT-PCR analysis of 
RIG-I mRNA level in WT and STAT1-/- cells transduced with RIG-I vector or treated with IFN-α (1000 
IU/mL) for 48 h (n =4-5). (C and D) qRT-PCR analysis of ISG mRNA levels in WT and STAT1-/- cells 
transduced with RIG-I or Fluc vector for 48 h (n = 4-5). For immunoblot results (A), band intensity of 
each lane was quantified by Odyssey Software. Immunoblot quantification results were normalized 
to β-actin expression and control was set as 1. Data in (C) were normalized to the untreated Fluc 
control (CTR, set as 1). Date in (D) and (E) were normalized to untreated WT and STAT1-/- cells, 
respectively (both set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant. 
Discussion 
Currently, IFNs in particular IFN-α have been approved for treating viral infections including 
chronic hepatitis B (HBV) and C virus (HCV) infections [6]. In some cases, IFN-α has been used 
as an off-label drug to treat chronic HEV infection [12, 25]. In vitro study also showed the 
inhibition of HEV replication by IFN-α treatment [13, 14, 26]. IFN-α exerts its antiviral ability 
through the induction of ISGs, but how these ISGs affect HEV replication are still largely 
unknown. This study comprehensively profiled the antiviral ability of many important human 
ISGs described previously [10]. We found that most of these ISGs showed minor anti-HEV 
effect. In contrast, several previously reported broad antiviral ISGs including MDA5, IRF1 and 
RIG-I were identified as strong anti-HEV ISGs. Previously, we have demonstrated that IRF1 
inhibits HEV replication by activating antiviral ISGs [17]. RIG-I is a pattern recognition receptor 
(PRR) and numerous studies have demonstrated that it plays important roles in defending a 
wide spectrum of virus infections such as HCV [10, 20], HBV [27] and influenza virus [28]. Here, in 
this study we comprehensively investigated the antiviral potential of RIG-I and its 
mechanism-of-action. 
RIG-I, as a PPR, senses the viral RNA in the cytoplasm during infection. Binding of RIG-
I with its ligand such as 5’-triphosphorylated RNA activates the downstream signaling 
pathway through the adaptor proteins mitochondrial antiviral signaling protein (MAVS). 
Classically, the aggregation of MAVS in mitochondrial subsequently leads to the production 
of type I and III IFNs through the phosphorylation of IRF3 and IRF7. The produced IFN 
proteins subsequently activate ISG expression in infected and bystander cells to eradicate 
the virus and prevent further infections. In this study, we observed overexpression of RIG-I 
activated transcription and expression of a wide range of ISGs, and many of them are known 
to have strong antiviral activities [10, 11, 17, 20, 29-32]. 
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Although working as a cytosolic nucleic acid sensor that triggers IFN production, RIG-I 
itself is also an ISG regulated by IFN-initiated JAK-STAT cascade. This feedback amplification 
loop is able to enhance the responsiveness of host cells to infection. It has been shown that 
5’pppRNA treatment induced a broader transcriptome compared to IFN-α treatment. 
Consistently, we found that a combinatorial action of IFN-α treatment and RIG-I 
overexpression in ISG induction and anti-HEV activity. Conversely, IFN-α induced ISG 
transcription was attenuated when RIG-I was deleted (Fig. 5). These results suggest that RIG-
I partially mediates the ISG transcription activity of IFN-α. 
Classically, the main antiviral function of RIG-I is believed via the induction of IFN 
production upon sensing cytosolic viral nucleic acid. However, we found that RIG-I 
overexpression in our models doesn’t induce the production of IFNs, but triggers the 
transcription of a wide range of genes including ISGs, chemokines and cytokines, without the 
activation of downstream MAVS pathway (Fig. 4E). In fact, emerging recent studies have 
proposed additional antiviral mechanisms of RIG-I that are partially dependent or 
independent of IFNs [27, 28, 33]. 
It has been demonstrated that induction of ISGs and antiviral ability by RIG-I 
activation were only partially reduced in the absence of IFN-α/β receptors [20]. Additionally, 
RIG-I can exert broad antiviral activity in the models that have defected IFN signaling [10]. We 
now observed that in cells that lacking of the key downstream components of RIG-I pathway 
(IRF3 and IRF7), the RIG-I activator 5’pppRNA is still able to induce ISG expression (Fig. 6A) 
without activating IFN genes. In line with this, we also observed that in Huh7.5 cells (a cell 
line which could not produce any IFN protein), RIG-I overexpression induces ISG 
transcription and exerts potent anti-HEV activity (Fig. 2). Together with recent reports, our 
observations strongly support that RIG-I can also execute its antiviral action via IFN-
independent mechanisms. However, these IFN-dispensable actions are diverse and their 
exact mechanisms remain largely elusive. 
Typically, the activation of RIG-I will trigger the activation of IRF3/7 and NF-κB 
through the MAVS antiviral singling.[20, 34] Activation of NF-κB pathway leads to the 
transcription of many pro-inflammatory genes including IFN genes. Our previous study also 
revealed that the NF-κB complex can directly bind to ISRE and drives its transcription of 
some ISGs.[35] Interestingly, many of the pro-inflammatory genes are regulated by both the 
NF-κB and JAK-STAT pathways. For instance, the transcription of CXCL10 is positively 
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regulated by ISRE and NF-κB during viral infection.[36] It has been reported that MEF cells 
with a defected NF-κB pathway were more sensitive to the antiviral action of type I IFN.[37] 
We also observed that the IFN induced expression of some ISGs was enhanced in NF-κB KO 
MEF cells; whereas the expression of other genes was lower or unaffected (Supporting Fig. 
S5). Furthermore, a subset of RIG-I induced ISGs were unaffected when JAK-STAT pathway 
was blocked (Fig 7E), indicating the involvement of additional regulatory mechanisms. Thus, 
RIG-I and its down downstream pathways form a large complex web. Besides JAK-STAT 
cascade, other pathways such as NF-κB may also involve the regulation of RIG-I mediated ISG 
induction and antiviral activity.  
A previous study demonstrated that RIG-I overexpression triggers STAT1 activation 
and ISG expression independent of its canonical MAVS pathway [21]. We now confirmed that 
overexpression of RIG-I activated STAT1 phosphorylation at 701 site (Fig. 7A) without the 
involvement of IFNs. We further addressed the contribution of STAT1 phosphorylation to the 
anti-HEV action of RIG-I. By using pharmacological inhibitors to block the JAK-STAT pathway, 
we demonstrated that RIG-I induced ISG transcription and anti-HEV activity is only partially 
but IFN-α mediated effect are totally dependent on this cascade. Furthermore, in a JAK-STAT 
deficient cell model, only a small proportion of RIG-I inducible ISGs were affected upon RIG-I 
overexpression. We thus classified these RIG-I inducible ISGs into two categories. One group, 
including STAT1, IRF1 and IRF9, is completely dependent on RIG-I-induced STAT1 
phosphorylation. The other group, including IFIT1, IFIH1 and RANTES, is induced 
independently of JAK-STAT pathway. Of note, both subsets may contribute to the anti-HEV 
ability of RIG-I, since the anti-HEV action of RIG-I was only partially attenuated by blocking 
JAK-STAT pathway (Fig. 7E). Recently, accumulating evidence unrevealed direct antiviral 
action of RIG-I independent of its downstream IFN production effect [27, 28, 33]. However, 
whether RIG-I has the direct anti-HEV effect is still unknown and need further investigation. 
IFN-α and ribavirin have been used as monotherapy or combination for treating 
chronic HEV patients. Ribavirin monotherapy appears effective in many patients but failed in 
a substantial proportion of cases probably due to the development of drug resistance 
mutations in the viral genome [38-40]. IFN-α seems also effective but is associated with organ 
rejection, since most of the chronic HEV patients are immunocompromised organ recipients 
[41]. It is also well-known that excessive exposure to IFNs can result in pathogenesis to the 
host, and treatment of IFN-α is associated with various severe side effects in patients [42]. 
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Therefore, dissecting the antiviral and the pathogenic mechanisms is necessary for 
developing specific antiviral strategies while avoiding unnecessary side effects. Our 
identification of RIG-I as a key anti-HEV ISG and its activation by the natural ligand 5’pppRNA 
exerting potent anti-HEV activity have provided proof-of-concept for designing such specific 
anti-HEV approach. Several RIG-I agonists (ImOl-100, Rigontec; MCT-465, Multicell 
Technologies; SB-9200, Spring Bank Pharmaceuticals) are at various stages of pre-clinical or 
clinical development for treating viral infections [43]. Thus, the possibility of using these RIG-I 
agonists in treating HEV infection deserves further evaluations.  
In conclusion, we have identified RIG-I as a key anti-HEV ISG that inhibit HEV 
replication. Biological or pharmacological activation of the RIG-I pathway potently inhibit 
HEV replication. We further observed ectopic overexpression of RIG-I activated the 
transcription of many antiviral ISGs to establish an anti-HEV status. This is dispensable of IFN 
production but partially through the activation of JAK-STAT cascade. Thus, this study 
revealed new insights of HEV-host interactions, and provided novel avenues for antiviral 
drug development. 
Funding Information 
This research is supported by the European Association for the Study of the Liver (EASL) for a 
Sheila Sherlock Fellowship (to Q. Pan), the Netherlands Organization for Scientific Research 
(NWO/ZonMw) for a VENI grant (No. 916-13-032) (to Q. Pan), the Dutch Digestive 
Foundation (MLDS) for a career development grant (No. CDG 1304) (to Q. Pan), the Daniel 
den Hoed Foundation for a Centennial Award fellowship (to Q. Pan), the Erasmus MC Mrace 
grant (to Q. Pan) and the China Scholarship Council for funding PhD fellowships to L. Xu 
(201306300027), W. Wang (201303250056), X. Zhou (No. 201206150075), Y. Yin 
(201307720045) and Y. Wang (201207720007). 
Acknowledgements 
The authors gratefully thank Dr. Charles M. Rice (the Rockefeller University) for generously 
providing the overexpression lentiviral vector, Dr. Suzanne U. Emerson (National Institute of 
Allergy and Infectious Diseases, NIH, USA) for generously providing the plasmids to generate 
subgenomic and full-length HEV genomic RNA, Dr. Ralf Bartenschlager and Dr. Volker 
Lohmann (University of Heidelberg, Germany) for providing the HCV replicon cells., Dr. 
Sanna M. Mäkelä (National Institute for Health and Welfare Viral Infections Unit, Helsinki, 
Chapter 5 
99 | P a g e  
 
Finland) for providing WT and RIG-I-/- MEF cells generated by Dr. Michael J. Gale 
(Department of Immunology University of Washington) and WT, IRF3/7-/- and NFκB-/- MEF 
cells generated by Dr. A. Hoffmann (Signaling Systems Lab, Los Angeles, CA). We also thank 
Dr. George R. Stark (Lerner Research Institute) for providing WT and STAT1-/- human 
fibrosarcoma cells. 
Abbreviations 
HEV, hepatitis E virus; ISGs, interferon stimulated genes; IFN, interferon; IFN-α, interferon-α; 
mIFN-α, mouse interferon-α; RIG-I, retinoic acid-inducible gene I; MDA5, melanoma 
differentiation-Associated protein 5; JAK1, janus kinase 1; STAT1, signal transducers and 
activators of transcription 1; Fluc, Photinus pyralis luciferase; IRF1/2/7/9, interferon 
regulatory factor 1/2/7/9; PRRs, pattern recognition receptors; ISRE, IFN-stimulated 
response element; ISGF3, IFN-stimulated gene factor 3; MEF, mouse embryonic fibroblasts; 
TagRFP, red fluorescent protein; FCS, fetal calf serum; qRT-PCR, quantitative RT-PCR; GFP, 
green fluorescent protein; shRNA, short hairpin RNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
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Supplemental Materials and Methods 
Reagents 
Human IFN-α (Thermo Fisher Scientific, Life Sciences, the Netherlands) was dissolved in PBS. 
Mouse IFN-α (mIFN-α) was obtained from Thermo Fisher Scientific (#121001, Life Sciences). 
CP-690550 (Tofacitinib) was obtained from Santa Cruz Biotechnology and dissolved in DMSO. 
JAK inhibitor 1 (CAS 457081-03-7) was also obtained from Santa Cruz Biotechnology and 
dissolved in DMSO at a final concentration of 5 mg/mL. Dimethyl sulfoxide (DMSO, Sigma, 
Zwijndrecht, the Netherlands) was used as vehicle control at different concentrations. 5’ppp-
dsRNA was purchased from InvivoGen (#tlrl-3prna, InvivoGen, CA, USA). Phospho-STAT1 
(Tyr701) (58D6, Rabbit mAb, #9167), STAT1 (Rabbit mAb, #9172), MDA5 (IFIH1) (D74E4, 
Rabbit mAb, #5321) and IRF7 (D2A1J, Rabbit mAb, #13014) antibodies were obtained from 
Cell Signaling Technology (Danvers, MA, USA). MAVS antibody (E-3, Mouse mAb, #sc-
166583), RIG-I antibody (H-300, Rabbit polyclonal, #sc-98911) and β-actin antibody (C-4, 
Mouse mAb, #sc-47778) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Chapter 5 
100 | P a g e  
 
800CW Goat anti-Rabbit IgG (H + L) or 680RD Goat anti-Mouse IgG (H + L) IRDye®-conjugated 
secondary antibodies were obtained from Li-COR Biosciences (Lincoln, NE, USA). 
Cell culture 
Huh7.5 cells, 293T cells and A549 cells were grown in Dulbecco’s modified Eagle medium 
(DMEM) (Lonza Biowhittaker, Verviers, Belgium) supplemented with 10% (v/v) fetal calf 
serum (FCS) (Hyclone, Lonan, Utah) and antibiotics. HepaRG cell line was maintained in 
William’s medium (Thermo Fisher Scientific Life Sciences) as described previously [17]. 
Hepatitis C virus (HCV) luciferase replication models (ET-Luc) was based Huh7.5 cells coupled 
with a subgenomic HCV bicistronic replicon (I389/NS3-3V/LucUbiNeo-ET). Huh7.5-ET-Luc 
cells were grown in DMEM with 250 μg/mL G418 (Sigma Aldrich, Zwijndrecht, the 
Netherlands). ISRE (IFN-stimulated response element) activation reporter model (Huh7-ISRE-
Luc) was based on Huh7 cells that expressing the firefly luciferase reporter gene driven by a 
promoter containing multiple ISRE elements (SBI Systems Biosciences, Mountain View, CA). 
Luciferase activity represents ISRE promoter activation level and this cell line was 
maintained in DMEM with 10% FCS and antibiotics.  
Mouse embryonic fibroblast cells (MEFs) were grown in DMEM with 10% FCS, 0.6 
µg/mL penicillin, 60 µg/mL streptomycin, 2 mM L-glutamine and 20 mM HEPES as described 
previously [29]. WT and RIG-I-/- MEF cells were generated by Dr. Michael J. Gale (Department 
of Immunology University of Washington). WT, IRF3/7-/- and NFκB-/- MEF cells were 
generated by Dr. A. Hoffmann (Signaling Systems Lab, Los Angeles, CA). All these MEF cells 
were kindly provided by Dr. Sanna M. Mäkelä (National Institute for Health and Welfare Viral 
Infections Unit, Helsinki, Finland) with the permission of Dr. Michael J. Gale and Dr. A. 
Hoffmann [29]. WT (fTGH) and STAT1 deficient (U3A, STAT1-/-) human fibrosarcoma cells were 
grown in DMEM with 10% FCS and antibiotics. WT and STAT1-/- fibrosarcoma cells were kind 
gifts of Prof. George R. Stark (Lerner Research Institute) [44].  
RNA and DNA transfection 
Polyethylenimine (PEI, Sigma-Aldrich, Zwijndrecht, the Netherlands) was used for 
transfection of 5’pppRNA in A549 and MEF cells. Cells were seeded in 96-well plates at a 
density of 1 × 104 cells per well. The next day, the medium was removed and cell layer was 
washed by Opti-MEM. Different concentrations of 5’pppRNA were transfected with PEI in a 
total volume of 100 µL Opti-MEM. After 5 h, the medium was changed to normal medium. 
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For lentiviral stocks failed to reach high-level transduction efficacy, DNA-transfection-based 
overexpression approach was used. Briefly, 7 × 104 Huh7.5 cells were seeded into 24-well 
plates per well. After cells adhered to the plate, 400 ng lentiviral ISG plasmids were 
transfected with PEI (Sigma-Aldrich, Zwijndrecht, the Netherlands) in a total volume of 1 mL 
Opti-MEM per well. After 5 h, the medium was changed to normal DMEM medium that 
contains 10% FBS.  
Measurement of luciferase activity 
Measurement of secreted Gaussia luciferase activity was conducted by using BioLux® 
Gaussia Luciferase Flex Assay Kit (New England Biolabs, Ipswich, MA, USA) according to the 
manufacturer’s instructions. Luminescence signal was monitored by using a LumiStar Optima 
luminescence counter (BMG Lab Tech, Offenburg, Germany). Measurement of firefly 
luciferase activity was conducted by adding luciferin potassium salt (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) to cells at a final concentration of 0.1 mM. 10 min after 
incubation, luciferase activity was measured.  
Interferon production bioassay 
10 × 104 cells per well were seeded into 6-well plates. Cells were transduced with control or 
RIG-I lentiviral pseudoparticles at 37 °C as described above. 72 h later, lentiviral particles 
were removed and cell layer was washed 3 times with PBS. Next, the medium wad refreshed 
and cultured for another 72 h to let the produced cytokines secreted into the medium. 
Subsequently, the supernatant (conditioned medium) was collected and then filtered by a 
0.45 μm filter. To detect the secreted IFN proteins in conditioned medium, two luciferase 
reporter models which are extremely sensitive to interferon treatments were used. Huh7.5-
ET-Luc luciferase model is an HCV replicon which the HCV-related firefly luciferase activity 
can be potently inhibited by low concentration of IFN-α treatments. Huh7-ISRE-Luc is a 
luciferase reporter model in which the firefly luciferase gene was driven by a promoter 
containing multiple ISRE elements. In this model, the firefly luciferase activity can be 
potently induced by low concentration of IFN-α treatment. Therefore, these two luciferase 
models can be used to sensitively assess the presence of IFN proteins in the conditioned 
medium. 
Real-time Quantitative RT-PCR (Real-time qRT-PCR) 
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RNA was isolated from cells using the Machery-NucleoSpin RNA II kit (Bioke, Leiden, 
Netherlands). RNA concentration was quantified by a Nanodrop ND-1000 
Spectrophotometer (Thermo, DE, USA). 500 ng RNA was reverse transcribed to cDNA by 
using Takara cDNA Synthesis Kit with random hexamer primers according to manufacturer’s 
instructions (Takara Bio, Inc., Shiga, Japan). Host gene expression and intracellular HEV level 
were quantified by SYBR-Green-based (Applied Biosystems® SYBR® Green PCR Master Mix, 
Thermo Fisher Scientific Life Sciences) real-time PCR on the StepOnePlus™ System (Thermo 
Fisher Scientific Life Sciences). For all human cell lines, two genes GAPDH and RP2 (Human 
retinitis pigmentosa 2) were used as housekeeping genes and expression level of target 
genes was normalized to GAPDH and RP2 by the 2-ΔΔCT method. For all mouse cell lines, one 
gene mGAPDH was used as housekeeping genes and expression level of target genes was 
normalized to mGAPDH by the 2-ΔΔCT method. Primers sets used for this study were listed in 
Table S2 and Table S3 in Supporting Information. 
Quantification of HEV replication 
Huh7.5-p6 and Huh7.5-p6-Luc are two well-established HEV models that could stably 
support HEV replication for a long term. In these two cell models, HEV-related Gaussia 
luciferase activity and HEV viral RNA level were measured over 3 months after 
electroporation when the HEV replication level was stable as described above. Lentivirus 
transduction and HEV RNA quantification were performed 2 weeks and 4 weeks after HEV 
RNA electroporation in A549-p6 and HepaRG-p6 models, respectively. WT and RIG-I-/- cells 
were infected with HEV virus stock as described in reinfection assays for 24 h. 3 days after 
HEV infection, cells were transfected with 5’pppRNA and HEV viral RNA was quantified 48 h 
after transfection. Intracellular HEV viral RNA was isolated from cellular lysates. The cells 
were lysed by using 350 mL RA1 buffer (Bioke, Leiden, The Netherlands) followed by RNA 
isolation as described above. Primer sequences for detecting HEV viral RNA were 5’-
ATCGGCCAGAAGTTGGTTTTTAC-3’ (sense) and 5’-CCGTGGCTATAACTGTGGTCT-3’ (antisense). 
qRT-PCR was performed as follows: 10 min at 95 °C, 40 cycles of 15 s at 95 °C, 30 s at 58 °C, 
and 30 s at 72 °C. 
Immunoblot analyses 
Whole cell lysates were suspended in SDS sample buffer and heated at 95 °C for 5 min. 
Proteins were separated in 10% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) gel 
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and were transferred onto a PVDF membrane (InvitroGen). Membranes were blocked for 1h 
at room temperature and then were probed with primary antibodies overnight at 4 °C. 
Rabbit anti-p-STAT1 (1: 1000), anti-STAT1 (1: 1000), anti-IRF7 (1: 1000), anti-MDA5 (1: 1000), 
anti-RIG-I (1: 1000) antibodies or mouse anti-MAVS (1: 1000) and anti-β-actin (1: 1000) were 
used. Membranes were incubated at room temperature with goat anti-rabbit or goat anti-
mouse IRDye®-conjugated secondary antibodies (Li-COR Biosciences, Lincoln, USA) (1: 5000). 
β-actin was served as loading control. Antibody signals were detected by Odyssey Infrared 
Imaging System and were visualized by Odyssey 3.0 software. Band intensity was quantified 
by Odyssey Software and normalized to the β-actin signal. The quantification result was 
showed below each band.  
MTT assay 
Cells were seeded in 96-well plates and cell viability was determined by adding 10 mM 3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) (Sigma, Zwijndrecht, the 
Netherlands). After 3 h, the medium was replaced with 100 μL of DMSO and was incubated 
for another 50 min. Absorbance was measured by absorbance reader (Bio-Rad, CA, USA) at a 
wavelength of 490 nm. 
Flow cytometry analysis 
The positive percentage of cells transduced with lentivirus was determined by directly detect 
TagRFP protein expression level. Cells were analyzed on a FACSAria™ flow cytometer (BD 
Biosciences) equipped with a 561-nm laser.  
Supplementary Table 1. Lentiviral shRNA sequences. 
No. Gene ACCESSI
ON 
Sequences Target 
Sequence 
shRIG-
I(1) 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 
NM_014
314.3 
CCGGCCAGAGAAACTTGCCAGTTATCTCG
AGATAACTGGCAAGTTTCTCTGGTTTTTTG 
CCAGAGA
AACTTGC
CAGTTAT 
shRIG-
I(2) 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 
NM_014
314.3 
CCGGCCAGAATTATCCCAACCGATACTCG
AGTATCGGTTGGGATAATTCTGGTTTTTT
G 
CCAGAAT
TATCCCA
ACCGATA 
Supplementary Table 2. Primer sequences for human cells. 
Gene F-Sequences (5’ to 3’) R-Sequences (5’ to 3’) 
ADAR TCCGTCTCCTGTCCAAAGAAGG TTCTTGCTGGGAGCACTCACAC 
CCL3 ACTTTGAGACGAGCAGCCAGTG TTTCTGGACCCACTCCTCACTG 
CCL4 GCTTCCTCGCAACTTTGTGGTAG GGTCATACACGTACTCCTGGAC 
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CXCL10 GGTGAGAAGAGATGTCTGAATCC GTCCATCCTTGGAAGCACTGCA 
DDX60 GGTGTTTTCACCAGGGAGTATCG CCAGTTTTGGCGATGAGGAGCA 
GAPDH TGTCCCCACCCCCAATGTATC CTCCGATGCCTGCTTCACTACCTT 
IFI27 CGTCCTCCATAGCAGCCAAGAT ACCCAATGGAGCCCAGGATGAA 
IFI44L TGCACTGAGGCAGATGCTGCG TCATTGCGGCACACCAGTACAG 
IFI6 TGATGAGCTGGTCTGCGATCCT GTAGCCCATCAGGGCACCAATA 
IFIH1(MDA5) GCTGAAGTAGGAGTCAAAGCCC CCACTGTGGTAGCGATAAGCAG 
IFIT1 GCCTTGCTGAAGTGTGGAGGAA ATCCAGGCGATAGGCAGAGATC 
IFIT2 GGAGCAGATTCTGAGGCTTTGC GGATGAGGCTTCCAGACTCCAA 
IFIT3 CCTGGAATGCTTACGGCAAGCT GAGCATCTGAGAGTCTGCCCAA 
IFITM3 CTGGGCTTCATAGCATTCGCCT AGATGTTCAGGCACTTGGCGGT 
IFN-α TGGGCTGTGATCTGCCTCAAAC CAGCCTTTTGGAACTGGTTGCC 
IFN-β1 CTTGGATTCCTACAAAGAAGCAGC TCCTCCTTCTGGAACTGCTGCA 
IFN-λ1 GGAAGACAGGAGAGCTGCAACT AACTGGGAAGGGCTGCCACATT 
IFN-λ2 TCGCTTCTGCTGAAGGACTGCA CCTCCAGAACCTTCAGCGTCAG 
IL-1β CCACAGACCTTCCAGGAGAATG GTGCAGTTCAGTGATCGTACAGG 
IL-32 TCAAAGAGGGCTACCTGGAGAC TCTGTTGCCTCGGCACCGTAAT 
IL-6 AGACAGCCACTCACCTCTTCAG TTCTGCCAGTGCCTCTTTGCTG 
IRF1 GAGGAGGTGAAAGACCAGAGCA TAGCATCTCGGCTGGACTTCGA 
IRF2 TAGAGGTGACCACTGAGAGCGA CTCTTCATCGCTGGGCACACTA 
IRF9 CCACCGAAGTTCCAGGTAACAC AGTCTGCTCCAGCAAGTATCGG 
ISG15 CTCTGAGCATCCTGGTGAGGAA AAGGTCAGCCAGAACAGGTCGT 
JAK1 GAGACAGGTCTCCCACAAACAC GTGGTAAGGACATCGCTTTTCCG 
MX1 GGCTGTTTACCAGACTCCGACA CACAAAGCCTGGCAGCTCTCTA 
NAMPT CTCCACCAGAACCGAAGGCAAT AGGGTTACAAGTTGCTGCCACC 
OASL GTGCCTGAAACAGGACTGTTGC CCTCTGCTCCACTGTCAAGTGG 
PKR GAAGTGGACCTCTACGCTTTGG TGATGCCATCCCGTAGGTCTGT 
PML CCGTCATAGGAAGTGAGGTCTTC GTTTTCGGCATCTGAGTCTTCCG 
RANTES CCTGCTGCTTTGCCTACATTGC ACACACTTGGCGGTTCTTTCGG 
RIG-I CACCTCAGTTGCTGATGAAGGC GTCAGAAGGAAGCACTTGCTACC 
RP2 CCCATTAAACTCCAAGGCAA AAGCTGAGGATGCTCAAAGG 
RSAD2 CCAGTGCAACTACAAATGCGGC CGGTCTTGAAGAAATGGCTCTCC 
STAT1 ATGGCAGTCTGGCGGCTGAATT CCAAACCAGGCTGGCACAATTG 
STAT2 CAGGTCACAGAGTTGCTACAGC CGGTGAACTTGCTGCCAGTCTT 
TRAIL TGGCAACTCCGTCAGCTCGTTA AGCTGCTACTCTCTGAGGACCT 
Supplementary Table 3. Primer sequences for mouse cells. 
Gene F-Sequences (5’ to 3’) R-Sequences (5’ to 3’) 
mIFIH1 TGCGGAAGTTGGAGTCAAAGCG TGCGGAAGTTGGAGTCAAAGCG 
mIFN-β AAGAGTTACACTGCCTTTGCCATC CACTGTCTGCTGGTGGAGTTCATC 
mIFN-λ CCAGTGGAAGCAAAGGATTGCC GCACCTCATGTCCTTCTCAAGC 
mIRF1 TCCAAGTCCAGCCGAGACACTA ACTGCTGTGGTCATCAGGTAGG 
mIRF7 CCTCTGCTTTCTAGTGATGCCG CGTAAACACGGTCTTGCTCCTG 
mIRF9 CAACATAGGCGGTGGTGGCAAT GTTGATGCTCCAGGAACACTGG 
mISG15 CATCCTGGTGAGGAACGAAAGG CTCAGCCAGAACTGGTCTTCGT 
mMX1 TGGACATTGCTACCACAGAGGC TGGACATTGCTACCACAGAGGC 
mPML GTCTAAGACCCAACCTGTGGCT CTTCATGGAGCCGACTGTCTGA 
mRIG-I AGCCAAGGATGTCTCCGAGGAA ACACTGAGCACGCTTTGTGGAC 
mSTAT1 GCCTCTCATTGTCACCGAAGAAC TGGCTGACGTTGGAGATCACCA 
mXAF CTGCGCTTCATAGTCCTTTGCC AGGGTGCTGTTGGCTTTCCTTG 
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Supplementary Figures 
 
Figure S1. ISG-coupled TagRFP overexpression and the validation of their anti-HCV activities. 
(A) Sequencing analysis of RIG-I mutation in Huh7.5 and A549 cells. The mutation of RIG-I in ORF nt 
164 in Huh7.5 cells was indicated as red. (B) Flow cytometry analysis of GFP or RFP positive cells in 
Huh7.5 cells transduced with GFP vector at the indicated doses for 48 h. (C-F) Flow cytometry 
analysis of RFP positive cells in Huh7.5 cells transduced with ISG.ires.RFP and Fluc vector at the 
indicated doses for 48 h. (G) Analysis of HCV related firefly luciferase activity in Huh7.5-ET-Luc cells 
transduced with ISG or GFP vector for 24 h, 48 h or 72 h (n = 4 independent experiments with each of 
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2 replicates). RLU: relative luciferase unit. Data in (G) were normalized to the GFP control (set as 1) 
and presented in dot plots. 
 
Figure S2. Gene knockdown of RIG-I in Huh7.5 cells does not affect HEV infection and 5’pppRNA 
does not stimulate an antiviral response in this cells. 
qRT-PCR analysis and immunoblot analysis of RIG-I expression in Huh7.5 cells transduced with 
lentiviral shRNA vectors targeting RIG-I (shRIG-I(1) and shRIG-I(2)) or scrambled control (shSCR). (B) 
Stable RIG-I knockdown or scrambled control (shSCR) Huh7.5 cells were infected with HEV and HEV 
viral RNA level was analyzed by qRT-PCR 72 h after infection. (C) Huh7.5 cells and A549 cells were 
infected with HEV and HEV viral RNA level was analyzed by qRT-PCR 72 h after infection. Date in (A) 
and (B) were normalized to the scrambled control (shSCR, set as 1). Date in (C) were normalized with 
one housekeeping gene RP2 and presented relative to RP2 expression. (D) Huh7.5-p6-Luc cells were 
transfected with various concentrations of 5’pppRNA (10 ng/mL, 100 ng/mL and 1000 ng/mL). HEV 
related Gaussia luciferase activity was analyzed at 24 h, 48 h or 72 h after transfection (n = 2 
independent experiments with each of 2 - 3 replicates). RLU: relative luciferase unit. Data were 
normalized to a control that transfected with PEI-Mix but without 5’pppRNA at each time point (24 h, 
48 h and 72 h, all set as 1), respectively. 
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Figure S3. The antiviral ability of 5’pppRNA is dependent on functional RIG-I signaling. 
WT (RIG-I+/+) and RIG-I deficient (RIG-I-/-) mouse embryonic fibroblasts (MEF) cells were transfected 
with various concentrations of 5’pppRNA (10 ng/mL, 100 ng/mL and 1000 ng/mL), mouse IFN genes 
(mIFN-β and mIFN-λ) and mouse ISGs including mMX1, mIRF9, mIFIH1, mSTAT1, mIRF1, mPML, 
mXAF, mIRF7, mISG15 and mRIG-I mRNA level was analyzed by qRT-PCR 24 h (A) or 48 h (B) after 
transfection (n = 6). Data were normalized to a control that transfected with PEI-Mix but without 
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5’pppRNA at each cell line (RIG-I+/+ and RIG-I-/-, both set as 1), respectively. Data are means ± SEM. *P 
< 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
 
Figure S4. IFN-α activates ISG transcription in different cell lines. 
qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells (A) and A549-p6 cells (C) treated with IFN-α 
(1000 IU/mL) for 48 h (n = 4). (B) qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells transduced 
with RIG-I or Fluc vector or treated with IFN-α (1000 IU/mL) for 48 h (n = 2 - 3). Data were normalized 
to the untreated Fluc control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 
0.001; NS, not significant.  
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Figure S5. The ISG induction ability of mIFN-α is not attenuated in IRF3/7-/- and NFκB-/- cells. 
qRT-PCR analysis of mouse ISG mRNA levels in WT, IRF3/IRF7 double deficient (IRF3/7-/-) or NFκB 
deficient (NFκB-/-) mouse embryonic fibroblasts (MEF) cells treated with mouse IFN-α (mIFN-α, 1000 
IU/mL) for 3 h (A) or 6 h (B) (n = 3). Data in (A) were normalized to the untreated Fluc control (CTR, 
set as 1). Data in (B) and (C) were normalized to untreated WT MEF cells (WT CTR, set as 1). Data are 
means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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Figure S6. RIG-I overexpression does not trigger ISG production in HepaRG cells. 
Plot of qRT-PCR analysis of IFN gene expression in Huh7.5-p6 (A) and HepaRG-p6 cells (B) transduced 
with RIG-I or Fluc (CTR) vector for 48 h. Rn: Fluorescence signal from the reporter dye normalized to 
that from the negative control. (C) qRT-PCR analysis of IFN gene mRNA levels in HepaRG-p6 cells 
transduced with RIG-I or Fluc vector for 48 h (n = 4). (D) Analysis of ISRE-related firefly luciferase 
activity in Huh7-ISRE-Luc cells treated with conditioned medium from HepaRG cells or IFN-α (100 
IU/mL) for 48 h (n = 2 independent experiments with each of 2 - 3 replicates). Data in (C) were 
normalized to the Fluc control (CTR, set as 1). Data in (D) were normalized to the untreated GFP 
control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant.  
 
 
 
Figure S7. JAK inhibitor CP-690550 totally abolishes IFN-α induced 
ISG transcription. 
(A) qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells treated 
with IFN-α (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h (n =5-6). 
(B) MTT assay analysis of cell viability in Huh7.5-p6 cells transduced 
with RIG-I vector or treated with IFN-α (1000 IU/mL) or CP-690550 
(1000 ng/mL) for 48 h (n = 2 independent experiments with each of 2 
replicates). Data were normalized to the untreated control (CTR, set 
as 1). Data are means ± SEM. 
 
 
 
 
  
Chapter 5 
111 | P a g e  
 
 
 
 
Figure S8. JAK inhibitor 1 partially diminishes RIG-I-induced ISG 
transcription and anti-HEV activity. 
(A) Immunoblot analysis of ISG protein levels in Huh7.5 cells-p6 
transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) or JAK 
inhibitor 1 (10 µM) for 48 h. qRT-PCR analysis of RIG-I mRNA level in 
Huh7.5-p6 cells (B), analysis of ISRE-related firefly luciferase activity in 
Huh7-ISRE-Luc cells (C) and MTT assay analysis of cell viability in Huh7.5 
cells (D) transduced with RIG-I vector or treated with IFN-α (1000 
IU/mL) or JAK inhibitor 1 (10 µM) for 48 h (qRT-PCR: n = 4; ISRE-Luc: n = 
3 independent experiments with each of 2 replicates; MTT: 2 independent experiments with each of 
2 replicates). (E) qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells treated with IFN-α (1000 
IU/mL) or JAK inhibitor 1 (10 µM) for 48 h (n =3). (F) qRT-PCR analysis of ISG mRNA levels in Huh7.5-
p6 cells transduced with RIG-I vector or treated with JAK inhibitor 1 (10 µM) for 48 h (n = 4). (G) qRT-
PCR analysis of HEV viral RNA level in Huh7.5-p6 cells transduced with RIG-I vector or treated with 
IFN-α (1000 IU/mL) or JAK inhibitor 1 (10 µM) for 48 h (n = 6). For immunoblot results (A), band 
intensity of each lane was quantified by Odyssey Software. Immunoblot quantification results were 
normalized to β-actin expression and control was set as 1. Data in (B, E, F and G) were normalized to 
the untreated Fluc control (CTR, set as 1). Date in (C and D) were normalized to the untreated GFP 
control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant.  
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Figure S9. JAK inhibitor 1 partially diminishes RIG-I-induced ISG 
transcription and anti-HEV activity in HepaRG cells. 
(A) Immunoblot analysis of RIG-I mRNA level in HepaRG-p6 cells 
transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) or JAK 
inhibitor 1 (10 µM) for 48 h. qRT-PCR analysis of ISG mRNA levels (B) and 
HEV viral RNA (C) level in HepaRG-p6 cells transduced with RIG-I vector or 
treated with JAK inhibitor 1 (10 µM) for 48 h. Immunoblot quantification 
results were normalized to β-actin expression and control was set as 1. 
Data in (B and C) were normalized to the untreated Fluc control (CTR, set 
as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant. 
 
 
Figure S10. IFN-α does not induce ISG expression in STAT1 deficient cells. 
(A) qRT-PCR analysis of ISG mRNA levels in WT and STAT1 deficient (STAT1-/-) fibrosarcoma cells 
treated with IFN-α (1000 IU/mL) for 48 h (n = 4). Date were normalized to untreated WT and STAT1-/- 
cells, respectively (both set as 1). Data are means ± SEM.  
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Abstract 
IFN regulatory factor 1 (IRF1) is one of the most important IFN-stimulated genes (ISGs) in 
cellular antiviral immunity. Although hepatitis E virus (HEV) is a leading cause of acute 
hepatitis worldwide, how ISGs counteract HEV infection is largely unknown. This study was 
conducted to investigate the effect of IRF1 on HEV replication. Multiple cell lines were used 
in 2 models that harbor HEV. In different HEV cell culture systems, IRF1 effectively inhibited 
HEV replication. IRF1 did not trigger IFN production, and chromatin immunoprecipitation 
sequencing data analysis revealed that IRF1 bound to the promoter region of signal 
transducers and activators of transcription 1 (STAT1). Functional assay confirmed that IRF1 
could drive the transcription of STAT1, resulting in elevation of total and phosphorylated 
STAT1 proteins and further activating the transcription of a panel of downstream antiviral 
ISGs. By pharmacological inhibitors and RNAi-mediated gene-silencing approaches, we 
revealed that antiviral function of IRF1 is dependent on the JAK-STAT cascade. Furthermore, 
induction of ISGs and the anti-HEV effect of IRF1 overlapped that of IFNα, but was 
potentiated by ribavirin. We demonstrated that IRF1 effectively inhibits HEV replication 
through the activation of the JAK-STAT pathway, and the subsequent transcription of 
antiviral ISGs, but independent of IFN production. 
Keywords: innate immunity; ribavirin; transcription 
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Introduction 
Hepatitis E virus (HEV) infection is one of the most common causes of acute hepatitis, 
particularly in developing countries [1]. Although it is often a self-limiting disease, fulminant 
hepatitis and high mortality have been reported in pregnant women [2]. In Western 
countries, chronic HEV has frequently been reported in immunocompromised patients and is 
the potential cause of graft loss and even mortality [3, 4]. However, the underlying 
mechanisms of how the host combats HEV infection remain largely elusive. 
Upon viral infection, the host rapidly reacts by producing panel of inflammatory 
cytokines and chemokines to orchestrate the immunologic reaction to the pathogenic 
invasion [5]. Within this group of anti-viral mediators, IFNs are vital cytokines for innate 
defense against viral infection [6]. Because of its potent antiviral activity, pegylated IFNα 
(PEG-IFNα) has been used for decades to treat chronic hepatitis B virus (HBV) and hepatitis C 
virus (HCV)infections [7, 8]. Because no registered medication is available for HEV infection, 
PEG-IFNα, ribavirin, or a combination of both has been used as off-label treatments for some 
cases of HEV infection, although the efficacy is still inconclusive [9]. Mechanistically, type I 
IFN molecules bind to cell surface receptors and subsequently initiate a signaling cascade. 
This binding triggers the phosphorylation of preassociated Janus kinase 1 (JAK1). 
Subsequently, the JAK1 phosphorylation leads to the recruitment and phosphorylation of 
signal transducers and activators of transcription 1 and 2 (STAT1 and -2), which further bind 
to IFN regulatory factor 9 (IRF9) to form the IFN-stimulated gene factor 3 (ISGF3) complex. 
ISGF3 translocates to the nucleus to activate transcription of IFN-stimulated genes (ISGs), 
which are in turn regulated by the IFN-stimulated response element (ISRE). The products of 
ISGs are thought to be the ultimate antiviral effectors [10]. 
Although there are hundreds of ISGs, in fact, only a few have specific or broad 
antiviral effects [10]. IRF1 is one of the most important ISGs that has been shown to 
effectively inhibit HCV, yellow fever virus, chikungunya virus, and Venezuelan equine 
encephalitis virus infections among the 380 tested ISGs [11]. A further follow-up study 
demonstrated that IRF1 potently inhibits the replication of 14 different viruses, representing 
7 families, including different DNA and RNA viruses [10]. However, the exact antiviral 
mechanism of IRF1 remains unclear.  
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Given the importance of IRF1 in innate defense against viral infection but insufficient 
knowledge of HEV, we investigated the role of IRF1 in HEV infection and the interactions 
with antiviral treatments by using cell culture models. We found that, independent of IFN 
production, IRF1 effectively restricts HEV replication through the activation of JAK-STAT 
cascade and the subsequent induction of a wide range of ISGs. We further demonstrated 
that the anti-HEV effect of IRF1 overlaps IFNα, but is augmented by ribavirin. 
Materials and Methods 
Reagents 
Human IFNα (Thermo Fisher Scientific Life Sciences, Waltham, MA, USA) was dissolved in 
PBS. Stocks of JAK inhibitor 1 (CAS 457081-03-7, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) were dissolved in DMSO with a final concentration of 5 mg/mL. Stocks of CP-690550 
(tofacitinib) (Santa Cruz Biotechnology) were dissolved in DMSO with a final concentration of 
10 mg/mL. Stock of ribavirin was dissolved in PBS with a final concentration of 10 mg/mL. 
Matched concentrations of DMSO were used as vehicle control. Phospho-STAT1 (Tyr701) 
(58D6, Rabbit mAb, 9167), STAT1 (Rabbit mAb, 9172), and IRF1 (D5E4, Rabbit mAb, 8478) 
antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). IRF9 antibody 
was obtained from LSBio (rabbit polyclonal, LS-C155416; Life Span BioSciences, Inc., Seattle, 
WA, USA). β-Actin antibodies (mouse monoclonal, sc-47778) were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Anti-rabbit and -mouse IRDye-conjugated secondary 
antibodies (Li-Cor Biosciences, Lincoln, NE, USA) were also used. 
Cell culture 
Naive or vector-transduced Huh7 human hepatoma cells, HEK293T cells, A549 human lung 
epithelial carcinoma cells, and MRC5 human fetal lung fibroblasts [12] were cultured in 
DMEM (Lonza Biowhittaker, Verviers, Belgium) complemented with 10% (v/v) fetal calf 
serum (FCS) (Hyclone, Logan, UT, USA), 100 IU/mL penicillin, and 100 mg/mL streptomycin. 
The HepaRG cell line was maintained in William’s medium (Thermo Fisher Scientific Life 
Sciences) supplemented with 10% FCS, 100 IU/mL penicillin, 100 mg/mL streptomycin, 5 
mg/mL insulin, and 5 × 10-7 M hydrocortisone hemisuccinate (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) [13]. Huh7 cells containing a subgenomic HCV bicistronic replicon 
(I389/NS3-3V/LucUbiNeo-ET, Huh7-ET-Luc) were maintained with 250 mg/mL G418 (Sigma-
Chapter 6 
120 | P a g e  
 
Aldrich), and viral replication was monitored by measuring firefly luciferase activity [14]. For 
the ISRE reporter model (Huh7-ISRE-Luc), Huh7 cells were transduced with a lentiviral 
transcriptional reporter system expressing the firefly luciferase gene driven by a promoter 
containing multiple ISRE promoter elements (SBI Systems Biosciences, Mountain View, CA, 
USA); luciferase activity represents ISRE promoter activation [15]. 
HEV cell culture models 
In this study, multiple cell lines were used for HEV replication, including a human hepatoma 
cell line, Huh7 [16, 17]; a human lung epithelial carcinoma cell line, A549 [18]; a human fetal 
lung fibroblast cell line, MRC5; and a hepatic cell line, HepaRG, that retains many 
characteristics of primary human hepatocytes. For the full-length HEV model, a plasmid 
construct containing the full-length HEV genome (Kernow-C1 p6 clone; GenBank Accession 
Number JQ679013) was used to generate HEV genomic RNA with the Ambion mMessage 
mMachine in vitro RNA transcription Kit (Thermo Fisher Scientific Life Sciences) [16]. Huh7 
and HepaRG cells were electroporated with full-length HEV genome RNA, to generate 
consecutive HEV-infected cell models, Huh7-p6 and HepaRG-p6. For the subgenomic HEV 
model, a construct containing subgenomic HEV in which the 5’ portion of HEV ORF2 was 
replaced with the in-frame Gaussia princeps luciferase reporter gene to yield p6-Luc [16]. 
Huh7 and A549 cells were electroporated with HEV subgenomic RNA to generate an HEV 
subgenomic model, Huh7-p6-Luc and A549-p6-Luc, in which the accumulation of secreted 
luciferase serves as a reporter for HEV replication. For the HEV genotype 1 replicon model, 
viral RNA was generated from a Sar55/S17/luc-encoding plasmid. Huh7 cells were 
electroporated with Sar55/S17/luc HEV RNA to generate a genotype 1 replicon model [16, 19].  
Reinfection assays  
Supernatant from a full-length Huh7-p6 HEV model was collected and purified by 
ultracentrifugation. The supernatant was first filtered through 0.45 mm filter followed by 
centrifugation at 10 000 rpm for 30 min to remove cell debris and then 22 000 rpm for 2 h to 
pellet HEV virus (SW28 rotor; Beckman Coulter, Brea CA, USA). The pellet was suspended 
and diluted to 1 × 107 HEV viral RNA copies/mL. The diluted HEV virus stock was stored at -
80 °C. For HEV infection, Huh7, HepaRG, A549, and MRC5 cells were seeded into 12-well 
plates at a density of 7 × 104 cells per well and incubated for 24 h. Next, different cells were 
incubated with 400 mL HEV stock diluted to 1 × 107 viral RNA copies/mL per well at 37 °C for 
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6 h. Then, the inoculum was removed, and cell layers were washed 3 times with 1 mL PBS, 
and 1 mL fresh medium was added to each well. For 6-well plates, different cells were 
seeded at a density of 1.4 × 105 cells per well and incubated for 24 h. Next, different cells 
were incubated with 800 mL HEV stock diluted to 1 × 107 viral RNA copies/mL per well at 
37 °C for 6 h. Then, the inoculum was removed, and cell layers were washed 3 times with 3 
mL PBS, and 2 mL fresh medium was added to each well.  
To investigate the anti-viral effect of IRF1 in HEV refection models, Huh7 cells were 
transduced with IRF1 or infected by HEV at the following time points: 1) HEV infection and 
IRF1 transduction were started at the same time. After 6 h, the inoculum was removed, and 
1 mL of medium with IRF1 lentivirus was added to each well. Intracellular HEV viral RNA was 
measured after 48 h. 2) Huh7 cells were first transduced with IRF1 for 48 h and then were 
infected with HEV for 6 h. Next, the inoculum was removed, and 1 mL of fresh medium was 
added to each well. HEV viral RNA was quantified 48 h after HEV infection. 3) Huh7 cells 
were first infected with HEV for 6 h. At 24 h after HEV infection, IRF1 was transduced, and 
HEV RNA was quantified at 48 h after transduction. 
Gene knockdown and overexpression by lentiviral vectors 
For gene knockdown, pLKO.1-based lentiviral vectors (Sigma-Aldrich) targeting IRF1, STAT1, 
IRF9, and nontargeted control vector (shCTR) were obtained from the Biomics Center in 
Erasmus Medical Center. Lentiviral pseudoparticles were generated in HEK293T cells 
according to a published method [20]. To generate a stable gene-knockdown cell line, Huh7 
cells were transduced with lentiviral particles for 3 d. Because the vectors also express a 
puromycin resistance gene, transduced cells were subsequently selected by adding 2.5 
µg/mL puromycin (Sigma-Aldrich) to the cell culture medium. After selection, cell lines 
showing optimal gene knockdown were chosen. pTRIP.CMV.IVSb.ISG.ires.TagRFP-based IRF1 
overexpression vector was a kind gift from Prof. Charles M. Rice (Rockefeller University, New 
York, NY, USA) [11]. Meanwhile, 2 vectors expressing reporter genes Photinus pyralis 
luciferase (Fluc) or green fluorescent protein (GFP) were used as the control (also kind gifts 
from Prof. Charles M. Rice). Lentiviral pseudoparticles were generated as described and 
stored at -80 °C. A spinoculation method was used, as described for the IRF1 transduction 
assay. Target cell lines were seeded into 12-well plates at a density of 7 × 104 cells per well 
and transduced with lentiviral pseudoparticles at 37 °C for 24, 48, or 72 h. The transduction 
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time of each experiment is described in the legend of each figure, along with the control 
vector used. 
Quantification of HEV replication 
Two Huh7-based HEV models, Huh7-p6 and Huh7-p6-Luc, were well-established models that 
could stably harbor HEV replication for the long term. In this study, HEV viral RNA and HEV-
related luciferase activity were measured; ~2 mo after HEV RNA electroporation when the 
HEV viral RNA level and luciferase activity were at a stable level. For the HepaRG-p6 and 
A549-p6-Luc models, lentivirus transduction and HEV RNA quantification were performed 4 
and 2 wk, respectively, after HEV RNA electroporation. MRC5 cells were infected by stock 
HEV virus medium as described in reinfection assays for 24 h. One week after HEV infection, 
IRF1 was transduced in MRC5 cells, and HEV RNA was quantified 48 h after transduction. For 
HEV-related Gaussia luciferase analysis (HEV-p6-Luc), the activity of secreted luciferase in 
the cell culture medium was measured by BioLux Gaussia Luciferase Flex Assay Kit (New 
England Biolabs, Ipswich, MA, USA), according to the manufacturer’s instructions. Luciferase 
activity was quantified with a LumiStar Optima luminescence counter (BMG Lab Tech, 
Offenburg, Germany). For the firefly and Photinus pyralis luciferases, luciferin potassium salt 
(100 mM; Sigma-Aldrich) was added to the cells and incubated for 10 min at 37 °C, and 
luciferase activity was measured. For the HEV-p6 model, intracellular RNA was isolated from 
cellular lysates. The cells were lysed with 350 mL RA1 buffer (Bioke, Leiden, the Netherlands). 
RNA was isolated by using the Machery-Nucleo Spin RNAII kit (Bioke) and quantified by a 
Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific Life Sciences). cDNA was 
prepared from total RNA with a cDNA Synthesis Kit (Takara Bio, Inc., Shiga, Japan) with 
random hexamer primers. Intracellular HEV level and host gene expression were quantified 
by SYBR-Green-based (Applied Biosystems SYBR Green PCR Master Mix; Thermo Fisher 
Scientific Life Sciences) real-time PCR with the StepOnePlus System (Thermo Fisher Scientific 
Life Sciences). PCR steps consisted of a 10 min holding stage (95 °C) followed by 40 cycles of 
15 s at 95 °C, 30 s at 58 °C, and 30 s at 72 °C. GAPDH and RP2 (human retinitis pigmentosa 2) 
were used as housekeeping genes, and all gene expression levels (relative) were normalized 
to GAPDH and RP2 using the 2-ΔΔCT method. The HEV primer sequences were 5’-
ATCGGCCAGAAGTTGGTTTTTAC-3’ (sense) and 5’-CCGTGGCTATAACTGTGGTCT-3’ (antisense); 
the primer sequences of housekeeping gene GAPDH were 5’-TGTCCCCACCCCCAATGTATC-3’ 
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(sense) and 5’-CTCCGATGCCTGCTTCACTACCTT-3’ (antisense); and the primers of 
housekeeping gene RP2 were 5’-CCCATTAAACTCCAAGGCAA-3’ (sense) and 5’-
AAGCTGAGGATGCTCAAAGG-3’ (antisense).  
IFN production bioassay  
Cells were seeded into 6-well plates at a density of 10 × 104 cells per well and transduced 
with IRF1 or control lentiviral particles at 37 °C. After 72 h, lentiviral particles were removed, 
and cells were washed 3 times with PBS and cultured for another 72 h. The cultured 
supernatant was subsequently collected and filtered through a 0.45 mm pore size 
membrane and added to 2 luciferase reporter cell lines, Huh7-HCV-Luc and Huh7-ISRE-Luc, 
that are sensitive to IFNs. 
Immunoblot analysis 
Whole-cell extracts were obtained and heated at 95 °C for 5 min. Proteins were subjected to 
a 10 - 15% sodium dodecyl sulfatepolyacrylamide gel (SDS-PAGE), separated at 120 V for 100 
min, and electrophoretically transferred onto a PVDF membrane (pore size: 0.45 mm; 
Thermo Fisher Scientific Life Sciences) for 1.5 h with an electric current of 250 mA. 
Subsequently, the membrane was blocked with blocking buffer (Li-Cor Biosciences) in 1 × 
PBS containing 0.1% Tween-20. Membranes were incubated with primary antibodies 
overnight at 4 °C. Rabbit anti-IRF1, p-STAT1, STAT1, IRF9 (1: 1 000) antibodies or mouse anti-
b-actin (1: 2 000) were diluted in 5% (mass/vol) bovine serum albumin in 1 × PBS containing 
0.1% Tween-20. The membrane was washed 3 times, followed by incubation for 1 h with 
anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies (1: 5 000; Li-Cor 
Biosciences) at room temperature. β-Actin served as the loading standard. The membrane 
was scanned by Odyssey Infrared Imaging System (Li-Cor Biosciences). Results were 
visualized with Odyssey 3.0 software. Band intensity data of each immunoblot was also 
quantified by Odyssey Software. 
MTT assay 
Cells were seeded in 96-well plates, and 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) was added. The plate was incubated at 
37 °C with 5% CO2 for 3 h, then the medium was removed, 100 mL of DMSO was added to 
each well, and the microplate was incubated at 37 °C for 50 min. The absorbance of each 
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well was read on the microplate absorbance reader (Bio-Rad, Hercules, CA, USA) at a 
wavelength of 490 nm. 
Confocal microscopy analysis 
Huh7 cells (1 × 104) were seeded on glass slides in a 6-well plate. The cells were transduced 
with overexpressed IRF1, Fluc, or GFP control lentiviruses for 48 h. For IRF1 protein 
immunofluorescence staining, IRF1 antibody (1: 200, D5E4, rabbit mAb, 8478; Cell Signaling 
Technology) was used as the primary antibody. Anti-rabbit-Alexa Fluor 488-conjugated 
antibody (1: 1 000; Cell Signaling Technology) was used as the secondary antibody. The cells 
were visualized in an inverted LSM 510 confocal microscope (Zeiss LSM 510, Jena, Germany) 
using a 40 × oil immersion objective with 1.7 × zoom in. All images were analyzed with a 
Zeiss LSM Image Browser (version 4.2). 
Chromatin immunoprecipitation-sequencing data analysis 
Chromatin immunoprecipitation-sequencing (ChIP-seq) datasets for IRF1 in K562 cells were 
retrieved from the ENCODE database (http://www.genome.ucsc.edu/ENCODE/dataMatrix/-
encodeData-MatrixHuman.htmL/; University of Santa Cruz, CA, USA). ChIP-seq datasets were 
processed and mapped to the hg19 reference genome [21]. ChIP-seq datasets with multiple 
replicates were merged. Model-based analysis for ChIP-seq (MACS 1.4.2) was used for peak 
calling and for the generation of binding profiles [22]. The sequencing profiles of IRF1 were 
created in the IGV browser [23]. 
Statistical analysis 
All results are presented as means ± SEM. Comparisons between groups were determined 
with the Mann-Whitney U test. Differences were significant at P < 0.05. 
Results 
IRF1 effectively inhibits HEV replication 
Although IRF1 exerts cell-autonomous antiviral activity toward a broad range of viruses [10, 11], 
its capacity to combat HEV infection remains unexplored. To determine the role of IRF1 in 
HEV infection, we first tested the effect of forced IRF1 expression in 2 Huh7 cell line-based 
HEV models. Successful overexpression of IRF1 was visualized by red fluorescent protein 
(TagRFP) expression under the confocal electron microscope, because the bicistronic 
lentiviral vector coexpresses IRF1 and a TagRFP reporter (Supplemental Fig. S1A). 
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Consistently, IRF1 mRNA expression (Fig. 1A) and protein level (Fig. 1B, C) were increased in 
overexpressing cells compared with those induced by high-dose IFNα (1000 IU/mL). Of note, 
immunofluorescence staining of IRF1 showed that it was predominantly located in the 
nucleus (Fig. 1C). To exclude the nonspecific effect of lentivirus transduction, we used 2 
control vectors that were used in previous study that expressed reporter genes Fluc or GFP 
[11]. Transduction efficiency was confirmed by different methods, including visualization of 
TagRFP expression (data not shown), measurement of Photinus pyralis luciferase activity 
(Supplemental Fig. S1B), and quantitation of TagRFP mRNA expression level in transduced 
cells. As expected, Fluc and GFP control did not affect HEV replication in 2 Huh7-based 
models (Supplemental Fig. S1C, D). 
Next, we showed that overexpression of IRF1 could profoundly inhibit HCV 
replication in an Huh7-based HCV luciferase replicon model, Huh7-ET Luc (Supplemental Fig. 
S1E), without affecting cell viability (Supplemental Fig. S1F), which was consistent with 
results reported earlier [11]. After 48 or 72 h of IRF1 transduction, HEV was significantly 
inhibited in both the HEV Huh7-p6-Luc replicon and full-length infectious models (Fig. 1D). 
The antiviral activity of IRF1 in both models was equivalent to high-dose IFNα (1000 IU/mL) 
treatment. Moreover, IRF1 could also effectively inhibit genotype 1 HEV-related luciferase 
activity in the Huh7-based genotype 1 HEV replicon model, Sar55/S17/luc (Fig. 1E). To 
further validate the antiviral ability of IRF1, we used 3 additional human cell lines. A human 
hepatic progenitor cell–derived cell line, HepaRG, which exhibits many characteristics of 
primary human hepatocytes [13]; a lung epithelial carcinoma cell line, A549, which is widely 
used for HEV propagation [18]; and a human fetal lung fibroblast cell line, MRC5 [12], were 
used to further confirm the anti-HEV effects of IRF1. The overexpression of IRF1 in these cell 
lines was confirmed by measuring IRF1 mRNA and protein expression (Supplemental Fig. S1G, 
H). Consistently, overexpression of IRF1 significantly inhibited the intracellular HEV RNA level, 
as well as HEV-related luciferase activity (Fig. 1F) in these cell lines. To validate the antiviral 
ability of IRF1 in the reinfection HEV model, Huh7 cells were infected by HEV or transduced 
with IRF1 at different time points (described previously). The result showed that 
overexpression of IRF1 significantly inhibited HEV infection when IRF1 was transduced with 
(same time, Supplemental Fig. S1I), before (pre, Supplemental Fig. S1J), or after (post, 
Supplemental Fig. S1K) HEV infection. Taken together, these results demonstrate that IRF1 
overexpression effectively inhibits HEV replication and infection in different cell culture 
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models. Furthermore, we investigated whether HEV infection would trigger IRF1 expression 
in different cell lines, including Huh7, HepaRG, A549, and MRC5. Each cell line was infected 
by HEV. We found that IRF1 expression can be induced at an early stage of HEV infection (2 h 
after infection) in HepaRG and A549 cells (Supplemental Fig. S2A, B). In MRC5 and Huh7 cells, 
IRF1 was just slightly induced 2 or 6 h after infection, respectively. 
Subsequently, we determined whether basal IRF1 is necessary for anti-HEV immunity. 
This investigation was pursued by a loss-of-function approach involving knockdown of IRF1 
by lentiviral-based short hairpin RNA (shRNA) constructs. A non-targeted vector was used as 
a control (shCTR). Gene silencing of IRF1 was confirmed by immunoblot analysis and real-
time quantitative RT-PCR (qRT-PCR) (Fig. 1G, H). Consistently, knockdown of IRF1 
significantly promoted HEV replication (Fig. 1H). Thus, both gain- and loss-of-function assays 
demonstrated that IRF1 plays an important role in restricting HEV replication.  
IRF1 overexpression does not trigger IFN production 
Because of the comparable anti-HEV effect of IRF1 and IFNα, we investigated whether IRF1 
triggers IFN production in our cell culture systems, since IRF1 has been reported to induce 
IFNβ expression in particular cell types [24].We first investigated the effect of IRF1 on the 
gene expression level of different IFNs, including IFNα, -β, and -λ in different cell lines. We 
found that the basal mRNA expression levels of several IFN genes including IFNα, -β, and -λ 
were very low in Huh7 and HepaRG cells (Supplemental Fig. S2C) and were not significantly 
affected, even by IRF1 overexpression (Fig. 2A). These results are consistent with those in 
another study that no IFN genes are affected in IRF1-overexpressing Huh7 cells. In addition, 
the expression of all 3 IFN genes was not affected by IRF1 overexpression in A549 and MRC5 
cells (Fig. 2B). As a positive control, the IFN β and-λ genes were effectively induced by the 
RIG-I activator 5’pppRNA [25] in A549 cells. To further confirm the lack of IFN production in 
IRF1-overexpressing cells, we collected the conditioned medium from the transduced cells 
(supernatant) and performed an IFN functional assay, as well as a highly sensitive HCV-based 
bioassay (Fig. 2C) [26]. To this end, we used a lentiviral transcriptional reporter system to 
mimic IFN response by expressing the firefly luciferase driven by a promoter containing 
multiple ISREs [15].  
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Figure 1. IRF1 effectively 
inhibits HEV replication.  
A) Real-time qRT-PCR 
analysis of IRF1 mRNA 
expression in Huh7 cells 
transduced with IRF1 or 
Fluc (control) vectors or 
treated with IFNα (1000 
IU/mL) for 48 h (n = 7). 
Data were normalized to 2 
housekeeping genes, 
GAPDH and RP2. B, C) 
Immunoblot (B) and 
immunofluorescence (C) 
analyses of Huh7 cells 
transduced with IRF1, Fluc 
(CTR) vector or treated 
with IFNα (1000 IU/mL) for 
48 h. Band intensity data of 
each immunoblot was 
quantified by Odyssey 
Software. All data were 
normalized to actin 
expression, and control 
was set as 1. Green: IRF1 
protein; blue: DAPI. Scale 
bar, 10 mm. D) HEV viral 
replication related Gaussia 
luciferase activity in Huh7-
p6-Luc model transduced 
with IRF1 or Fluc vector or 
treated with IFNα (1000 
IU/mL) for 24 h, 48 h or 72 
h (n = 4 independent 
experiments with each of 3 
- 4 replicates) and real-time 
qRT-PCR analysis of HEV 
viral RNA in Huh7-p6 full-
length HEV model 
transduced with IRF1 or 
Fluc vector or treated with 
IFNα (1000 IU/mL) for 48 h 
(n = 7). RLU: relative 
luciferase unit. E) 
Genotype 1 HEV 
(Sar55/S17/luc) viral 
replication-related Gaussia luciferase activity in Huh7-Sar55/S17/luc model transduced with IRF1 or 
Fluc vector for 48 h (n = 4 independent experiments with each of 3 - 4 replicates). F) HEV viral 
replication-related Gaussia luciferase activity in a A549-p6-Luc model (n = 4 independent 
experiments with each of 3 - 4 replicates) or qRT-PCR analysis of HEV viral RNA in HepaRG-p6-HEV 
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and MRC-5-p6 HEV models transduced with IRF1 or Fluc vector for 48 h (HepaRG: n = 4; MRC-5: n = 
5). G) Immunoblot analysis of Huh7 cells transduced with lentiviral shRNA vectors targeting IRF1 or 
nontargeted control (shCTR). H) Real-time qRT-PCR analysis of IRF1 and HEV viral RNA level relative 
to shCTR (n = 3-5). Data were normalized to Fluc control (CTR, set as 1) (D-F) and are means ± SEM. 
*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
As shown in Fig. 2D, the supernatant from IRF1-overexpressing Huh7 cells was unable 
to stimulate an IFN response in the ISRE reporter assay. Meanwhile, supernatants from 
HepaRG, A549, and MRC5 cells did not stimulate IFN response (Fig. 2F) in the ISRE reporter 
assay. Although the HCV replicon is very sensitive to IFN, the supernatant collected from 
IRF1 transduced cells did not affect HCV replication (Fig. 2E). These data indicate that IRF1 
overexpression does not trigger IFN production in Huh7, HepaRG, A549, and MRC5 cells. 
 
Figure 2. IRF1 overexpression does not trigger IFN production.  
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A, B) Real-time qRT-PCR analysis of IFN gene expression in Huh7 (A), HepaRG (A), A549 (B) and MRC5 
(B) cells transduced with IRF1 or Fluc vector for 48 h (n = 3). For A549 cells, 5’pppRNA (0.1 mg/mL) 
was transfected as a positive control (IRF1, n = 3; 5’pppRNA, n = 1). Data were normalized to Fluc 
control (CTR, set as 1). C) Production of conditioned medium (supernatant). D, E) ISRE firefly 
luciferase activity in Huh7-ISRE-Luc model (D) and HCV luciferase activity in Huh7-ET-Luc model (E) 
treated with conditioned medium from Huh7 cells or IFNα for 48 h (n = 3 independent experiments 
with each of 3–4 replicates). F) ISRE firefly luciferase activity in Huh7-ISRE-Luc treated with 
conditioned medium from HepaRG, A549, or MRC5 cells for 48 h (n = 3 independent experiments 
with each of 2 - 3 replicates). Data were normalized to GFP control (D-F) (CTR, set as 1). Data are 
means ± SEM. **P < 0.01. NS, not significant. 
IRF1 activates STAT1 gene transcription leading to enhanced protein 
expression and phosphorylation 
IRF1 was first described as a transcription factor [24] and has more than 200 binding sites in 
the human genome [27]. By retrieving genome-wide IRF1 ChIP-seq data from the ENCODE 
ChIP-seq Experiment Matrix database, we unexpectedly found that IRF1 bound directly to 
the promoter region of the STAT1 gene (Fig. 3A), a key component of IFN signaling. 
To validate whether IRF1 induces transcription of STAT1 in our system, we first tested 
mRNA expression of STAT1 in IRF1-overexpressing Huh7 cells. Indeed, we observed that 
overexpression of IRF1 potently induced mRNA expression of STAT1 (Fig. 3B), but not JAK or 
STAT2 (Fig. 3C). In addition, IRF1 also potently induced STAT1 mRNA expression in HepaRG, 
A549, and MRC5 cells (Fig. 3D). Induction led to enhanced expression of STAT1 protein and 
activation of STAT1 phosphorylation at the Tyr701 site, which is an indispensable marker of 
STAT1 activation (Fig. 3E). In addition, IRF1 led to enhanced expression of STAT1 protein and 
activation of STAT1 phosphorylation in HepaRG, A549, and MRC5 cells (Fig. 3F). The results 
demonstrated that IRF1 effectively activates STAT1 gene transcription, resulting in enhanced 
protein expression and phosphorylation. 
IRF1 activates the transcription of antiviral ISGs  
In general, binding of IFNs to their receptors activates JAK1, resulting in tyrosine 
phosphorylation of STAT1 and -2, followed by the formation and nuclear translocation of the 
STAT1-STAT2-IRF9 complex, a transcription factor complex known as ISGF3, which in turn 
binds to the ISRE motifs in the genome DNA and subsequently drives the global transcription 
of ISGs to establish an antiviral status [28]. Since IRF1 activates STAT1, we further investigated 
whether it can also trigger functional effects of STAT1 activation including ISG transcription. 
Indeed, IRF1 could significantly increase ISRE-regulated luciferase activity (Fig. 4A) 
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comparable to high-dose IFNα treatment in the Huh7-ISRE-Luc model. Furthermore, IRF1 
stimulated the expression of 17 tested ISGs at various levels (Fig. 4B and Supplemental Fig. 
S2D), whereas the control GFP or Fluc vectors did not affect their expression (Supplemental 
Fig. S2E). The stimulation of ISGs by IRF1 was further confirmed in HepaRG, A549, and MRC5 
cells (Fig. 4C-E). These results triggered us to further investigate whether these actions of 
IRF1 occur totally via the JAK-STAT pathway. 
 
Figure 3. IRF1 activates STAT1 gene transcription leading to enhanced protein expression and 
phosphorylation.  
A) STAT1 genes with IRF1 binding to their promoter regions. The normalized binding signals were 
used as the input data. Binding peak detection was performed with PeakSeq v1.01 for identifying and 
ranking peak regions in ChIP-Seq data analysis. The y-axis value represents the binding signaling 
value; the black bar in the left corner represents the scale (5000 bp). B, C) Real-time qRT-PCR analysis 
of STAT1 expression (B, n = 8) and STAT2 and JAK1 expression (C, n = 3) in Huh7 cells transduced with 
IRF1 vector or treated with IFNα (1000 IU/mL) for 48 h. D) Real-time qRT-PCR analysis of STAT1 
expression in HepaRG, A549, and MRC5 cells transduced with IRF1 vector or treated with IFNα (1000 
IU/mL) for 48 h (n = 5-6). E, F) Immunoblot of Huh7 (E), HepaRG (F), A549 (F) and MRC5 (F) cells 
overexpressing IRF1 or treated with IFNα (1000 IU/mL) for 48 h. pSTAT1 (Tyr701), STAT1 
phosphorylated at the Tyr701 site. Data were normalized to Fluc control (CTR, set as 1) (B-D) and are 
means ± SEM. *P < 0.05; ***P < 0.001; NS, not significant. 
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Figure 4. IRF1 
activates the 
expression of 
ISGs.  
A) ISRE 
promoter-
related firefly 
luciferase 
activity in Huh7-
ISRE-Luc model 
transduced with 
IRF1 vector or 
treated with 
IFNα (1000 
IU/mL) for 48 h 
(n = 4 
independent 
experiments 
with each of 3 - 
4 replicates). B-
E) Real-time 
qRT-PCR analysis 
of gene 
expression in 
Huh7 (B), 
HepaRG (C), 
A549 (D), and 
MRC5 (E) cells 
transduced with 
IRF1 or Fluc 
vector or 
treated with 
IFNα (1000 
IU/mL) for 48 h 
(n = 3-5). Data 
were normalized 
to GFP (A, CTR, 
set as 1) or Fluc 
control (B-E) (set 
as 1, not shown) 
and are means ± 
SEM. *P < 0.05; 
**P < 0.01; ***P 
< 0.001; NS, not 
significant. 
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Induction of ISGs and anti-HEV of IRF1 relies on STAT1 phosphorylation  
JAK1 is the key upstream kinase that dictates STAT1 phosphorylation and the activation of 
IFN signaling. Activation of STAT1 phosphorylation by IFNα or IRF1 overexpression was 
almost completely blocked by a pharmacological JAK inhibitor, JAK inhibitor 1 (Fig. 5A). 
Similarly, JAK inhibitor 1 significantly diminished IRF1- and IFNα-induced ISRE promoter 
activation (Fig. 5B) and ISG transcription (Fig. 5C, D) without affecting vector delivered IRF1 
overexpression (Fig. 5E) and cell viability (Fig. 5F). In line with the abrogation of ISG 
induction, the anti-HCV and -HEV capability of IRF1 was diminished by JAK inhibitor 1 in an 
HCV replicon model (Fig. 5G) and in HEV subgenomic and full-length models (Fig. 5H, I). To 
further validate our observations, another JAK inhibitor, CP-690550 (tofacitinib), was used, 
and similar results were obtained (Supplemental Fig. S3).  
The anti-HEV ability of IRF1 also requires key components of the ISGF3 
complex 
To further investigate the antiviral ability of IRF1 related to the JAK-STAT pathway, we 
studied the effects of the ISGF3 complex, which is a downstream element of the JAK-STAT 
cascade. The ISGF3 complex consists of STAT1, STAT2, and IRF9 and mediates ISG 
transcription. Gene knockdown of STAT1 (Fig. 6A) significantly promoted HEV replication (Fig. 
6B), suggesting a basal defense function of this pathway. When STAT1 was silenced, IRF1- or 
IFNα-induced ISRE promoter activation was significantly attenuated (Fig. 6C). Consistently, 
ISG induction as well as anti-HEV effects of IRF1 were significantly attenuated in STAT1-
silenced Huh7 cells (Fig. 6D, E). Next, we silenced IRF9, another component of the ISGF3 
complex (Fig. 6F). Similarly, HEV replication was also significantly promoted when IRF9 was 
silenced (Fig. 6G), also suggesting a basal anti-HEV function. Consistently, the depletion of 
IRF9-attenuated IRF1 induced ISRE promoter activation and ISG expression (Fig. 6H, J). As 
expected, the antivirals of IRF1 and IFNα were also attenuated (Fig. 6I). These collective 
results suggest that the ISGF3 complex is necessary for the induction of ISGs and the anti-
HEV effect of IRF1.  
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Figure 5. Inhibition of JAK1 diminishes the induction of ISG and the anti-HEV effect of IRF1.  
A) Immunoblot analysis of Huh7 cells transduced with IRF1 vector or treated with JAK inhibitor 1 (10 
mM) for 48 h or IFNα (1000 IU/mL) for 30 min or 48 h. B) ISRE firefly luciferase activity in Huh7-ISRE-
Luc model transduced with IRF1 vector or treated with IFNα (1000 IU/mL) or JAK inhibitor 1 (10 mM) 
for 48 h (n = 4 independent experiments with each of 3 - 4 replicates). C-F) Real-time qRT-PCR 
analysis of ISG expression (C, n = 6; D, n = 3), IRF1 (E) (n = 4) and MTT assay analysis of cell viability (F) 
(n = 3 independent experiments with each of 3 - 4 replicates) in an Huh7 cell HEV model transduced 
with IRF1 vector or treated with IFNα (1000 IU/mL) or JAK inhibitor 1 (10 mM) for 48 h. G-I ) HCV viral 
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replication-related firefly luciferase activity in the Huh7-ET-Luc model (G, n = 3 independent 
experiments with each of 2 - 3 replicates) and HEV-related luciferase activity (H, n = 4 independent 
experiments with each of 3 - 4 replicates) as well as HEV viral RNA (I, n = 7) in the Huh7-based cell 
HEV model transduced with IRF1 vector or treated with IFNα (1000 IU/mL) or JAK inhibitor 1 (10 mM) 
for 48 h. Data were normalized to untreated GFP (B, G) or Fluc (C-F, H, I) control (CTR) (set as 1). Data 
presented as means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
 
Figure 6. The antiviral function of IRF1 requires key components of the ISGF3 complex. 
A) Immunoblot and real-time qRT-PCR analyses (n = 4) of Huh7 cells transduced with lentiviral shRNA 
vectors that targeting STAT1 or nontargeted control vector shCTR. B) Real-time qRT-PCR analysis of 
HEV viral RNA in Huh7-p6 model with STAT1 knockdown relative to shCTR (n = 4). Data were 
normalized to shCTR control (A, B). C) ISRE firefly luciferase activity in STAT1 knockdown Huh7-ISRE-
Luc cells transduced with IRF1 vector (stock with 100 times dilution) or treated with IFNα (1 IU/mL) 
(n = 3 independent experiments with each of 4 replicates). D) Real-time qRT-PCR analysis of HEV viral 
RNA in STAT1-knockdown Huh7-p6 model transduced with IRF1 vector or treated with IFNα (1000 
IU/mL) for 48 h (n = 6). Data were normalized to untreated shCTR or STAT1sh1 cells, respectively 
(both set as 1) (C, D). E) Real-time qRT-PCR analysis of gene expression in STAT1 knockdown or shCTR 
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cells transduced with IRF1 or Fluc vector for 48 h (n = 4). Data were normalized to shCTR cells that 
transduced Fluc vector (set as 1, not shown). F) Immunoblot analysis of Huh7 cells transduced with 
lentiviral shRNA vectors that target IRF9 or nontargeted control vector shCTR. G) Real-time qRT-PCR 
analysis of HEV viral RNA in Huh7-p6 model with IRF9 knockdown relative to shCTR (n = 4). H) ISRE 
firefly luciferase activity in IRF9 knockdown Huh7-ISRE-Luc model transduced with IRF1 vector (stock 
with 1003 dilution) or treated with IFNα (1 IU/mL) (n = 3 independent experiments with each of 3 
replicates). Data were normalized to untreated shCTR and IRF9sh1 cells (both set as 1). I) Real-time 
qRT-PCR analysis of HEV viral RNA and gene expression (J) in IRF9 knockdown Huh7-p6 model 
transduced with IRF1 vector or treated with IFNα (1000 IU/mL) for 48 h (n = 5). Data were normalized 
to untreated shCTR and IRF9sh1 cells (both set as 1) and are means ± SEM (H-J). *P < 0.05; **P < 
0.01; ***P < 0.001; NS, not significant. 
The induction of ISGs and the anti-HEV effect of IRF1 overlaps with IFNα but is 
potentiated by ribavirin  
We observed that the patterns of ISG induction by IFNα and IRF1 correlated highly, 
suggesting a potential overlap of these two anti-HEV mechanisms (Fig. 7A). Gene knockdown 
of IRF1 did not impair the IFNα-mediated anti-HEV effect (Fig. 7B) and ISG induction (Fig. 7C, 
D). Furthermore, combined IFNα and IRF1 overexpression did not yield additional induction 
of STAT1 and IRF1 expression (Fig. 7E, F) or additional anti-HEV activity (Fig. 7G, H). These 
results suggest that IFNα and IRF1 converged in the JAK-STAT pathway to exert anti-HEV 
effects. 
One study showed that ribavirin potentiates an antiviral IFN response by augmenting 
ISG induction [29]. Thus, we tested the combined effect of ribavirin and IRF1 overexpression 
on ISG induction. Consistent with the previous study, we observed that ribavirin alone could 
up-regulate several ISGs. In contrast to IFNα, ribavirin further promoted IRF1-induced ISG 
expression including IRF1 in Huh7 cells (Fig. 8A). Furthermore, ribavirin also enhanced the 
ISG induction and anti-HEV ability of IRF1 in HepaRG, A549, and MRC5 cells (Supplemental 
Fig. S4A-C). More important, the combination of ribavirin and IRF1 further augmented their 
anti-HCV and -HEV effects (Fig. 8B-D). Overall, these results indicate that the induction of 
ISGs and the anti-HEV effect of IRF1 overlaps with IFNα but is potentiated by ribavirin (Fig. 9). 
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Figure 7. The induction of ISGs and the anti-HEV action of IRF1 overlaps with IFNα.  
A) Correlation analysis of ISG expression in Huh7 cells transduced with IRF1 vector or treated with 
IFNα (1000 IU/mL) for 48 h. Data were normalized to Fluc control (set as 1) and were analyzed by the 
2-tailed Pearson correlation method. B) Real-time qRT-PCR analysis of HEV viral RNA in IRF1-
knockdown cells treated with IFNα (10, 100, or 1000 IU/mL) for 48 h (shCTR: n = 4; IRF1sh1 and -2: n 
= 3). Data were normalized to untreated shCTR, IRF1sh1, or IRF1sh2 cells, respectively (all set as 1). C, 
D) Real-time qRT-PCR analysis of IRF1 and STAT1 (C) and ISG15, MX1, and IFI6 (D) expression in IRF1-
knockdown Huh7 cells treated with IFNα (10, 100, or 1000 IU/mL) for 48 h (n = 3). IRF1 expression 
was normalized to untreated shCTR (set as 1). STAT1, ISG15, MX1, and IFI6 expression was 
normalized to untreated shCTR, IRF1sh1, and IRF1sh2 cells, respectively (all set as 1). G-H) Real-time 
qRT-PCR analysis of IRF1 (E, n = 5), STAT1 (F, n = 5), and HEV viral RNA (H, n = 6) expression and HEV-
related luciferase activity (G, n = 3 independent experiments with each of 2-4 replicates) in the Huh7-
p6-Luc model transduced with IRF1 vector or treated with different doses of IFNα (10, 100, and 1000 
IU/mL) for 48 h. Data were normalized to Fluc control without IFNα treatment (set as 1) and are 
means ± SEM (E-H). *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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Figure 8. Ribavirin potentiates IRF1-mediated ISG induction and anti-HEV activity.  
A) Real-time qRT-PCR analysis of IRF1, STAT1, DDX58, RSAD2, ISG15, IRF9, and IFI6 expression in 
Huh7 cells transduced with IRF1 vector or treated with ribavirin (1, 10, or 100 mM) for 48 h (n = 5). B) 
HCV-related luciferase activity in Huh7-ET-Luc model and transduced with IRF1 vector (stock with 
503 dilution) or treated with ribavirin (1, 10, or 100 mM) for 48 h (n = 3 independent experiments 
with each of 4 replicates). C) HEV-related luciferase activity in Huh7-p6-Luc model and transduced 
with IRF1 vector or treated with ribavirin (1, 10, or 100 mM) for 48 h (n = 3 independent experiments 
with each of 4 replicates) and real-time qRT-PCR analysis of HEV viral RNA in Huh7-p6 model 
transduced with IRF1 vector or treated with ribavirin for 48 h (n = 5). Data were normalized to GFP 
(B) or Fluc (A, C, D) control without ribavirin treatment (set as 1). Data are means ± SEM.*P < 0.05; 
**P < 0.01; ***P < 0.001; NS, not significant. 
Chapter 6 
138 | P a g e  
 
 
Figure 9. IRF1 restricts HEV replication by activating STAT1 to induce the expression of ISGs.  
IRF1 could induce the expression of STAT1. The induction of STAT1 expression further activated the 
transcription of a panel of downstream antiviral ISGs. The production of these ISGs could inhibit HEV 
replication. 
Discussion 
Innate immunity is the frontier in the battle against viral pathogens [30]. The activation of 
innate immune response relies on the recognition of pathogens by specific pattern 
recognition receptors (e.g., Toll-like, RIG-I-like, and NOD like receptors) [31], leading to the 
production of cytokines and chemokines such as IFNs. IFN triggers transcription of hundreds 
of ISGs through the JAK-STAT pathway. The products of these ISGs ultimately exert antiviral 
functions [30]. Several recent studies have focused on the characterization of individual ISGs, 
with respect to their antiviral efficacy and potential mechanism of action [32-34]. Two large-
scale screening studies unexpectedly showed that only a small subset of ISGs have antiviral 
effects and some even have proviral effects on certain viruses [10, 11]. Among more than 380 
tested ISGs, IRF1 was one of the strongest antiviral agents against a broad spectrum of 
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viruses. In this study, we found IRF1 to be basally expressed in liver cells and to confer 
resistance to HEV infection. Ectopic overexpression of IRF1 effectively inhibits HEV 
replication, as shown in multiple cellular systems.  
Although IRF1 has been reported to induce the expression of some ISGs similar to 
type I IFNs [10, 11], the exact antiviral mechanism of IRF1 remains largely elusive. It has been 
reported that IRF1 could act as a transcription factor that activates either IFNβ gene 
expression in virus infected fibroblasts [24] or IFNα gene expression in uninfected cells [35]. 
Therefore, we initially hypothesized that the anti-HEV effect of IRF1 may act via the 
induction of IFN production in the cell model. However, we convincingly demonstrated that 
HEV cell models including a human hepatoma cell line (Huh7), primary human hepatocyte-
like cell line (HepaRG), human lung epithelial carcinoma cell line (A549), and human fetal 
lung fibroblast cell line (MRC-5) do not produce IFNs upon IRF1 overexpression by both gene 
expression and functional assays. Our observation in this respect is consistent with a 
previous study showing that the Huh7 cell line responds to IFN but does not produce IFN [36]. 
Furthermore, microarray analysis has shown that no IFN genes were up-regulated in IRF1-
overexpressing Huh7 cells [11]. 
IFNα was widely used to treat chronic HBV and HCV infection [28]. In some cases, IFNα 
was also used to treat chronic HEV infection [9]. In our previous study, we demonstrated that 
IFNα had moderate and delayed anti-HEV effects in cell culture models and IFNβ/α/γ did not 
show a notable antiviral effect on HEV replication [37]. Similarly, Todt et al. [38] reported a 
weak to moderate inhibition of HEV replication by different types of IFNs. Our study 
demonstrated that IRF1 could effectively inhibit HEV replication without triggering IFN 
production in host cells. This finding may provide new ideas for developing anti-HEV 
strategies. Surprisingly, both studies demonstrated that HEV could down-regulate ISG 
expression induced by different IFN types [37, 38]. These observations suggest that some HEV 
strategies would subvert host antiviral defenses. Consistently, we observed that IRF1 was 
induced at the early stage in most cell lines (Supplemental Fig. S2A, B). This result indicates 
that, after the infection is established, HEV can suppress the immune response elicited by 
itself. 
Given the fact that IRF1 is also a transcription factor and has more than 200 binding 
sites in the human genome [27], we have explored this scenario to understand its anti-HEV 
mechanism of action. Indeed, the IRF1 data retrieved from the ChIP-seq database revealed 
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that IRF1 could directly bind to the promoter region of the STAT1 gene. Consistently, our 
functional assay demonstrated that IRF1 could drive the transcription of STAT1, resulting in 
protein expression and phosphorylation Tyr701 site, which is an indispensable marker of 
STAT1 activation. Correspondingly, the IRF1 induced STAT1 phosphorylation leading to the 
transcription of a series of individual ISGs. We further showed that ISG induction and anti-
HEV ability of IRF1 rely heavily on STAT1 phosphorylation. Furthermore, the integrity of the 
ISFG3 complex is also required. Although previous study has reported the induction of some 
ISGs in STAT1-deficient fibroblasts by IRF1 [11], this finding may indicate that there are 
multiple mechanisms mediating the function of IRF1, including STAT1-dependent or -
independent mechanisms, probably depending on the cell type and particular circumstances. 
In this study, we reported a new antiviral mechanism of IRF1 by inducing the expression and 
phosphorylation of STAT1 without triggering IFN production. This process subsequently 
activated the JAK-STAT pathway to transcribe antiviral ISGs. It would be interesting to 
address the relevance of this mechanism in IRF1-mediated effects on other viruses. 
Because IRF1 and IFNα converged in the JAK-STAT cascade to drive ISG transcription, 
we further evaluated the combinatory effects of IFNα and IRF1. As expected, combination of 
IFNα and IRF1 did not further promote ISG induction and anti-HEV activities. In contrast, 
IFNα and ribavirin have moderately synergistic anti-HEV effects in 2 HEV cell-culture 
replication models [39]. As a broad antiviral agent [40], ribavirin can potentiate IFN by 
augmenting ISG induction in an HCV culture model, which is mediated by a novel mechanism 
different from the classic IFN or intracellular RNA sensing pathways [29]. In this study, we also 
tested the combined effects of IRF1 and ribavirin, and ribavirin further enhanced IRF1-
induced ISG expression. More important, combination of IRF1 and ribavirin reinforced ISG 
induction and its anti-HEV effects, although the exact mechanism remains to be further 
investigated. 
In summary, we characterized IRF1 as an important host factor that effectively 
inhibits HEV replication. Mechanistically, without triggering IFN production in host cells, IRF1 
activates gene transcription of STAT1, which subsequently enhances its protein expression 
and phosphorylation to stimulate antiviral ISG transcription. Furthermore, the induction of 
ISGs and the anti-HEV effect of IRF1 overlapped IFNα but were potentiated by ribavirin. Thus, 
this study has shed new light on the molecular insight into an important anti- HEV ISG, which 
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may help in understanding the complexity of HEV-host interactions and in developing new 
antiviral strategies. 
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Supplementary Figures 
 
Fig. S1. Over-expression of control vectors does not affect HEV replication. 
(A) Fluorescent microscopic analysis of Huh7 cells transduced with TagRFP-IRF1 lentiviral vector for 
48 h. Red indicates TagRFP and blue indicates DAPI (Scale bar: 50 µm). (B) Photinus pyralis luciferase 
activity (n = 4-8) and qRT-PCR analysis of TagRFP mRNA expression (n = 3) in Huh7 cells transduced 
with Fluc, GFP vector or untreated (CTR) for 48 h. HEV viral replication-related Gaussia luciferase 
activity in Huh7-p6-Luc model (C) transduced with GFP, Fluc vector or untreated (CTR) for 24 h, 48 h 
and 72 h (n = 3 independent experiments with each of 2 - 3 replicates) and qRT-PCR analysis of HEV 
viral RNA in Huh7-p6 full-length HEV model (D) transduced for 48 h (n = 3). RLU: relative luciferase 
unit. HCV-related firefly luciferase activity in Huh7-ET-Luc model (E) (n = 4 independent experiments 
with each of 3 - 4 replicates) and MTT assay analysis of cell viability in Huh7 cells (F) (n = 3 
independent experiments with each of 3 - 4 replicates) transduced with IRF1, GFP vector or treated 
with IFNα (1000 IU/mL) for 48 h. qRT-PCR analysis (G, n = 6) or immunoblotting analysis (H) of 
HepaRG cells, A549 cells and MRC5 cells transduced with IRF1, Fluc vector or treated with IFNα (1000 
IU/mL) for 48 h. (I, J, K) qRT-PCR analysis of HEV and IRF1 expression in Huh7 cells transduced with 
IRF1 or infected by HEV at indicted time point. Date presented as mean ± SEM (*, P < 0.05; **, P < 
0.01; ***, P < 0.001; NS, not significant). 
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Fig. S2. HEV infection induces IRF1 expression in some cell lines. 
qRT-PCR analysis (A, n = 5) and immunoblotting analysis (B) of Huh7, HepaRG, A549 and MRC5 cells 
infected by HEV for 6 h (For 2 h post infection, cells were incubated with HEV for 2 hours and then 
cells were lysed). At different time point post HEV infection (2 h, 6 h, 24 h or 48 h post infection), HEV 
RNA and IRF1 expression level was quantified. HEV RNA level was normalized to 2 h post infection. 
IRF1 mRNA level and protein level was normalized to un-infected cells at each time point. (C) Plot of 
qRT-PCR analysis of interferon gene expression in Huh7 and HepaRG cells transduced with IRF1 or 
Fluc (CTR) vector for 48 h. Rn: Fluorescence signal from the reporter dye normalized to that from the 
negative control. (D) qRT-PCR analysis of gene expression in Huh7 cells transduced with IRF1 vector 
or treated with IFNα (1000 IU/mL) for 48 h. (E) qRT-PCR analysis of gene expression in Huh7 cells 
transduced with GFP, Fluc vector or untreated for 48 h (n = 3). Data was normalized to untreated 
control (CTR, set as 1, not shown). Date presented as mean ± SEM (*, P < 0.05; NS, not significant). 
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Fig. S3. JAK 
inhibitor, CP-
690550 
diminishes the 
induction of ISG 
and the anti-
HEV effect of 
IRF1. 
(A) 
Immunoblotting 
analysis of Huh7 
cells transduced 
with IRF1 vector 
or treated with 
CP-690550 
(1000 ng/mL) 
for 48 h or IFNα 
(1000 IU/mL) 
for 30 min or 48 
h. (B) ISRE 
firefly luciferase 
activity in Huh7-
ISRE-Luc model 
transduced with 
IRF1 vector or 
treated with 
IFNα (1000 
IU/mL) or CP-
690550 (1000 
ng/mL) for 48 h 
(n = 4 
independent 
experiments 
with each of 3 - 
4 replicates). 
qRT-PCR 
analysis of ISG 
expression (C, n 
= 4; D, n = 3), 
IRF1 (E, n = 5) 
and MTT assay 
analysis of cell 
viability (F, n = 3 independent experiments with each of 3 - 4 replicates) in Huh7 cell HEV model 
transduced with IRF1 vector or treated with IFNα (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h. 
HEV-related luciferase activity (G, n = 4 independent experiments with each of 4 replicates) and HEV 
viral RNA (H, n = 6) in Huh7-based cell HEV model transduced with IRF1 vector or treated with IFNα 
(1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h. Data was normalized to untreated GFP (B) or Fluc 
(C, D, E, F and H) control (CTR, set as 1). Date presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, 
P < 0.001; NS, not significant). 
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Fig. S4. Ribavirin 
potentiates 
IRF1-mediated 
ISG induction 
and anti-HEV 
activity in 
different cell 
lines. 
qRT-PCR analysis 
of IRF1, STAT1, 
DDX58, IFIH1, 
ISG15, IRF9, 
IFI27, MX1 
expression and 
HEV viral RNA 
level in HepaRG-
p6 model (A), 
A549-p6 model 
(B) and HEV 
infected MRC5 
cells (C) 
transduced with 
IRF1 vector or 
treated with 
ribavirin (1, 10 
or 100 μM) for 
48 h (n = 4-6). 
Date presented 
as mean ± SEM 
(*, P < 0.05; **, 
P < 0.01; ***, P < 
0.001; NS, not 
significant). 
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Abstract 
IFN-α has been used for decades to treat chronic hepatitis B and C, and as an off-label 
treatment for some cases of hepatitis E virus (HEV) infection. TNF-α is another important 
cytokine involved in inflammatory disease, which can interact with interferon signaling. 
Because interferon-stimulated genes (ISGs) are the ultimate antiviral effectors of the 
interferon signaling, this study aimed to understand the regulation of ISG transcription and 
the antiviral activity by IFN-α and TNF-α. In this study, treatment of TNF-α inhibited 
replication of HCV by 71  ±  2.4% and HEV by 41  ±  4.9%. Interestingly, TNF-α induced the 
expression of a panel of antiviral ISGs (2-11 fold). Blocking the TNF-α signaling by Humira 
abrogated ISG induction and its antiviral activity. Chip-seq data analysis and mutagenesis 
assay further revealed that the NF-κB protein complex, a key downstream element of TNF-α 
signaling, directly binds to the ISRE motif in the ISG promoters and thereby drives their 
transcription. This process is independent of interferons and JAK-STAT cascade. Importantly, 
when combined with IFN-α, TNF-α works cooperatively on ISG induction, explaining their 
additive antiviral effects. Thus, our study reveals a novel mechanism of convergent 
transcription of ISGs by TNF-α and IFN-α, which augments their antiviral activity against HCV 
and HEV. 
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Introduction 
Cytokines orchestrate cellular communication in an autocrine, juxtacrine, or paracrine 
fashion through binding to distinct families of receptors, triggering specific immune 
responses against invading pathogens. The interferon (IFN)-mediated innate immune 
response is probably the most prominent response and provides a robust first defense line. 
Among different types of interferons, IFN-α (a type I member) has been used for decades to 
treat chronic hepatitis B or C infection in the clinic [1]. When stimulated by its cognate ligand, 
interferon receptors respond by the activation of kinases of the Janus family (JAKs), which in 
turn phosphorylate tyrosine residues in the intracellular tail of the interferon receptors. 
These phosphotyrosines serve as docking sites for recruitment and phosphorylation of the 
Signal Transducers and Activators of Transcription (STAT) family, which provokes STAT1 and 
STAT2 dimerization and subsequent binding to interferon regulatory factor 9 (IRF9) to form 
the IFN-stimulated gene factor 3 (ISGF3) complex. The ISGF3 complex translocates into the 
nucleus, and binds to specific promotor elements denoted as interferon signaling response 
elements (ISREs) and thus mediate the transcription of so-called interferon-stimulated genes 
(ISGs). ISGs are the ultimate antiviral effectors of the interferon signaling. 
It is generally believed that ISGs are predominantly induced by interferons. However, 
ISGs are still up-regulated in embryonic fibroblasts from IFN alpha/beta receptor knockout 
mouse upon infection of West Nile virus [2]. These observations suggest the existence of 
alternative mechanisms of regulating ISG transcription. But these non-canonical mechanisms 
remain largely unknown. 
Tumor necrosis factor alpha (TNF-α) is another important cytokine that mediates 
host response to infections. TNF-α/TNFR interactions can play decisive roles in the outcome 
of a number of viral infections, contributing to virus control or immune mediated pathology 
[3]. Deregulation of TNF-α is associated with many pathological conditions, including various 
types of arthritis and inflammatory bowel disease (IBD) [4]. TNF-α inhibitors have been 
successfully used in the clinic to treat these chronic immune-mediated diseases [5]. However, 
patients receiving TNF-α inhibitors are often at high risk of viral infections [6]. Treatment with 
TNF-α inhibitors have been reported to increase reactivation of concurrent chronic hepatitis 
B and potentially increase hepatitis C virus (HCV) replication [7], further supporting the 
importance of TNF-α in defending the human body against viral infections. Interestingly, 
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several previous studies reported crosstalk between TNF-α and the antiviral interferon 
signaling and ISG expression in the setting of vesicular stomatitis virus [8], hepatitis C virus 
(HCV) [9], respiratory virus [10] and poxvirus infections [11]. 
However, the exact antiviral mechanisms of TNF-α and how it cooperates with the 
interferon signaling remain largely elusive, thus prompting us to explore their molecular 
basis. Here we report that TNF-α alone was sufficient to induce the expression of ISGs and to 
exert antiviral activity against HCV and hepatitis E virus (HEV). This is through the activation 
of the NF-κB signaling but independent of the canonical interferon pathway. Surprisingly, we 
found a consensus DNA binding sequence between the NF-κB and ISRE motif with 
bioinformatics analysis. Functional assays revealed that the NF-κB complex is able to bind to 
the ISRE motif and directly activates the transcription of antiviral ISGs. Combination of TNF-α 
with IFN-α further boosts the induction of ISGs and results in augmented antiviral activity 
against HCV and HEV. Thus, this study identified a non-canonical mechanism of driving 
antiviral ISG transcription, which provides the molecular basis for the antiviral action of TNF-
α and its additive antiviral effect with interferon. 
Results 
TNF-α activates ISG transcription and exerts antiviral activity against HCV and 
HEV 
TNF-α is involved in host responses to a variety of pathogen invasions, including HCV and 
HEV infections [9, 12]. To assess the direct effects of TNF-α on HCV and HEV replication, we 
employed a human hepatocyte cell line, i.e. Huh7, transfected with a HCV or HEV replicon 
luciferase as reporters. In parallel, Huh7 cells constitutively expressing a non-secreted firefly 
luciferase under control of the human phosphoglycerate kinase (PGK) promoter (LV-PGK-Luc) 
were also used for normalization of nonspecific effects on luciferase signals. Both HCV and 
HEV replicon luciferase activity were significantly inhibited by treatment of cells with TNF-α 
(Fig. 1A, B). For instance, 100  ng/mL TNF-α inhibited HCV to 29  ±  2.4% (n  =  5, P  <  0.001), 
HEV to 59  ±  4.9% (n =  5, P  <  0.01) at 72 hrs. 
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Figure 1: TNF-α activates ISG transcription and exerts antiviral activity against HCV and HEV. 
(A) In the Huh7 cell-based subgenomic HCV replicon, treatment with recombinant human TNF-α 
(100 ng/mL) inhibited HCV replication-related luciferase activity as measured at 3 different time 
points (n  =  5). (B) Same as (A) for the Huh7 cell-based subgenomic HEV replicon model. (C) In the 
Huh7 cell-based ISRE luciferase reporter cells, treatment with IFN-α resulted in a dose-dependent 
induction of ISRE-related luciferase activity (n  =  3 independent experiments with 2 - 3 replicates 
each). (D) Same as (C) for TNF-α. (E) Expression profile of 20 antiviral ISGs in Huh7 cells as measured 
by qRT-PCR. Most ISGs were highly up-regulated with TNF-α treatment (n  =  5). Data presented as 
mean  ±  SD (*P  <  0.05; **P  <  0.01; ***P  <  0.001). 
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Since TNF-α has been reported to interacts with interferon signaling and ISGs are the 
ultimate antiviral effectors of the interferon cascade, we thus attempted to investigate 
whether TNF-α alone has any effect on ISG transcription. Based on the knowledge that 
interferon induces ISG expression via the activation of the ISRE motifs within the promoters 
of ISGs, a Huh7 cell line stably harboring a ISRE-driven luciferase reporter was used [13]. As 
expected, IFN-α treatment induced a strong transactivation of ISRE-driven luciferase value 
(Fig. 1C). Surprisingly, TNF-α stimulation also provoked a strong transactivation of the ISRE 
transcription elements (Fig. 1D). This interesting result prompted us to investigate the 
relative expression level of a panel of well-studied antiviral ISGs by qRT-PCR. Consistently, 
treatment of TNF-α provoked the induction of most tested ISGs, ranging from 1.7 to 11.3 
fold increase (Fig. 1E). These data demonstrate that TNF-α transactivates the ISRE motif, 
resulting in the induction of ISGs, which in turn mediate the antiviral effects of TNF-α against 
HCV and HEV. 
Activation of ISRE transcription by TNF-α does not require interferon 
production 
The fact that TNF-α can induce ISGs inspired us to investigate the straightforward possibility 
that TNF-α merely triggers the production of interferons. Interferon regulatory factor 1 (IRF1) 
was demonstrated to be important in a TNF-α triggered IFN-β autocrine loop in primary 
macrophage cells [14]. To dissect whether a similar mechanism exist in our experiment 
system, we first studied the potential involvement of IRF1. Lentiviral vector was used to 
overexpress IRF1 in Huh7 based ISRE-driven luciferase reporter cells and the successful 
overexpression of IRF1 was confirmed at both mRNA and protein levels (Fig. 2A, B). IRF1 
overexpression significantly increased ISRE-regulated luciferase activity (Fig. 2C). Surprisingly, 
the combination of IRF1 overexpression and TNF-α induced a strong additive ISRE activation 
(Fig. 2C). Furthermore, stable IRF1 knockdown by lentiviral RNAi (Fig. 2D, E) had no 
significant effect on TNF-α induced ISRE activation (Fig. 2F). In addition, the involvement of 
another interferon regulatory factor, IRF7, was also examined via loss-of-function assay. 
TNF-α induced ISRE activation was not affected even upon the efficient IRF7 knockdown 
(Supplementary Figure 1A-C). These results suggest that TNF-α triggered ISRE activation is 
independent of IRF1 and IRF7. 
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Figure 2: Activation of ISRE transcription by TNF-α does not require interferon production and the 
JAK-STAT signaling. 
(A) qRT-PCR analysis of IRF1 overexpression by lentiviral vectors in the Huh7 based ISRE luciferase 
reporter cells. Compared to the control vector transduced cells, the IRF1 lentiviral vector showed 
strong IRF1 induction on RNA level. (B) Western blot analysis confirmed the successful 
overexpression of IRF1 by lentiviral vectors in the Huh7 based ISRE luciferase reporter cells. (C) In the 
Huh7 cell-based ISRE luciferase reporter cells, the combination of IRF1 overexpression and TNF-α 
induced a strong additive ISRE activation as measured at 3 different time points (n  =  5). (D) qRT-PCR 
analysis of IRF1 knockdown by lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter 
cells. Compared to the control vector transduced cells, the IRF1 shRNA treated clones showed strong 
reduction of IRF1 RNA levels. (E) Western blot analysis confirmed the successful knockdown of IRF1 
by lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. (F) Knockdown of IRF1 in 
Huh7 based ISRE luciferase reporter cells did not block TNF-α induced ISRE-related luciferase 
activation (n  =  4). (G) The relative IFN-α and β1 expression levels in Huh7 cells were determined by 
qRT-PCR. GAPDH and RP2 served as internal reference genes. (H) IFN-α and β1 expression levels in 
Huh7 cells were not up-regulated upon TNF-α treatment as measured by qRT-PCR (n  =  6). (I) JAK 
inhibitor I (5 μM) did not abrogate TNF-α induced ISRE-related luciferase activation (n  =  3 
independent experiments with 2 - 3 replicates each). Data presented as mean  ±  SD (*P  <  0.05; **P  
<  0.01; ***P  <  0.001; ns, not significant). 
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We next investigated the effects of TNF-α on gene expression of type I interferons. As 
determined by qRT-PCR, the constitutive expression levels of IFN-α and β1 in Huh7 cells are 
rather low, compared to the reference genes GAPDH and RP2 (Fig. 2G). Moreover, TNF-α 
treatment did not significantly increase IFN-α and IFN-β1 mRNA levels (Fig. 2H). This is 
consistent with a previous study showing that the Huh7 cell line responds to interferon but 
does not produce interferon [15]. These data collectively indicate that activation of ISRE 
transcription by TNF-α does not require interferon production in our model system. 
TNF-α induced ISRE activation is independent of the JAK-STAT signaling 
Classically, ISGs are induced by interferons via the JAK-STAT signaling. Following receptor 
activation by interferons, JAK1 phosphorylates STAT1 and Tyrosine kinase 2 (TYK2) 
phosphorylates STAT2. This provokes STAT1 and STAT2 dimerization and subsequent binding 
to IRF9 to form the ISGF3 complex. The ISGF3 complex translocates into the nucleus, binds 
to the ISRE motif [5′-CAGTTTCACTTTCC-3′] and drives the transcription of ISGs 
(Supplementary Figure 2A). To test whether activation of ISRE by TNF-α require JAK-STAT 
signaling, we first examined the role of JAKs. Strikingly, neither JAK inhibitor (an inhibitor of 
JAK1, JAK2, JAK3 and TYK2) nor Bayer-18 (a selective TYK2 inhibitor) abrogated TNF-α 
induced ISRE activation (Fig. 2I and Supplementary Figure 2B). Consistently, TNF-α induced 
ISG expression was not affected by the treatment of JAK inhibitor I (Supplementary Figure 
2D). In contrast, both IFN-α induce ISRE activation and ISG expression were largely blocked 
by JAK inhibitor I (Supplementary Figures 2C and 3A). Interestingly, the selective TYK2 
inhibitor, Bayer-18, did not significantly affect IFN-α induced ISRE activation (Supplementary 
Figure 2C). This is consistent with a previous study, showing that TYK2 plays a restricted role 
in IFN-α signaling [16]. 
Furthermore, to see if TNF-α treatment has any effect on STATs activation and 
translocation, we examined the phosphorylation status of STAT1 at amino acid 701 (Y701P) 
and STAT2 at amino acid 690 (Y690), which are indispensable signature of STAT1 and STAT2 
activation, respectively. WB results showed TNF-α treatment had no effects on the 
phosphorylation of both STAT1 and STAT2 at indicated sites (Fig. 3A, B). Confocal microscopy 
analysis also confirmed that IFN-α induced the activation and nuclear translocation of STAT1 
and STAT2 via the phosphorylation at indicated sites, while TNF-α had no effects (Fig. 3C, D). 
To further exclude a role of STAT1 in TNF-α induced ISRE activation, lentiviral RNAi was used 
Chapter 7 
158 | P a g e  
 
to knockdown STAT1. The stable STAT1 knockdown (Fig. 3E, F) had no effect on both TNF-α 
induced ISRE activation and ISG expression (Fig. 3G, H). Collectively, TNF-α triggered ISRE 
activation is totally independent of STAT1.  
In addition, the role of IRF9 was also verified, which is a key downstream element of 
interferon pathway. IRF9 was up-regulated and translocated into cell nucleus upon IFN-α 
stimulation, whereas TNF-α stimulation did not induce the translocation of IRF9 into cell 
nucleus (Supplementary Figure 3B). These results collectively demonstrate that TNF-α 
induced ISRE activation is independent of the JAK-STAT signaling. 
TNF-α activates ISRE via TNF receptor 1 
TNF receptor (TNFR) is the important upstream component in TNF-α induced signaling 
transduction. TNF acts through two receptors, TNFR1 and TNFR2. TNFR1 is the major 
signaling receptor for TNF-α and is expressed by all human tissues, while TNFR2 is mostly 
expressed in immune cells and mediates limited biological responses [17]. In light of the fact 
that TNF-α is capable of activating ISG transcription, we sought to determine whether this 
action of TNF-α was mediated via TNFR. For this, the ISRE reporter cell line was transduced 
with integrating lentiviral RNAi vectors to silence TNFR1, resulting in a profound down-
regulation of TNFR1 expression (Fig. 4A). As expected, IFN-α induced ISRE activation was not 
influenced (Fig. 4B), but TNF-α induced ISRE luciferase activity was largely abrogated in 
TNFR1 knockdown cells when compared to control cells (Fig. 4C). Consistently, the induction 
of ISGs by TNF-α was also blocked by TNFR1 knockdown (Supplementary Figure 4A). 
To further confirm these results, the clinically widely used drug for rheumatoid 
arthritis patients and Crohn’s disease, Humira (adalimumab), was used. Humira binds 
specifically to TNF-α and blocks its interaction with TNF receptors. As expected, Humira 
effectively blocks TNF-α induced activation of NF-κB luciferase activity (Fig. 5A), NF-κB 
activity being a well-known downstream effect of TNF-α receptor ligation. Importantly, both 
TNF-α induced ISRE luciferase activity and ISG expression were also abrogated by Humira 
treatment (Fig. 5B, C). This effect was not limited to Huh7 cells, but also observed in a 
human lung cell line, A549 (Supplementary Figure 4B). More relevantly, Humira totally 
abolished TNF-α mediated antiviral effect against HCV and HEV (Fig. 5D, E), providing a 
possible explanation for the high risk of infection in patients treated with TNF-α inhibitors. 
Next, we collected serum samples from anti-TNF-α treatment naive Crohn’s disease patients 
Chapter 7 
159 | P a g e  
 
 
Figure 3: TNF-α activates ISRE in a STAT1 
independent manner. 
(A) Western blot analysis of total STAT1 and 
phosphorylated STAT1 (Y701P) protein levels under 
the treatment of TNF-α (100 ng/mL), IFN-α (1000 
IU/mL). (B) Same as (A) for the detection of total 
STAT2 and phosphorylated STAT2 (Y690P) protein 
levels under the treatment of TNF-α, IFN-α. (C) 
Confocal microscopy analysis of phosphorylated 
STAT1 (Y701P) localization in Huh7 cells treated 
with IFN-α or TNF-α. STAT1 was phosphorylated 
and translocated to the nucleus upon IFN-α, but not 
TNF-α treatment. Phosphorylated STAT1 (Y701P) antibody (green). Nuclei were visualized by DAPI 
(blue). (D) Same as (C) for the detection and localization of phosphorylated STAT2 (Y690P). (E) qRT-
PCR confirmed the successful STAT1 knockdown by lentiviral shRNA vectors in the Huh7 based ISRE 
luciferase reporter cells. (F) Western blot analysis confirmed the successful knockdown of STAT1 by 
lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. (G) STAT1 knockdown had 
no significant influence on TNF-α induced ISRE-related luciferase activation as measured at 3 
different time points (n  =  3 independent experiments with 2 -3 replicates each). (H) STAT1 
knockdown exerts no effect on TNF-α induced ISG expression as measured by qRT-PCR (n  =  3). 
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and measured the serum TNF-α levels by ELISA. 3 serum samples with high TNF-α levels 
were selected to treat Huh7 based ISRE-driven luciferase reporter cells (Fig. 5F). Consistently, 
all 3 serum samples exerted higher ISRE activity compared to control serum sample (Fig. 5F, 
right). Furthermore, Humira decreased the serum induced ISRE activity (Supplementary 
Figure 4C). More interestingly, serum samples with higher TNF-α levels inhibited HCV-related 
luciferase activity compared to control serum sample (Supplementary Figure 4D). 
Collectively, these results demonstrate that TNF-α acts via its receptor to activate ISG 
transcription and exerts antiviral activity, which can be blocked by clinically used TNF-α 
inhibitor. 
 
Figure 4: TNF-α activates ISRE via TNF receptor I. 
(A) qRT-PCR analysis of TNFR1 knockdown by lentiviral shRNA vectors in the Huh7 based ISRE 
luciferase reporter cells. Compared to the control vector transduced cells, the two shRNA treated 
clones (sh-02 and sh-03) showed strong reduction of TNFR1 RNA levels. (B) TNFR1 knockdown had no 
significant influence on IFN-α induced ISRE-related luciferase activation as measured at 3 different 
time points (n  =  3 independent experiments with 2 - 3 replicates each). (C) TNFR1 knockdown 
blocked TNF-α induced ISRE-related luciferase activation as measured at 3 different time points (n  = 
 3 independent experiments with 2 - 3 replicates each). 
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Figure 5: Both TNF-α induced ISG expression and antiviral activity against HCV and HEV were 
abrogated by its inhibitor Humira. 
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(A) In the Huh7 cell-based NF-κB luciferase reporter cells, the TNF-α inhibitor, Humira, abrogated 
TNF-α induced NF-κB-related luciferase activation as measured at 3 different time points (n  =  3 
independent experiments with 2 - 3 replicates each). (B) Same as (A) for the Huh7 cell-based ISRE 
luciferase reporter cells. (C) In Huh7 cells, the TNF-α inhibitor, Humira, abrogated TNF-α induced ISG 
expression as measured by qRT-PCR (n  =  4). (D) In the Huh7 cell-based subgenomic HCV replicon, 
Humira abrogated the TNF-α induced anti-HCV effect as measured at 3 different time points (n  =  3 
independent experiments with 2 - 3 replicates each). (E) Same as (D) for Huh7 cell-based subgenomic 
HEV replicon. (F) TNF-α levels in serum samples collected from anti-TNF-α treatment naive Crohn’s 
disease patients were measured by ELISA kit (left). Serum samples with higher TNF-α levels showed 
stronger ISRE-related luciferase activity compared with control serum as measured at 3 different 
time points. Data presented as mean  ±  SD. (*P  <  0.05; **P  <  0.01; ***P  <  0.001; ns, not 
significant). 
TNF-α mediates the activation of ISRE through NF-κB signaling 
Activation of NF-κB signaling is one of the most important canonical responses to the 
stimulation of TNF-α. Following TNF receptor activation by TNF-α, inhibitor of kappa B (IκB) 
proteins undergo phosphorylation dependent ubiquitination and degradation, resulting in 
the activation and translocation of NF-κB dimers into the cell nucleus. In the cell nucleus, NF-
κB dimers bind to the specific NF-κB motifs, [5′-GGGAA/CTTTCC-3′], within the promoter 
regions driving the expression of NF-κB target genes (Supplementary Figure 5A). Because 
some studies have reported that TNF-α can also increase the transcriptional activity of 
activator protein-1 (AP-1) in some specific cell types [18, 19], we thus created Huh7 based 
stable NF-κB or AP-1 driven luciferase reporter cell lines, respectively. As shown in 
Supplementary Figure 5B, stimulation with TNF-α led to strong activation of NF-κB luciferase 
activity, but no significant effect on AP-1 activity. Therefore, we only focused on NF-κB 
signaling for the following investigation. 
The NF-κB complex is the endpoint of its signal transduction, which comprises the 
heterodimeric RelA (P65)-P50 complex. Indeed, unstimulated cells display little nuclear RelA, 
but the RelA protein level in the cell nucleus was substantially elevated following TNF-α 
stimulation (Fig. 6A). Thus, to dissect the role of the RelA (P65)-P50 complex in TNF-α 
induced ISRE activation, the Huh7 ISRE reporter cell line was transduced with integrating 
lentiviral RNAi vectors to silence RelA (P65), resulting in profound down-regulation of RelA 
expression (Fig. 6B). Consistently, TNF-α induced ISRE luciferase activity and ISG expression 
was largely demolished in RelA knockdown cells when compared with control cells (Fig. 6C, 
D). On the contrary, IFN-α induced ISRE activation was not affected (Fig. 6E). Thus, NF-κB 
signaling appears to be essential for TNF-α mediated ISRE activation. 
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Figure 6: TNF-α mediates the 
induction of ISRE by activation 
of the NF-κB signaling. 
(A) Confocal microscopy 
analysis of RelA induction and 
localization in Huh7 cells 
treated with TNF-α. RelA was 
induced and translocated to 
the nucleus upon TNF-α 
treatment. RelA antibody 
(green). Nuclei were visualized 
by DAPI (blue). (B) Western blot 
analysis confirmed the 
successful knockdown of RelA 
by lentiviral shRNA vectors in 
the Huh7 based ISRE luciferase 
reporter cells. (C) RelA 
knockdown largely blocked 
TNF-α induced ISRE-related 
luciferase activation as 
measured at 3 different time 
points (n =  3 independent 
experiments with 2 - 3 
replicates each). (D) RelA 
knockdown largely blocked 
TNF-α induced ISG expression 
as measured by qRT-PCR (n  = 
 4). (E) RelA knockdown has no 
significant influence on IFN-α 
induced ISRE-related luciferase 
activation as measured at 3 
different time points (n  =  3 
independent experiments with 
2 - 3 replicates each). Data 
presented as mean  ±  SD (*P  < 
 0.05; **P  <  0.01; ***P  < 
 0.001; ns, not significant). 
 
 
Chapter 7 
164 | P a g e  
 
The NF-κB complex directly binds to ISRE and drives its transcriptional activity 
Upon TNF-α stimulation and signaling activation, the transcription factor complex, NF-κB, 
can directly bind to a sequence specific motif [5’-GGGAA/CTTTCC-3’] to promote target gene 
transcription [13, 20-22]. The puzzling role of NF-κB in the transactivation of ISRE led us to 
perform an in silico analysis comparing the ISRE motif and the NF-κB DNA binding site. 
Surprisingly, we identified a partial consensus sequence region in common within these two 
motifs (Fig. 7A). We thus hypothesized that NF-κB might bind to this consensus sequence 
within the ISRE motif to drive transcription of corresponding ISGs. To test this hypothesis, we 
retrieved genome wide RelA and STAT1 (positive control) ChIP-seq data from the ENCODE 
ChIP-seq Experiment Matrix database. ChIP-seq datasets were processed and analyzed. 
Confirming our hypothesis, we found that RelA showed a similar genome-wide binding 
pattern with STAT1. For a large cohort of genes, RelA overlapped with STAT1 in their gene 
binding site (Fig. 7B, left). To be more specifically, we further analyzed the RelA and STAT1 
binding sites that were within 1 kb of a transcription start site. This region is frequently 
located at the site of the promoter. Consistently, RelA still overlaps with STAT1 in the 
specific binding sites near gene transcription start sites. Since most genes bound and 
regulated by STAT1 are ISGs, this indicates that RelA also possesses the ability to bind and 
regulate a large cohort of ISGs. Then we analyzed RelA binding on a list of well-established 
antiviral ISGs. Convincingly, RelA shows strong and specific binding on the promoters of 
indicated ISGs, while the rabbit-IgG (negative control) shows no significant binding (Fig. 7C). 
To further confirm that NF-κB binds to the consensus sequence within the ISRE motif to 
drive corresponding ISG transcription, we mutated the consensus nucleotide sequence 
within the ISRE motif based on the lentiviral transcriptional reporter vector expressing the 
firefly luciferase gene driven by multiple ISREs. In theory, RelA will not be able to bind to this 
mutant ISRE sequence (Supplementary Figure 6). Huh7 cells were transduced with this 
vector to create a stable reporter cell line. As expected, TNF-α failed to activate this mutated 
ISRE (Fig. 7D). Hence, NF-κB can directly bind to the ISRE motif and activate its 
transcriptional activity. 
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Figure 7: The NF-κB complex directly binds to ISRE and drives its transcriptional activity. 
(A) NF-κB and ISRE sequence specific binding regions. Their consensus nucleotides are labeled in red 
color, and the consensus region is enclosed by the rectangular box. (B) Heatmaps display the 
normalized ChIP-seq reads representing the binding intensity of STAT1 and RelA. Displayed are 8 kb 
regions centered on the summits of significant STAT1 and/or RelA binding sites. The heatmap are 
clustered for the STAT1 and RelA binding signal based on the central 0.5 kb of the heatmap. left) 
Heatmaps of all significant STAT1 and RelA binding sites (n  =  13367). right) Heatmap of all significant 
STAT1 and RelA binding sites that are within 1 kb of a transcription start site (n  =  4545). (C) Binding 
of RelA to the promoters of the indicated ISGs. Sequence reads from anti-RelA ChIP-seq or rabbit-
IgG-control were plotted relative to chromosomal position. Genome location of corresponding ISGs is 
shown beneath the track signaling. RelA shows strong and specific binding on the promoters of 
indicated ISGs, while the rabbit-IgG, serving as negative control, shows no significant binding. (D) In 
the Huh7 cell-based mutant ISRE luciferase reporter cells, TNF-α did not induce mutant ISRE related 
luciferase activation as measured at 3 different time points (n  =  3 independent experiments with 2–
3 replicates each). Data presented as mean ± SD (*P <  0.05; **P <  0.01; ***P <  0.001; ns, not 
significant). 
TNF-α cooperates with IFN-α in ISG induction and antiviral action 
Because of the distinct signaling cascades that finally converge the transcription of antiviral 
ISGs by TNF-α and interferons, we further investigated the combinatory effects of TNF-α 
with IFN-α on ISG induction and antiviral action. Thus, we quantified the expression levels of 
a list of well-known antiviral ISGs in the Huh7 cell line with treatment of TNF-α, IFN-α or a 
combination thereof. Both TNF-α and IFN-α can induce significant up-regulation of tested 
ISGs, and their combination resulted in a strong additive induction of ISGs (Fig. 8A). 
Consistent with a previous publication [23], our results of ISG antiviral assay 
(Supplementary Figure 7) again highlight the important antiviral role of ISGs. Thus, the 
cooperation in ISG induction prompted us to test whether an additive antiviral effect can be 
achieved with the combination of TNF-α and IFN-α. Hence, we employed the Huh7 cell line 
based HCV or HEV replicon luciferase reporter as the cell models for the test. As shown in Fig. 
8B and 8C, the combination of TNF-α and IFN-α resulted in additive antiviral effects in both 
HCV and HEV replicon models. Thus, TNF-α cooperates with IFN-α in ISG induction, 
explaining their additive antiviral effects against HCV and HEV as we observed. 
Discussion 
TNF-α is a cytokine within the TNF superfamily, which acts as a central mediator of 
inflammation and immune regulations. Although TNF-α was first noted for its role in the 
killing of tumor cells [24], it has pleiotropic functions that include the inflammatory response 
and host resistance to pathogens. Indeed, numerous studies have demonstrated the 
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Figure 8: TNF-α cooperates with IFN-α in ISG induction and antiviral action. 
(A) In the Huh7 cells, the combination of TNF-α and IFN-α induced a strong additive ISG expression 
compared with treatment of either TNF-α or IFN-α alone as measured by qRT-PCR (n  =  6). (B) In the 
Huh7 cell-based subgenomic HCV replicon model, the combination of TNF-α and IFN-α induced a 
strong additive anti-HCV effect compared with treatment of either TNF-α or IFN-α alone as measured 
at 3 different time (n  =  3 independent experiments with 2 - 3 replicates each). (C) Same as (B) for 
the Huh7 cell-based subgenomic HEV replicon model. 
importance of TNF-α in protection against pathogens, including Mycobacterium tuberculosis, 
Cryptococcus neoformans, vesicular stomatitis virus, encephalomyocarditis virus, herpes 
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simplex virus, influenza virus and hepatitis B virus [25-29]. Disordered TNF-α regulation may 
have a significant negative role in inflammation and pathogenesis. Based on this, TNF-α 
antagonists have been proven to be highly effective in the treatment of certain 
inflammatory diseases, such as rheumatoid arthritis [30], psoriatic arthritis [31], juvenile 
rheumatoid arthritis [32], and Crohn’s disease [33]. Several TNF-α inhibitors have been 
approved for the treatment of these inflammatory illnesses by the US Food and Drug 
Administration (FDA). Contradictory, many studies have demonstrated an increased risk of 
opportunistic infections and difficulty in clearing infections once they develop in patients 
treated with TNF-α inhibitors, such as HBV or HCV infection [34-36]. Our experimental results 
showing that clinically used anti-TNF-α inhibitors can totally abrogate the antiviral activity of 
TNF-α appear to support those clinical observations and highlight the primary role of TNF-α 
in host defense against infections. 
As a first line defense, TNF-α and type I interferons are induced by microbial stimuli 
and mediate innate immune responses. Despite the fact that cells at sites of infection are 
continuously exposed to both cytokines, the interactions between TNF-α and interferons 
remain under investigated [37]. Although previous studies have reported that TNF-α interacts 
with antiviral interferon signaling and regulates ISG expression in the setting of different 
virus infections [8-10], the molecular mechanisms behind these interactions have not been 
delineated. In this study, we demonstrated that the activation of NF-κB signaling by TNF-α 
was able to directly transactivate the ISRE motif, resulting in the induction of antiviral ISGs. 
This whole process is independent of IFN production and the canonical JAK-STAT cascade, 
but relies on TNF-α induced NF-κB activity. NF-κB is a homo- or heterodimeric complex 
formed by the Rel-like domain-containing proteins: RelA (P65), RelB, c-Rel, P50 and P52 and 
the heterodimeric RelA (P65)-P50 complex appear to be the most abundant one. The dimers 
bind to the sequence specific NF-κB response element in the promoter region of their target 
genes to regulate transcription. To our surprise, in silico analysis discovered a consensus 
nucleotide sequence shared by the ISRE motif and NF-κB DNA binding site. ChIP-seq data 
analysis reveals RelA (P65) can directly bind to the promoter region of a large cohort of ISGs. 
Our loss-of-function and mutagenesis assay further confirmed that NF-κB could directly drive 
ISRE-controlled gene transcription. Since NF-κB is also the key downstream effector of most 
Toll-like receptors (TLR), this novel mechanism may also partially explain the antiviral 
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activities of TLR agonists in clinic, such as the TLR7 agonists, which are being therapeutically 
targeted and explored for HCV treatment in clinic trial [38]. 
More excitingly, TNF-α not only activates antiviral ISGs transcription, but also 
cooperates with IFN-α, explaining the additive antiviral outcome of their combination. This 
highlights the important facts that different cytokines orchestrate innate immune responses 
by activating signaling cascades to protect against infection efficiently. 
In conclusion, we revealed a novel antiviral mechanism of TNF-α. TNF-α, via the 
activation of NF-κB cascade, can drive the transcription of antiviral ISGs through direct 
binding of ISREs. This antiviral mechanism may provide clues for tackling the high rise of 
infections caused by TNF-α inhibitor treatment in patients. More interestingly, TNF-α also 
acts cooperatively with IFN-α in antiviral ISGs induction to exert additive antiviral effects. 
These findings not only provide new clues for understanding virus-host interactions but also 
assign a novel function of the canonical NF-κB pathway. 
Materials and Methods 
The HCV subgenomic replicon comprised Huh7 cells containing a subgenomic HCV bicistronic 
replicon (1389/NS3-3 V/LucUbiNeo-ET) linked to the firefly luciferase reporter gene were 
maintained with 250 μg/mL G418 (Sigma, Zwijndrecht, the Netherlands). The HEV 
subgenomic model was based on Huh7 cells containing the subgenomic HEV sequence 
(Kernow-C1 p6/luc) coupled to a Gaussia luciferase reporter gene. Lentiviral pLK.O 
knockdown vectors (Sigma-Aldrich) targeting IRF1, TNFR1, RelA were obtained from the 
Erasmus Biomics Center and produced in HEK293T cells as previously described [39]. The use 
of serum samples from IBD patients was approved by the Medical Ethical Committee of the 
Erasmus Medical Center (Medisch Ethische Toetsings Commissie Erasmus MC), and the 
informed consent was obtained from all subjects. All methods were carried out in 
accordance with the approved guidelines. For more details, see Supplementary Information. 
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Supplementary Materials and Methods 
Reagents 
Recombinant human TNF-α (Peprotech, USA) and human IFN-α (Thermo Scientific, the 
Netherlands) was dissolved in PBS. Stocks of JAK inhibitor 1 (Santa Cruz Biotech, CA) and 
Bayer-18 (Synkinase, China) were dissolved in DMSO with a final concentration of 5 mg/mL. 
Antibodies phospho-STAT1 (Tyr701) (58D6, #9167), STAT1 (#9172), RelA (P65) (C22B4, 
#4764), IRF1 (D5E4), IRF7 (D2A1J), Anti-rabbit IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 
conjugate) and Anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) were 
purchased from Cell Signaling Technology. IRF9 antibody was obtained from LSBio (Life Span 
BioSciences, Inc.). β-actin, STAT2 (sc-476), phospho-STAT2 (Tyr690) were purchased from 
Santa Cruz Biotechnology; anti-rabbit or anti-mouse IRDye-conjugated antibodies were used 
as secondary antibodies for western blotting (Stressgen, Victoria, BC, Canada). 
Cell models 
The HCV subgenomic replicon comprised Huh7 cells containing a subgenomic HCV bicistronic 
replicon (1389/NS3-3V/LucUbiNeo-ET) linked to the firefly luciferase reporter gene were 
maintained with 250 μg/mL G418 (Sigma, Zwijndrecht, the Netherlands). The HEV 
subgenomic model was based on Huh7 cells containing the subgenomic HEV sequence 
(Kernow-C1 p6/luc) coupled to a Gaussia luciferase reporter gene. Luciferase normalization 
cells (LV-PGK-Luc) were generated by transducing Huh7 cells with a lentiviral vector 
expressing the firefly luciferase gene under control of the human phosphoglycerate kinase 
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(PGK) promoter. ISRE, NF-κB, AP-1 luciferase reporter cells were generated by transducing 
Huh7 cells with lentiviral vectors expressing the firefly luciferase gene under the control of 
the promoters containing the ISRE, NF-κB, AP-1 motifs, respectively (System Biosciences). 
Gene knockdown or overexpression by lentiviral vectors  
Lentiviral pLKO.1 knockdown vectors (Sigma-Aldrich) targeting IRF1, IRF7, STAT1, TNFR1, 
RelA (P65) were obtained from the Erasmus Biomics Center and produced in HEK293T cells. 
After a pilot study, the shRNA vectors exerting optimal gene knockdown were selected. 
Stable gene knockdown cells were generated after lentiviral vector transduction and 
puromycin (2 μg/mL; Sigma) selection. IRF1, IFI6 and DDX58 lentiviral overexpression vectors 
were a kind gift from Prof. Charles M. Rice, the Rockefeller University [23]. Meanwhile, two 
control vectors expressing reporter genes Photinus pyralis luciferase (Fluc) or Green 
fluorescent protein (GFP) were also used.  
Measurement of luciferase activity 
For Gaussia luciferase analysis, the activity of secreted luciferase in the cell culture medium 
was measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs) according 
to the manufacturer’s instructions. For firefly luciferase, luciferin potassium salt (100 mM; 
Sigma) was added to cells and incubated for 10 min at 37 °C The luciferase activity was 
quantified with a LumiStar Optima luminescence counter (BMG Lab Tech, Offenburg, 
Germany). 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was synthesized from 
total RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA of all detected genes was 
amplified for 50 cycles and quantified with a SYBR-Green-based real-time PCR (Applied 
Biosystems) according to the manufacturer’s instructions. GAPDH and RP2 were considered 
as reference genes to normalize gene expression. All the primer sequences are included in 
Supplemental Table 2. 
Western Blot Assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT and heated 5 mins 
at 95 °C, followed by loading onto a 10% sodium dodecyl sulfate polyacrylamide gel and 
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separation by electrophoresis. After 90 mins running at 120 V, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride membrane (Invitrogen) for 
1.5 hrs with an electric current of 250 mA. Subsequently, the membrane was blocked with a 
mixture of 2.5 mL blocking buffer (Odyssey) and 2.5 mL phosphate-buffered saline 
containing 0.05% Tween 20. It was followed by overnight incubation with primary antibodies 
(1: 1 000) at 4 °C. The membrane was washed 3 times followed by incubation for 1 h with 
IRDye-conjugated secondary antibody (1: 5 000). After washing 3 times, protein bands were 
detected with the Odyssey 3.0 Infrared Imaging System. 
Enzyme-linked immunosorbent assay (ELISA) 
Serum samples were collected and stored at -80 °C. TNF-α level was measured by an ELISA 
kit (eBioscience, USA) according to manufacturer’s instructions. The absorbance was 
measured at 450 nm in an automatic microplate reader. Results were calculated based on a 
standard curve. 
Confocal laser electroscope assay 
Huh7 cells were seeded on glass coverslips. After 12 hrs, cells were washed with PBS, fixed in 
4% PBS-buffered formalin for 10 mins and blocked with tween-milk-glycine medium (PBS, 
0.05% tween, 5 g/L skim milk and 1.5 g/L glycine). Samples were incubated with primary 
antibodies overnight at 4 °C. Subsequently, samples were incubated with 1:1 000 dilutions of 
the anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) or anti-rabbit 
IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 conjugate) secondary antibodies. Nuclei were 
stained with DAPI (4, 6-diamidino-2-phenylindole; Invitrogen). Images were detected using 
confocal electroscope. 
ChIP-seq data analysis 
ChIP-seq datasets for STAT1 in Gm12878 cells and RelA in the TNFα stimulated Gm12878 
cells were retrieved from the ENCODE database. ChIP-seq datasets were processed and 
mapped to hg38 reference genome as described [40]. ChIP-seq datasets with multiple 
replicates were merged. MACS 1.4.2 was used for peak calling and for the generation of 
binding profiles [41]. MACS was run with -p 1e-10, using the mock control of TNF-α stimulated 
cell as control dataset for both the STAT1 and RelA ChIP-seq. Heatmaps were generated 
based on a unified peak list. If the centers of two binding regions reported by MACS were 
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100 bp or less apart, they were unified to a single binding region. Heatmaps were 
normalized for each individual factor by calculating the RPM based on the sum of all reads 
displayed by the heatmap. RPM was log2 transformed and manhattan clustering was 
performed. The heatmap images were generated in R. The sequencing profiles were 
generated in the IGV browser [42]. 
Construction of mutant ISRE reporter cell line 
Based on the sequence specific ISRE motif, a mutant version of ISRE was designed and 
synthesized (Forward: 5’-
aattcAGTTTCGTCAAGTCTTTCAGTTTCGTCAAGTCTTTCAGTTTCGTCAAGTCTTTCAGTTTCGTCAAG
TCTTTa-3’; Reverse: 5’-
ctagtAAAGACTTGACGAAACTGAAAGACTTGACGAAACTGAAAGACTTGACGAAACTGAAAGACTT
GACGAAACTg-3’), which shows no consensus sequence with the NF-κB motif. EcoRI and SpeI 
sites are included (shown in italics) to facilitate directional cloning into the pGreenFire Lenti-
Reporter vector (System Biosciences). The recombinant plasmid was verified by restriction 
enzyme digestion and DNA sequencing. Stable mutant ISRE reporter cells were generated 
after lentiviral vector transduction and puromycin (2 μg/mL; Sigma) selection. 
Statistical analysis 
All results were presented as mean ± SD. Comparisons between groups were performed 
with Mann-Whitney test. Differences were considered significant at a P value less than 0.05.  
Ethics Statement 
The use of serum samples from IBD patients was approved by the Medical Ethical 
Committee of the Erasmus Medical Center (Medisch Ethische Toetsings Commissie Erasmus 
MC). The volunteers or patients agreed to participate by written informed consent. 
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Supplementary Figure and Figure Legends 
 
Figure S1. TNF-α induced ISRE activation is independent of IRF7. 
(A) qRT-PCR analysis of successful IRF7 knockdown by lentiviral shRNA vectors in the Huh7 based 
ISRE luciferase reporter cells. (B) Western blot analysis confirmed the successful knockdown of IRF7 
by lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. (C) IRF7 knockdown had 
no significant influence on TNF-α induced ISRE-related luciferase activation as measured at 2 
different time points (n = 3 independent experiments with 2 - 3 replicates each). 
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Figure S2. TNF-α induced ISRE activation is independent of interferon and the JAK-STAT signaling. 
(A) Illustration of key elements in IFN-α induced JAK-STAT signaling pathway. (B) The selective TYK2 
inhibitor, Bayer-18, did not abrogate TNF-α induced ISRE-related luciferase activation (n = 3 
independent experiments with 2- 3 replicates each). (C) In Huh7 based ISRE luciferase cells, TYK2 
selective inhibitor, Bayer-18, did not exert significant effect on IFN-α (1000 IU/mL) induced ISRE-
luciferase activity (left), while JAK inhibitor I (10 μM) abrogated IFN-α (1000 IU/mL) induced ISRE 
luciferase activity as measured at 24, 48 and 72 hrs (n = 3 independent experiments with 2 - 3 
replicates each). (D) JAK inhibitor I exerts no significant influence on TNF-α induced ISG expression as 
measured by qRT-PCR. (n = 4). 
 
 
 
Figure S3. IFN-α induced ISRE activation 
depends on the JAK-STAT signaling. 
(A) In Huh7 cells, JAK inhibitor I (10 μM) 
abrogated IFN-α (1000 IU/mL) induced ISG 
expression as measured by qRT-PCR. (B) 
Confocal microscopy analysis of IRF9 
localization in Huh7 cells treated with IFN-α 
or TNF-α. IRF9 was induced and 
translocated to the nucleus upon IFN-α, but 
not TNF-α treatment. IRF9 antibody (green). 
Nuclei were visualized by DAPI (blue).  
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Figure S4. TNF-α activates ISRE via TNF receptor. 
(A) TNFR1 knockdown blocked TNF-α induced ISG expression as measured by qRT-PCR (n = 4). (B) In 
A549 cells, TNF-α inhibitor, Humira, abrogated TNF-α induced ISG expression as measured by qRT-
PCR (n = 4). (C) Humira decreased serum samples (with higher TNF-α levels) induced ISRE-related 
luciferase activity. (D) Serum samples with higher TNF-α levels inhibited HCV-related luciferase 
activity compared with control serum. 
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Figure S5. TNF-α efficiently activate NF-κB signaling pathway. 
(A) Illustration of key elements in TNF-αinduced NF-κB signaling pathway. (B) In the Huh7 cell-based 
NF-κB or AP1 luciferase reporter cells, TNF-α dose-dependently induced activation of NF-κB-related 
luciferase activity, while no significant effect on AP1-related luciferase activity as measured at 3 
different time points (n = 3 independent experiments with 2 - 3 replicates each). 
 
Figure S6. The nucleotide sequence of NF-
κB, ISRE and the ISRE mutant binding 
regions.  
Their consensus nucleotides are labeled in 
red color, and the consensus region is 
marked in a rectangular box. The mutated 
nucleotides are shown in purple color. The 
ISRE (mutant) sequencing result is shown 
in the illustration below. 
 
 
 
Fig. S7. ISG, e.g. IRF1, IFI6 or DDX58 exerts strong 
antiviral effect against HCV. 
Huh7 cell based HCV replicon luciferase reporter was 
transduced with integrating lentiviral vectors to 
overexpress ISG, e.g. IRF1, IFI6 or DDX58, showing strong 
antiviral potency against HCV. 
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Abstract 
Interferon-stimulated genes (ISGs) are antiviral effectors that are efficiently induced by 
interferons (IFNs) via the formation of a tripartite transcription factor ISGF3 (IRF9, 
phosphorylated STAT1 and STAT2). However, we found that IFN-independent ISG expression 
was detectable in immortalized cell lines, primary intestinal and liver organoids, and liver 
tissues. We report that the constitutive expression of ISGs was mediated by the 
unphosphorylated ISGF3 (U-ISGF3) complex, which was formed by IRF9 together with 
unphosphorylated STAT1 and STAT2. Under homeostatic conditions, the nuclear localization 
of endogenous STAT1, STAT2, and IRF9 was observed. Analysis of a chromatin 
immunoprecipitation–sequencing (ChIP-seq) dataset revealed that STAT1 specifically bound 
to the promoters of ISGs even in the absence of IFNs. Knockdown of STAT1, STAT2, or IRF9 
by RNA interference (RNAi) led to the decreased expression of a range of ISGs in Huh7.5 cells, 
which was confirmed in mouse embryonic fibroblasts (MEFs) from STAT1-/-, STAT2-/-, or 
IRF9-/- mice. Furthermore, decreased ISG expression was accompanied by the increased 
replication of hepatitis C virus (HCV) and hepatitis E virus (HEV). Conversely, simultaneous 
overexpression of all of the ISGF3 components, but not any single factor, induced the 
expression of ISGs and inhibited viral replication. However, no phosphorylated STAT1 and 
STAT2 was detected. Substitution of wild-type STAT1 with a phosphorylation-deficient 
mutant had comparable effect on IFN-independent expression of ISGs or antiviral activity, 
suggesting that ISGF3 works in a phosphorylation-independent manner. These data suggest 
that the U-ISGF3 complex is both necessary and sufficient for constitutive ISG expression and 
antiviral immunity under homeostatic conditions. 
Keywords: U-ISGF3; HCV; HEV; basal ISG; transcription 
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Introduction 
Interferon-stimulated genes (ISGs) are hardwired within genomes and provide a robust first 
line of defense against invading pathogens. Canonically, following pathogen invasion and 
interferon (IFN) stimulation, IFN receptors respond with activation of the Janus kinases JAK1 
and TYK2, which in turn phosphorylate tyrosine residues in the intracellular tail of the IFN 
receptors. Subsequently, STAT1 and STAT2 are phosphorylated, which provokes dimerization 
and subsequent binding to interferon regulatory factor 9 (IRF9) to form the IFN-stimulated 
gene factor 3 (ISGF3) complex. The ISGF3 complex translocates into the nucleus, and binds 
to specific promotor elements denoted as IFN-stimulated response elements (ISREs), leading 
to the rapid transcriptional activation of hundreds of ISGs. This leads to an effective antiviral 
state against positive-, negative-, and double-stranded RNA viruses, DNA viruses, and 
intracellular bacteria and parasites [1]. Interestingly, an IFN regulated non-canonical 
mechanism of ISG transcription was recently reported. When cells are continuously exposed 
to a low amount of exogenous interferon, unphosphorylated ISGF3 (U-ISGF3), formed by 
interferon induced IRF9 and unphosphorylated STAT1 and STAT2, leads to steady-state 
increased expression of a subset of ISGs [2].  
In the absence of interferon activation, constitutive ISG expression is also critical in 
determining cellular susceptibility to viral infection [3]. Inefficient replication of influenza A 
virus has been reported in human bronchial epithelial cells (BEAS-2B) with a higher 
expression level of basal ISGs, compared with other respiratory epithelial cell lines [4]. Similar 
observation was reported with regard to reovirus replication in cardiac myocytes [5, 6]. 
Conversely, abnormal regulation of basal ISG expression is associated with adverse 
consequences in patients. Patients with chronic hepatitis C virus (HCV) infection who have 
abnormally high levels of basal ISG expression in the liver are prone to poor sustained 
virologic response (SVR) to pegylated IFN-α and ribavirin therapy [7, 8]. Abnormally high 
expression levels of basal ISGs have been reported to promote tumor growth, and confer 
resistance to chemotherapy and radiotherapy [9, 10]. Thus, the question as to the mechanisms 
maintaining and determining the level of constitutive ISG expression is of utmost importance. 
Here, we report that under homeostatic status, nuclear localization of endogenous 
STAT1, STAT2 and IRF9 were observed in cell lines, 3-D cultured primary intestinal and liver 
organoids, and liver tissues. In the absence of interferons, constitutive ISG expression is 
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mediated by endogenous U-ISGF3 complex, formed by IRF9, and unphosphorylated STAT1 
and STAT2. This process is totally independent of IFN production and the upstream elements 
of IFN signaling, but effectively confers resistance of host cells to HCV and HEV infections. 
Thus, the endogenous U-ISGF3 complex is both necessary and sufficient for sustaining 
constitutive ISG transcription and antiviral immunity in host cells under homeostatic 
condition. 
Results 
Constitutive ISG transcription is independent of IFN production 
The profile of constitutive ISG expression in human liver tissue, 3D-cultured primary human 
liver and intestinal organoids (fig. S1A), and three different cell lines (Huh7.5, Caco2, and 
A549) was quantified by quantitative reverse-transcription polymerase chain reaction (qRT-
PCR) analysis. ISG expression was readily detectable in all tested models under homeostatic 
conditions (Fig. 1, A and B). This finding was further confirmed by the quantification of the 
gene copy numbers of four representative ISGs, as normalized to the corresponding plasmid 
template using a standard curve calculation method (Fig. 1C and fig. S1B). 
The classical role of IFN in the induction of ISG expression prompted us to investigate 
the potential involvement of IFN in our system. Thus, we collected conditioned medium 
from these cultured cells (after 48 hours) and added to a transcriptional reporter system 
that mimics IFN response with a luciferase reporter gene that was driven by multiple ISREs 
(ISRE-Luc). Cell culture medium from all three cell lines failed to stimulate any response in 
the ISRE-luc model(Fig. 1D). Consistently, the conditioned medium failed to stimulate ISG 
expression in Huh7.5 cells (fig. S1C). In addition, conditioned culture medium was also used 
to perform a functional assay on the IFN sensitive HCV-replicon model, Huh7.5-HCV-luc; 
however, we found that the culture media did not affect HCV replication (Fig. 1E). JAK1 is the 
key upstream component that drives the activation of IFN signaling. IFN-α-stimulated STAT1 
phosphorylation and ISG expression were blocked by a pharmacological JAK inhibitor, JAK 
inhibitor I (fig. S2, A and B). However, JAK inhibitor I did not decrease constitutive ISG 
expression in Huh7.5, Caco2, or A549 cells (Fig. 1F and fig. S2, C and D). Together, these data 
suggest that constitutive ISG expression is independent of IFN production. 
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Figure 1. Cell sustains basal ISG transcription independent of interferon production.  
(A and B) Total RNA was extracted from human liver tissue samples, primary human liver organoids, 
human intestinal organoids (A), and from Huh7.5 cells, A549 cells, and Caco2 cells (B). The relative 
abundances of mRNAs of the indicated ISGs were quantified by qRT-PCR. Human liver organoids, 
intestinal organoids, Huh7.5 cells, A549 cells, and Caco2 cells treated for 24 hours with IFN-α (1000 
IU/ml) served as the positive controls for ISG expression. GAPDH was used as reference gene. Data 
are means ± SEM from three independent experiments. (C) The gene copy numbers of the four 
indicated ISGs were quantified relative to the appropriate plasmid templates using a standard curve 
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calculation method. Data are means ± SEM from  three independent experiments. (D) Huh7.5-ISRE-
luccells were left untreated or were treated for 24 hours with conditioned medium from Huh7.5, 
Caco2, or A549 cells or with IFN-α (10 IU/ml) as a positive control. ISRE luciferase values were then 
measured and the fold-increase in activity relative to that of untreated cells was determined. Data 
are means ± SEM from three independent experiments. (E) HCV viral replication-related firefly 
luciferase activity was measured upon the treatment of Huh7.5-HCV-luc cells with conditioned 
medium from Huh7.5, Caco2, or A549 cells. As a positive control, the cells were treated with the 
indicated range of concentrations of IFN-α. Data are means ± SEM from three independent 
experiments. (F) Huh7.5 cells were treated with vehicle (CTR) or with 5 µM JAK inhibitor I for 24 
hours before being subjected to qRT-PCR analysis of the relative abundances of the indicated 
mRNAs. Data are means ± SEM of four independent experiments. *P < 0.05; **P < 0.01; ns, not 
significant. 
STAT1, STAT2, and IRF9 are required for constitutive ISG transcription and 
they constrain HCV and HEV replication 
Upon IFN stimulation, STAT1 is a vital transcription factor to drive ISG transcription. Thus, we 
first examined the role of STAT1 in basal ISG transcription under homeostatic conditions. 
Because nuclear localization is a primary determinant for the transcriptional function of 
STAT1, we investigated the cellular location of endogenous STAT1. We found that the 
staining of endogenous STAT1 protein in both cytoplasm and nucleus was apparent. in 
human and mouse liver tissue samples as determined by immunohistochemistry (IHC) (Fig. 
2A). Consistently, the cellular localization of STAT1 was similar in primary human liver and 
intestinal organoids and in three different cell lines (Fig. 2, B to E, fig. S3, A and B). To 
investigate whether STAT1 in the cell nucleus could bind to the promoter regions of ISGs, we 
retrieved genome-wide STAT1 ChIP-seq data (GSE31477) from the ENCODE ChIP-seq 
Experiment Matrix database and Gene Expression Omnibus [11]. The STAT1 ChIP-seq datasets 
were then processed and analyzed. Even without IFN stimulation, STAT1 showed specific 
binding peaks on the promoter regions of a large cohort of ISGs (186 out of 350 ISGs 
analyzed), including IRF1, IRF9, STAT1, and ISG15 (Fig. 2F), whereas rabbit immunoglobulin G 
(IgG, which was the negative control) showed no specific binding peak. 
To further investigate the role of STAT1 in basal ISG expression, Huh7.5 cells were 
transduced with an integrating lentiviral vector expressing STAT1-specific short hairpin RNA 
(shRNA), which resulted in a marked decrease in STAT1 abundance (Fig. 3A). Knockdown of 
endogenous STAT1 led to the decreased expression of 13 out of 14 tested ISGs, with 
inhibitory efficiency ranging from 30 to 90% (Fig. 3B). In addition, we performed 
experiments with mouse embryonic fibroblasts (MEFs) from wild-type (WT) and STAT1-/- 
Chapter 8 
188 | P a g e  
 
mice to examine the effect of STAT1 on ISG expression (Fig. 3, C and D). We found that the 
abundances of ISG mRNAs were reduced in STAT1-/- MEFs compared to those in WT MEFs 
(Fig. 3E). Furthermore, shRNA mediated STAT1 knockdown increased viral replication of HCV 
(2.2-fold) (Fig. 3F) and HEV (1.7-fold) (Fig. 3G) compared to its shRNA control in Huh7.5-
based HCV-luc and HEV-luc models. In contrast, over-expression of STAT1 did not 
substantially affect ISG expression or viral replication (Fig. 3, H to J), suggesting that STAT1, 
although important for such responses, does not work alone. 
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Figure 2. A substantial fraction of endogenous STAT1 is localized in the nucleus and binds to ISG 
promoters under homeostatic conditions.  
(A) Representative immunohistochemical staining analysis of the cellular localization of endogenous 
STAT1 in cells in human (top) and mouse (bottom) liver sections. As a negative control (CTR), primary 
antibody against STAT1 was replaced with PBS containing 0.05% Tween. Images are representative of 
three independent experiments. (B to D) Confocal laser electroscope  analysis of endogenous STAT1 
localization in human liver organoids (B), human intestinal organoids (C), and Huh7.5 cells (D). STAT1 
is shown in green in organoids and in red in Huh7.5 cells. Nuclei were visualized by DAPI (blue). As a 
negative control (CTR), primary antibody against STAT1 was replaced with PBS containing 0.05% 
Tween. Images are representative of multiple organoids or cells from three independent 
experiments. (E) Huh7.5 cell lysates were fractionated into cytoplasmic (Cy) and nuclear (Nu) 
fractions and then were analyzed by Western blotting with antibodies against the indicated proteins. 
Cyclophilin A and Lamin A/C were used as cytosolic and nuclear markers, respectively. Western blots 
are representative of three independent experiments. (F) The ChIP-seq dataset for STAT1 (GSE31477) 
was retrieved from the ENCODE database. Binding profiles of endogenous STAT1 to the promoter 
regions of the indicated ISGs. Sequence reads from anti-STAT1 antibody or rabbit-IgG-control ChIP-
seq data were plotted relative to chromosomal position. The genome locations of the corresponding 
ISGs are shown beneath the track signaling. 
Next, we examined the involvement of STAT2. Under homeostatic conditions, STAT2 
was abundantly present in both the cytoplasm and nuclei of human liver tissue, human liver 
organoids, human intestinal organoids, and cell lines (Fig. 4, A to D). Furthermore, 
knockdown of STAT2 by lentiviral shRNA (Fig. 4E) led to the decreased expression of ISGs (10 
out of 12 tested ISGs), ranging from a 30 to 70% decrease (Fig. 4F). MEFs from STAT2-/- mice 
(Fig. 4G) had reduced amounts of many ISG mRNAs compared to those in WT MEFs (Fig. 4H). 
ShRNA mediated STAT2 knockdown increased replication of HCV (1.5-fold) (Fig. 4I) and HEV 
(1.6-fold) (Fig. 4J) compared to its shRNA control in Huh7.5-based HCV-luc and HEV-luc 
models. However, overexpression of STAT2 did not affect either ISG expression or viral 
replication (Fig. 4, K to M), mirroring the results obtained from experiments with 
overexpressed STAT1. 
Finally, the role of IRF9 was also investigated. Substantial nuclear localization of IRF9 
was observed in human and mouse liver tissues (Fig. 5A), human liver organoids (Fig. 5B), 
human intestinal organoids (Fig. 5C), and Huh7.5 cells (Fig. 5D). Knockdown of endogenous 
IRF9 by lentiviral vector based IRF9-specific shRNA (Fig. 5E) resulted in decreased ISG 
expression in Huh7.5 cells (Fig. 5F). Consistently, compared with WT MEFs, IRF9-/- MEFs (Fig. 
5G) had reduced amounts of ISG mRNAs under homeostatic conditions (Fig. 5H). ShRNA 
mediated IRF9 knockdown  increased replication of both HCV (3.8-fold) (Fig. 5I) and HEV 
(1.8-fold) (Fig. 5J) compared to its shRNA control in Huh7.5-based HCV-luc and HEV-luc 
models. Over-expression of IRF9 in Huh7.5 cells had no effect on ISG expression (Fig. 5K). 
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Whereas overexpression of IRF9 in these cells inhibited HCV replication (Fig. 5L), it had no 
effect on HEV replication (Fig. 5M). The idea that the reduced replication of HCV was ISG-
independent was supported by the observation that over-expression of IRF9 in Caco2 cells 
had no substantial effect on either ISG expression or rotavirus replication (fig. S3, C and D). 
Together, these results suggest that STAT1, STAT2, and IRF9 are all required and likely 
cooperate to regulate the basal expression of ISGs. 
 
Figure 3. STAT1 is required for sustaining the basal expression of ISGs and constraining viral 
replication 
(A) Huh7.5 cells were transduced with lentiviruses expressing control shRNA (shCTR) or three 
different STAT1-targeting shRNAs. After the puromycin selection for two weeks, cells were analyzed 
by Western blotting with antibodies against the indicated proteins. Western blots are representative 
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of three independent experiments. (B) Huh7.5 cells expressing control shRNA or the indicated STAT1-
specific shRNAs were analyzed by qRT-PCR to determine the relative abundances of the indicated 
mRNAs. Data are means ± SEM of four independent experiments. (C) WT and STAT1-/- MEFs were 
analyzed by qRT-PCR to determine the relative abundance of STAT1 mRNA. Data are means ± SEM of 
four independent experiments. (D) WT and STAT1-/- MEFs were analyzed by Western blotting with 
antibodies against the indicated proteins. Western blots are representative of three independent 
experiments. (E) WT and STAT1-/- MEFs were subjected to qRT-PCR analysis of the relative abundance 
of the indicated mRNAs. Data are means ± SEM of three independent experiments. (F)  HCV replicon 
positive Huh7.5 cells were transduced with lentiviruses expressing control or STAT1-specific shRNAs 
before being subjected to a HCV replication–related luciferase activity. Data are means ± SEM of 
three independent experiments. (G) HEV replicon positive Huh7.5 cells were transduced with 
lentiviruses expressing control or STAT1-specific shRNAs before being subjected to a HEV replication–
related luciferase activity. Data are means ± SEM of three independent experiments. (H) Huh7.5 cells 
transduced with lentivirus expressing control or STAT1-specific shRNA were subjected to qRT-PCR 
analysis of the relative abundances of the indicated mRNAs. Data are means ± SEM of three 
independent experiments. (I and J) HCV replicon positive (I) and HEV replicon positive (J) Huh7.5 cells 
transduced with control lentivirus or with lentivirus expressing STAT1 were subjected to qRT-PCR 
analysis of the relative abundances of the indicated mRNAs. Data are means ± SEM of three 
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. 
 
Chapter 8 
192 | P a g e  
 
 
Figure 4. STAT2 is essential for sustaining the basal expression of ISGs and constraining viral 
replication. 
(A) Immunohistochemical staining of the cellular localization of endogenous STAT2 in cells from 
human liver tissue. As a negative control, primary antibody against STAT2 was replaced with PBS 
containing 0.05% Tween. Images are representative of three independent experiments. (B to D) 
Confocal laser electroscope analysis of the cellular localization of endogenous STAT2 in human liver 
organoids (B), human intestinal organoids (C), and Huh7.5 cells (D). STAT2 antibody staining is shown 
in green, whereas nuclei were visualized by DAPI (blue). As a negative control, primary antibody 
against STAT2 was replaced with PBS containing 0.05% Tween. Images are representative of multiple 
organoids or cells from three independent experiments. (E) Huh7.5 cells transduced with lentiviruses 
expressing control shRNA or the indicated STAT2-specific shRNAs were analyzed by Western blotting 
with antibodies against the indicated proteins. Western blots are representative of three 
independent experiments. (F) Huh7.5 cells expressing control shRNA or the indicated STAT2-specific 
shRNAs were analyzed by qRT-PCR to determine the relative abundances of the indicated mRNAs. 
Data are means ± SEM of four independent experiments. (G) WT and STAT2-/- MEFs were analyzed by 
Western blotting with antibodies against the indicated proteins. Western blots are representative of 
three independent experiments. (H) WT and STAT2-/- MEFs were subjected to qRT-PCR analysis of the 
relative abundance of the indicated mRNAs. Data are means ± SEM of three independent 
experiments. (I and J) HCV replicon positive (I) and HEV replicon positive (J) Huh7.5 cells were 
transduced with lentiviruses expressing control or STAT2-specific shRNAs before being subjected to 
assays of viral replication–related luciferase activity. Data are means ± SEM of three independent 
experiments. (K) Huh7.5 cells transduced with control lentivirus or with lentivirus expressing STAT2 
were subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are 
means ± SEM of three independent experiments. (L and M) HCV-positive (L) and HEV-positive (M) 
Huh7.5 cells transduced with control lentivirus or with lentivirus expressing STAT2 were subjected to 
qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are means ± SEM of three 
independent experiments. *P < 0.05; **P < 0.01; ns, not significant. 
STAT1, STAT2, and IRF9 function as the U-ISGF3 complex to drive ISG 
expression and exert antiviral effects against HCV and HEV 
Because STAT1, STAT2, and IRF9 alone were all necessary, but not sufficient, to drive 
constitutive ISG expression, we investigated whether these three factors in combination 
functioned as the ISGF3 complex independently of activation by exogenous IFN. Thus, we 
over-expressed STAT1, STAT2, and IRF9 in Huh7.5 cells through lentiviral transduction (Fig. 6 
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Figure 5. IRF9 is also required for the basal expression of ISGs and for limiting viral replication. 
(A) Immunohistochemical staining of the cellular localization of endogenous IRF9 in cells from human 
(top) and mouse (bottom) liver tissue. As a negative control, primary antibody against IRF9 was 
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replaced with PBS containing 0.05% Tween. Images are representative of three independent 
experiments. (B to D) Confocal laser electroscope analysis of the cellular localization of endogenous 
IRF9 in human liver organoids (B), human intestinal organoids (C), and Huh7.5 cells (D). IRF9 antibody 
staining is shown in green, whereas nuclei were visualized by DAPI (blue). As a negative control, 
primary antibody against IRF9 was replaced with PBS containing 0.05% Tween. Images are 
representative of multiple organoids or cells from three independent experiments. (E) Huh7.5 cells 
transduced with lentiviruses expressing control shRNA or IRF9-specific shRNAs were analyzed by 
Western blotting with antibodies against the indicated proteins. Western blots are representative of 
three independent experiments. (F) Huh7.5 cells expressing control shRNA or IRF9-specific shRNAs 
were analyzed by qRT-PCR to determine the relative abundances of the indicated mRNAs. Data are 
means ± SEM of four independent experiments. (G) WT and IRF9-/- MEFs were analyzed by Western 
blotting with antibodies against the indicated proteins. Western blots are representative of three 
independent experiments. (H) WT and IRF9-/- MEFs were subjected to qRT-PCR analysis of the 
relative abundance of the indicated mRNAs. Data are means ± SEM of three independent 
experiments. (I and J) HCV-positive (I) and HEV-positive (J) Huh7.5 cells were transduced with 
lentiviruses expressing control or IRF9-specific shRNAs before being subjected to assays of viral 
replication–related luciferase activity. Data are means ± SEM of three independent experiments. (K) 
Huh7.5 cells transduced with control lentivirus or with lentivirus expressing IRF9 were subjected to 
qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are means ± SEM of three 
independent experiments. (L and M) HCV-positive (L) and HEV-positive (M) Huh7.5 cells transduced 
with control lentivirus or with lentivirus expressing IRF9 were subjected to qRT-PCR analysis of the 
relative abundances of the indicated mRNAs. Data are means ± SEM of three independent 
experiments. *P < 0.05; **P < 0.01; ns, not significant. 
A), which led to a substantial antiviral effect and induction of ISG expression (Fig. 6, B to D), 
as compared to the over-expression of any one of the three factors alone. These data 
suggest that the integrity of the ISGF3 complex is necessary for these effects. 
To rule out any interference by endogenous WT STAT1 or STAT2 (should any be 
present in the cells) and to further confirm the role of ISGF3, we overexpressed STAT1, 
STAT2, and IRF9 in U3A cells (which are STAT1-deficient) and U6A cells (which are STAT2-
deficient) (fig. S4, A to D) [12], which led to a substantial induction of ISG expression in both 
cell types (fig. S4, B and D), mirroring the results observed in Huh7.5 cells. STAT1 
phosphorylated at Tyr701 (pSTAT1-Tyr701) and STAT2 phosphorylated at Tyr690 (pSTAT2-Tyr690) 
were undetectable even when either protein was overexpressed (Fig. 6A), which suggests 
that ISGF3 complex occurs through a phosphorylation-independent mechanism. Indeed, no 
pSTAT1-Tyr701 or pSTAT2-Tyr690 was detected in either human or mouse liver tissue samples 
by IHC (Fig. 6E and fig. S4E) or in three individual liver tissue samples that were examined by 
Western blotting (Fig. 6F). The same observation was also made by examining human liver 
organoids (Fig. 6G), intestinal organoids (fig. S4, F to H), and Huh7.5 cells (Fig. 6H). 
Furthermore, overexpression of a mutant STAT1 (Y701F-STAT1), which cannot be 
phosphorylated at Tyr701 [13], together with STAT2 and IRF9 in Huh7.5 cells led to a 
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comparable potency of antiviral effect and ISG induction (Fig. 6, I to K). This was further 
confirmed in U3A cells (fig. S4, I and J).  
In addition to the tyrosine phosphorylation sites in STAT1 and STAT2, 
phosphorylation of the sites Ser708 and Ser727 in STAT1 correlates with ISG expression [14, 15]. 
However, we were unable to detect pSTAT1-Ser727 in either Huh7.5 cells (fig. S4K) or human 
liver tissue samples (fig. S4L). Generally, STAT1 or STAT2 is phosphorylated by specific 
kinases upon cellular stimulation (for example, by IFNs). Furthermore, pSTAT1 and pSTAT2 
proteins undergo dephosphorylation. Thus, the phosphorylation and dephosphorylation 
processes are coordinated to maintain the phosphorylation states of these proteins to an 
extent that achieves a balance between their beneficial, antiviral actions and their 
detrimental, proinflammatory effects. Consequently, the inhibition of phosphatases would 
alter this balance, resulting in increased amounts of pSTAT1 and pSTAT2 and to the greater 
induction of ISG expression (fig. S5A) [16]. Thus, we performed experiments with the 
phosphatase inhibitor NSC87877 (which has IC50 values of 0.318 μM for SHP-2, 0.355 μM for 
SHP-1, and 1.691 μM for PTP1B) to specifically inhibit the key phosphatases involved in 
pSTAT1 and pSTAT2 dephosphorylation at both tyrosines and serines [16-18]. However, we 
found that NSC87877 had no effect on basal ISG expression in either Huh7.5 cells or Caco2 
cells (Fig. 7A and fig. S5B). NSC87877 also had no effect on ISG expression induced by the 
simultaneous over-expression of STAT1, STAT2, and IRF9 (Fig. 7B). Together, these data 
suggest that STAT1, STAT2, and IRF9 function as part of U-ISGF3 to drive ISG expression, 
which leads to antiviral effects. 
The basal expression of particular ISGs is enhanced in chemotherapy-resistant cancer 
cells and in chronic HCV patients who are resistant to IFN therapy; however, under these 
conditions, pSTAT1 is almost undetectable [2, 19]. Thus, we overexpressed Y701F-STAT1, 
STAT2, and IRF9 together in Huh7.5 cells and examined the basal expression of several ISGs 
that were previously identified as potential makers to predict responsiveness to IFN therapy 
in patients chronically infected with HCV [7, 8]. As expected, the expression of all of these ISGs 
was increased upon overexpression of the components of the U-ISGF3 (fig. S5C). Note that 
IFNs stimulate the expression of antiviral ISGs and of negative regulatory ISGs to avoid 
excessive IFN responses [20]. We found that the expression of four of five of these negative 
regulatory ISGs was also enhanced upon overexpression of U-ISGF3 (fig. S5D). 
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Figure 6. U-ISGF3 stimulates the expression of ISGs and constrains viral replication. 
Huh7.5 cells were transduced with control lentivirus (C) or with lentiviruses expressing the indicated 
proteins before being subjected to Western blotting analysis with antibodies against the indicated 
proteins. As a positive control for the detection of pSTAT1 and pSTAT2, Huh7.5 cells were treated 
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with IFN-α for 30min. Western blots are representative of three independent experiments. (B and C) 
HCV-positive (B) and HEV-positive (C) Huh7.5 cells were transduced with control lentivirus or with 
lentiviruses expressing the indicated proteins before being subjected to assays of viral replication–
related luciferase activity. Data are means ± SEM of three independent experiments. (D) Huh7.5 cells 
were transduced with control lentivirus or with lentiviruses expressing the indicated proteins before 
being subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are 
means ± SEM of three independent experiments. (E) Representative immunohistochemical analysis 
of pSTAT1-Tyr701 and pSTAT2-Tyr690 in human liver tissue samples. Neither protein was detected. As 
negative controls (CTR), the primary antibodies were replaced with PBS containing 0.05% Tween. (F) 
Samples from three individual human liver samples were analyzed by Western blotting with 
antibodies against the indicated proteins. As a positive control for pSTAT proteins, Huh7.5 cells were 
treated with IFN-α for 30 min. Western blots are representative of three independent experiments. 
(G and H) Confocal laser electroscope analysis of pSTAT1-Tyr701 (top) and pSTAT2-Tyr690 (bottom) in 
human liver organoids (G) and Huh7.5 cells (H). The pSTAT1 and pSTAT2 proteins are shown in green, 
whereas nuclei were visualized by DAPI (blue). Human liver organoids or Huh7.5 cells treated with 
IFN-α for 30 min served as the corresponding positive controls. Images are representative of multiple 
organoids or cells from three individual experiments. (I and J) HCV-positive (I) and HEV-positive (J) 
Huh7.5 cells transduced with control lentivirus or lentiviruses expressing WT or Y701F mutant STAT1 
together with STAT2 and IRF9 were subjected to assays of viral replication–related luciferase activity. 
Data are means ± SEM of three independent experiments. (K) Huh7.5 cells transduced with control 
lentivirus or lentiviruses expressing WT or Y701F mutant STAT1 together with STAT2 and IRF9 were 
subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are means ± 
SEM of three independent experiments. *P < 0.05; **P < 0.01; ns, not significant. 
U-ISGF3 drives ISG transcription without stimulating IFN production 
To further dissect whether the U-ISGF3–induced expression of ISGs was independent of IFN 
production, we measured the basal abundances of mRNAs of several IFNs, including IFNA, 
IFNB, IFNG, IL29, and IL28A (fig. S5E). The abundances of IFNA and IFNBmRNAs were not 
statistically significantly increased by the overexpression of STAT1, STAT2, or IRF9 alone or in 
combination (Fig. 7, C and D), whereas the mRNAs encoding IFNG, IL29, and IL28A were 
undetectable with or without overexpression of the U-ISGF3 components (fig. S5E). To 
further confirm the lack of IFN production, we collected the conditioned medium of these 
cells (fig. S5F) and performed functional assays. Conditioned culture medium from any of the 
overexpressing Huh7.5 cells was unable to stimulate an IFN response in an ISRE reporter 
assay (fig. 7E). Consistently, treatment of Huh7.5 cells with these conditioned media had no 
effect on ISG expression (fig. S5G). These data suggest that the U-ISGF3–induced expression 
of ISGs is IFN-independent. 
U-ISGF3 drives ISG expression independently of the upstream components of 
the IFN signaling pathway 
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IFNs are mainly produced by so-called IFN-producing cells (IPCs). In our study, we included 
three types of well-known IPCs, human plasmacytoid dendritic cells (pDCs), myeloid 
dendritic cells (mDCs), and T cells to demonstrate the classical IFN-dependent mechanisms 
of ISG transcription and antiviral action. As expected, these IPCs produced IFNs to activate 
the JAK-STAT pathway, drive ISG transcription, and exert antiviral activity. These effects 
were specifically blocked by JAK inhibitor I (fig. S6). Therefore, upon IFN stimulation, the 
intact JAK-STAT signaling pathway is a prerequisite for the formation of its downstream 
transcription factor complex, ISGF3, which drives the expression of ISGs (fig. S7A). To dissect 
the involvement of its upstream elements in basal ISG transcription, we knocked down 
either IFN-αR1 or IFN-λR1 in Huh7.5 cells by lentiviral shRNA (Fig. 7F). Efficient knockdown of 
IFN-αR1 or IFN-λR1 had no effect on constitutive ISG expression (Fig. 7G). In addition, 
knockdown of endogenous JAK1 in Huh7.5 cells (Fig. 7, H and I) did not inhibit the 
constitutive expression of ISGs (Fig. 7J). This finding was further confirmed in experiments 
with Caco2 cells (fig. S7, B to D). Conversely, collective overexpression of STAT1, STAT2, and 
IRF9 by lentiviral transduction in IFN-αR1-, IFN-λR1-, or JAK1-knockdown Huh7.5 cells 
showed comparable ISG induction ability compared with control lentiviral vector (Fig. 7K). 
These results suggest that U-ISGF3 drives the basal expression of ISGs independently of the 
upstream elements of the IFN signaling pathway. 
Discussion  
ISGs are the ultimate antiviral effectors of the IFN signaling. They function either by targeting 
different steps of the viral life cycle or by reinforcing host defense by further activation of 
ISG expression [1, 21]. Classically, upon IFN stimulation, STAT1 and STAT2 are phosphorylated, 
leading to the association with IRF9 to form the transcription factor complex ISGF3. 
Phosphorylated ISGF3 translocates into cell nucleus and binds to the promoter regions of 
ISGs to activate the transcription of these hundreds of ISGs. However, when cells are 
continuously exposed to a low level of exogenous interferon, unphosphorylated ISGF3 (U-
ISGF3), formed by interferon stimulated IRF9 and unphosphorylated STAT1 and STAT2, can 
also lead to increased expression of a subset of ISGs [2]. Importantly, both regulatory 
mechanisms require the activation by IFN. 
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Figure 7. U-ISGF3 stimulates the expression of ISGs independently of IFN production and the 
upstream elements of the IFN signaling pathway 
(A) Huh7.5 cells were left untreated (CTR) or were treated with 5 μΜ NSC87877 (phosphatase 
inhibitor) before the cells were subjected to qRT-PCR analysis of the relative abundances of the 
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indicated mRNAs. Data are means ± SEM of three independent experiments. (B to D) Huh7.5 cells 
were transduced with control lentivirus or with lentiviruses expressing STAT1, STAT2, and IRF9, 
individually or in combination, before being treated with vehicle or NSC87877. The cells were then 
subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs for ISGs (B), IFNA 
(C), and IFNB (D). Data are means ± SEM of three independent experiments. (E) Huh7.5 cells 
transduced with lentiviruses expressing the indicated proteins were cultured for 48 hours before the 
cell culture medium was collected and used to treat an ISRE luciferase reporter cell line. As a positive 
control, culture medium was collected from cells treated with IFN-α (10 IU/ml). Data are means ± 
SEM of three independent experiments. (F) Huh7.5 cells transduced with lentiviruses expressing 
control shRNA, IFNAR1-specific shRNA, or IFNLR1-specific shRNA were analyzed by qRT-PCR to 
determine the extent of knockdown of the indicated mRNAs. Data are means ± SEM of three 
independent experiments. (G) Huh7.5 cells transduced with lentiviruses expressing control shRNA, 
IFNAR1-specific shRNA, or IFNLR1-specific shRNA were analyzed by qRT-PCR to determine the 
relative abundances of the indicated mRNAs. Data are means ± SEM of three independent 
experiments. (H and I) Huh7.5 cells transduced with lentiviruses expressing control or JAK1-specific 
shRNAs were analyzed by qRT-PCR to determine the extent of knockdown of JAK1 mRNA (H) or by 
Western blotting with antibodies against the indicated proteins (I). Data in (H) are means ± SEM of 
three independent experiments. Western blots are representative of three independent 
experiments. (J) Huh7.5 cells transduced with lentiviruses expressing control or JAK1-specific shRNAs 
were analyzed by qRT-PCR to determine the relative abundances of the indicated mRNAs. Data are 
means ± SEM of three independent experiments. (K) Huh7.5 cells were transduced with lentiviruses 
expressing control shRNA or shRNAs specific for JAK1, IFNAR, or IFNLR. After the puromycin 
selection, they were not (-) or were (+) transduced with lentiviruses expressing STAT1, STAT2, and 
IRF9. The cells were then subjected to qRT-PCR analysis of the relative abundances of the indicated 
mRNAs. Data are means ± SEM of three independent experiments.  *P < 0.05; **P < 0.01; ns, not 
significant. (L) Illustration of the mechanism of basal expression of ISGs under homeostatic 
conditions. Unphosphorylated STAT1, STAT2, and IRF9 shuttle between the cytoplasm and the 
nucleus. When these three components are present in the nucleus, they function as the 
constitutively active transcription factor complex U-ISGF3 to sustain the basal expression of ISGs. The 
products of these expressed ISGs confer protection to the cell from viral infection. 
Classically, IFNs are mainly produced by so-called IFN-producing cells (IPCs) These 
IPCs produced IFNs to activate the JAK-STAT pathway, drive ISG transcription, and exert 
antiviral activity. Huh7.5Huh7.5Here, we highlighted the existence of an IFN-independent 
mechanism that sustains the constitutive expression of IFN-encoding genes. We found that 
constitutive ISG expression was mediated by the endogenous U-ISGF3 complex. This 
regulatory mechanism was independent of IFN production and the upstream elements of 
IFN signaling, but conferred the cells with resistance against viral infections (Fig. 7L). Thus, 
these data suggest that both IFN-dependent and -independent antiviral mechanisms co-exist 
and work cooperatively.  
As a critical element in determining cellular susceptibility to viral infection, 
constitutively expressed ISGs also determine the rapid response and intensity of cellular 
antiviral activity. Because many ISGs are key components of antiviral pathways, their basal 
expression is necessary for the quick activation of these signaling pathways upon ligand 
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engagement. Taking the JAK-STAT pathway as a typical example, because the key 
components of this cascade are present in the cell under homeostatic conditions, the 
synthesis of new protein components of this pathway in response to stimulation with IFN is 
not required. Therefore, activation of this signaling pathway can rapidly occur, resulting in a 
timely and effective way of controlling invading pathogens. Furthermore, most of the 
necessary components of the JAK-STAT pathway are encoded by ISGs. 
In particular circumstances, deficiency of a single ISG can lead to compromised 
immunity following virus infection. Mice genetically deficient for STAT1, STAT2 or IRF9 
developed persistent virus infection or even lethal disease in response to virus invasion, 
including those provoked by choriomeningitis virus, respiratory syndrome coronavirus and 
vesicular stomatitis virus [22-25]. In contrast, cells maintaining relatively higher levels of 
baseline ISGs show stronger resistance against virus infection. Nevertheless, the abnormal 
regulation of constitutive ISG expression is closely associated with treatment outcome in 
cancer or chronic HCV patients. Chronic hepatitis C patients with abnormally high levels of 
ISG expression in the liver at baseline poorly respond to pegylated IFN-α/ribavirin therapy [7, 
8]. In cancer patients, abnormally high expression of ISGs promotes tumor growth, 
metastasis, and confers resistance to chemotherapy and radiation [9, 10]. Thus, constitutive 
ISGs at requisite levels are vital to prepare the host cells into a “combat ready” or “pre-
arming” mode, but also determine the treatment responses in particular diseases in patients. 
In conclusion, we have demonstrated that endogenous U-ISGF3 function as the constitutive 
transcription factor to sustain basal ISG transcription, conferring cell resistance against virus 
infection. In contrast, the absence of U-ISGF3 can lead to decreased ISG expression at 
baseline, being susceptible to virus infection.  
Supplementary Materials and Methods 
Study approval 
The animal study was approved by the institutional animal ethics committee (Dier 
Experimenten Commissie). Human intestinal or liver tissues were obtained from patients 
during surgical resection. The patients agreed to participate by written informed consent, 
and the study was approved by the Medical Ethical Committee of the Erasmus Medical 
Center (Medisch Ethische Toetsings Commissie Erasmus MC). 
Reagents 
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Human IFN-α (Thermo Scientific) was dissolved in phosphate-buffered saline (PBS) before 
use. Antibody against pSTAT1-Tyr701 (58D6; rabbit monoclonal; #9167) was obtained from 
Cell Signaling Technology. Antibodies against STAT1 (rabbit polyclonal; sc-592), STAT2 (rabbit 
polyclonal; SC-476), pSTAT2-Tyr690 (rabbit polyclonal; sc-21689-R), pSTAT1-Ser727 (rabbit 
polyclonal; sc-16570-R), ISGF-3γ p48 (H-143; rabbit polyclonal; sc-365893), and β-actin were 
purchased from Santa Cruz Biotechnology. Anti-rabbit or anti-mouse IRDye-conjugated 
secondary antibodies were obtained from LI-COR Biosciences. Stocks of JAK inhibitor 1 and 
NSC87877 (Santa Cruz Biotechnology) were dissolved in DMSO at a concentration of 10 mM. 
3-D primary human intestinal or liver organoids models 
Human intestinal crypt isolation and primary human intestinal organoids culture was 
described previously [26]. Human liver cell isolation and primary human liver organoids 
culture was described accordingly [27]. 
Cell models 
Huh7.5 cells (a human hepatoma cell line), Caco2 cells (a human epithelial colorectal 
adenocarcinoma cell line), and A549 cells (a human alveolar basal epithelial cell line) were 
cultured in Dulbecco’s modified Eagle medium (DMEM, Lonza Biowhittaker) complemented 
with 10% (v/v) fetal calf serum (FCS, Hyclone), 100 IU/ml penicillin, and 100 µg/ml 
streptomycin. Wild-type (WT) MEFs and MEFs from STAT1-/- [28] and STAT2-/- [29] mice were 
generously provided by Prof. Andrea Kröger (Helmholtz Centre for Infection Research) and 
Christian Schindler (Columbia University, NY), respectively. IRF9-/- mice and the 
corresponding WT MEFs [30] [30] were generously provided by K. Mossman (McMaster 
University, Canada). STAT1-deficient (U3A) and STAT2-deficient (U6A) cell lines were kindly 
provided by G. R. Stark (Lerner Research Institute). Huh7.5 cells expressing the HCV 
subgenomic replicon containing a subgenomic HCV bicistronic replicon (1389/NS3-
3V/LucUbiNeo-ET) linked to the firefly luciferase reporter gene were maintained in 
Dulbecco’s modified Eagle medium (DMEM) complemented with 10% (v/v) fetal calf serum, 
100 IU/ml penicillin, and 100 μg/ml streptomycin and 250 μg/ml G418 (Sigma) [31]. The HEV 
subgenomic model: Huh7.5 cells containing the subgenomic HEV sequence (Kernow-C1 
p6/luc) coupled to a Gaussia luciferase reporter gene [32, 33]. Luciferase normalization cells 
(Huh7.5-norm) were generated by transducing Huh7.5 cells with a lentiviral vector 
expressing the firefly luciferase gene under the control of the human phosphoglycerate 
Chapter 8 
203 | P a g e  
 
kinase (PGK) promoter. For the ISRE reporter model, Huh7.5 cells were transduced with a 
lentiviral transcriptional reporter system that expressed the firefly luciferase gene driven by 
a promoter containing multiple ISRE promoter elements (SBI Systems Biosciences), and 
luciferase activity was used as a reporter of ISRE promoter activation [34, 35]. Human 
plasmacytoid dendritic cells (pDCs), myeloid dendritic cells (mDCs), and T cells were purified 
from the buffy coats of healthy blood donors and were cultured in round-bottom, 96-well 
plates [36]. Culture medium of these cells was harvested after 48 hours and served as 
conditioned medium for further experiments. For simian rotavirus experiments, SA11, a 
well-characterized and broadly used laboratory strain of the virus, was used to inoculate the 
Caco2 cell line as a rotavirus infection model [26]. 
Gene knockdown or overexpression by lentiviral vectors  
Lentiviral pLKO knockdown vectors (Sigma-Aldrich) expressing shRNAs targeting IFN-αR1, 
IFN-λR1, JAK1, STAT1, STAT2, or IRF9 and their appropriate controls were obtained from the 
Erasmus Biomics Center and were produced in HEK 293T cells. After a pilot study, those 
shRNA-expressing vectors that exerted optimal gene knockdown were selected. These 
shRNA sequences are listed in table S1. Stable gene knockdown cells were generated after 
lentiviral vector transduction and selection in medium containing puromycin (3 μg/ml; 
Sigma). The pTRIP.CMV.IVSb.ISG.ires.TagRFP–based STAT1, STAT2, and IRF9 overexpression 
lentiviral vectors were a kind gift from C. M. Rice (Rockefeller University) [37]. Control vectors 
expressing green fluorescent protein (GFP) was also used. The pLV-tetO-CMV-SV40-Puro-
LoxP–based lentiviral vectors expressing WT STAT1 or the Y701F-STAT1 mutant (which 
cannot be phosphorylated) were kindly provided by G. R. Stark (Lerner Research Institute) 
[13]. Lentiviral pseudoparticles were generated as described previously [13, 37]. 
Ultracentrifugation was used to achieve high-titer lentiviruses with superior transduction 
efficiency. 
Measurement of luciferase activity 
For Gaussia luciferase analysis, the activity of secreted luciferase in the cell culture medium 
was measured with the BioLux Gaussia Luciferase Flex Assay Kit (New England Biolabs) 
according to the manufacturer’s instructions. For firefly luciferase assays, luciferin potassium 
salt (100 mM; Sigma) was added to the cells and incubated for 10 min at 37°C. Luciferase 
activity was then quantified with a LumiStar Optima luminescence counter (BMG Lab Tech). 
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Quantitative RT-PCR analysis 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke) and quantified with a 
Nanodrop ND-1000 spectrophotometer (Wilmington). All RNA samples were adjusted to a 
concentration of 62.5 ng/μL. RNA (500 ng) was used as template for the generation of 
complementary DNA (cDNA) with the reverse transcription system (TAKARA BIO INC). The 
cDNA (10 ng/well) of all detected genes was amplified for 50 cycles and quantified with a 
SYBRGreen-based real-time PCR system (Applied Biosystems) according to the 
manufacturer’s instructions. GAPDH was considered as reference gene to normalize gene 
expression. Relative gene expression (based on mRNA abundance) was normalized to that of 
GAPDH using the formula: 2−ΔΔCT (ΔΔCT = ΔCTsample − ΔCTcontrol) [38]. All of the primer 
sequences are included in table S2. 
Quantification of gene copy numbers 
To generate a template with which to quantify ISG copy number under basal conditions, 
vectors containing the corresponding ISG genes were used. A series of dilutions, from 10−2 to 
10−10, were prepared and then were amplified and quantified by qRT-PCR to generate a 
standard curve. The standard curve was generated by plotting the log of the copy number 
against the cycle threshold (CT) value (fig. S1A). Copy numbers were calculated with the 
following equation: Copy number (molecules/μg) = (1 μg/0.01 μg) × [concentration (ng/μL) × 
6.022×1023 (molecules/mol)] / [length of amplicon × 640 (g/mol) × 109 (ng/g)]. 
Nuclear extraction and Western blotting analysis 
Nuclear and cytoplasmic proteins were extracted with the nuclear and cytoplasmic protein 
extraction kit (Active Motif) according to the manufacturer’s instructions. All samples were 
lysed in Laemmli sample buffer containing 0.1 M DTT and heated for 5 min at 95°C, which 
was followed by loading the samples onto a 10% sodium dodecyl sulfate polyacrylamide gel 
(SDS-PAGE) and separation by electrophoresis. After 90 min running at 120 V, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride (PVDF) membrane 
(Invitrogen) for 1.5 hours with an electric current of 250 mA. Subsequently, the membrane 
was blocked with a mixture of 2.5 ml of blocking buffer (Odyssey) and 2.5 ml of PBS 
containing 0.05% Tween 20. This was followed by overnight incubation with the appropriate 
primary antibody (at a 1:1000 dilution) at 4°C. The membrane was washed three times, 
which was followed by incubation for 1 hour with IRDye-conjugated secondary antibody (1: 
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5000). After the membrane was washed three times, protein bands were detected with the 
Odyssey 3.0 Infrared Imaging System. 
IFN production assay 
Huh7.5 cells were seeded into 6-well plates at a density of 10 × 104 cells per well and then 
were transduced with lentiviruses expressing STAT1, STAT2, or IRF9 singly or in combination 
at 37°C. Forty-eight hours later, the lentiviral particles were removed and the cells were 
washed three times with PBS. The culture medium was refreshed and the transduced cells 
were cultured for another 48 hours. The culture medium was subsequently collected and 
added to an ISRE luciferase reporter cell line that is sensitive to IFNs. The conditioned 
medium was also used to treat Huh7.5 cells for 24 hours, which was followed by 
quantification of ISG expression by qRT-PCR analysis. 
Confocal laser electroscope assay 
Cells were seeded on glass coverslips. After 12 hours, the cells were washed with PBS, fixed 
in 4% PBS-buffered formalin for 10 min, and blocked with Tween-milk-glycine medium [PBS, 
0.05% Tween, skim milk (5 g /L), and glycine (1.5 g/L)]. Samples were incubated with primary 
antibodies overnight at 4 °C. The samples were then incubated with anti-mouse IgG (H+L), 
F(ab')2 Fragment (Alexa Fluor 488 conjugate), or anti-rabbit IgG(H+L), F(ab') 2 Fragment 
(Alexa Fluor 488 conjugate) secondary antibodies (each at a 1:1000 dilution). Nuclei were 
stained with DAPI (4,6-diamidino-2-phenylindole; Invitrogen). Images were detected with 
confocal electroscope (lens: 40 ×, software: ZenLightEdition). 
Immunohistochemistry (IHC) 
Paraffin-embedded liver tissue sections were deparaffinized in xylene, rehydrated in graded 
alcohols, and rinsed once in PBS containing 0.05% Tween. After antigen retrieval, 1.5% H2O2 
was used to block endogenous peroxidase for 10 min at room temperature. The slides were 
incubated in 5% milk blocking solution, which was followed by overnight incubation with 
primary antibody at a 1:200 dilution before the tissue sections were then counterstained 
with hematoxylin. As a negative control, the primary antibody was replaced with PBS 
containing 0.05% Tween. 
ChIP-seq data analysis 
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The ChIP-seq dataset for STAT1 (GSE31477) was retrieved from the ENCODE database. ChIP-
seq datasets were processed and mapped to the hg19 reference genome as described 
previously [11]. ChIP-seq datasets with multiple replicates were merged. MACS 1.4.2 software 
was used for peak-calling and for the generation of binding profiles [39]. If the centers of two 
binding regions reported by MACS were 100 bp or less apart, then they were unified to a 
single binding region. The sequencing profiles were generated in the IGV browser [40]. 
Statistical analysis 
All results were presented as means ± SEM. Comparisons between groups were performed 
with the Mann-Whitney test. Differences were considered to be statistically significant when 
P < 0.05. 
Supplementary Figures  
Fig. S1. Cells sustain basal ISG 
expression under homeostatic 
conditions. 
(A) Representative microscopy image 
of cultured human primary liver 
organoids (left) and intestinal 
organoids (right). (B) Standard curve 
for quantifying ISG genes copy 
numbers. Plasmids containing the 
corresponding ISG genes (STAT1, 
STAT2, IRF9, and IFITM1) were used. 
The plasmids were extracted, 
followed by a series of dilutions, from 
10-2 to 10-10, were prepared and then 
were amplified and quantified by qRT-
PCR. Standard curve was generated 
by plotting the cycle threshold (CT) 
value with regard to the log copy 
number. (C) With the treatment of 
Huh7, Caco2, A549 conditioned 
medium or IFN-α (10 IU/ml, positive 
control) for 24 hours, the expression 
levels of IRF9, IFITM1, and ISG15 in 
Huh7 cells were quantified by qRT-
PCR (n = 3 independent experiments). 
*P < 0.05; **P < 0.01; ns, not 
significant. 
Chapter 8 
207 | P a g e  
 
Fig. S2. Sustained basal 
ISG expression is 
independent of IFN 
production.  
(A) Representative 
Western blotting 
analysis (from three 
experiments) of total 
STAT1 and pSTAT1 
(Tyr701) protein levels 
under the treatment of 
IFN-α (1000IU/ml), JAK 
inhibitor I (5uM) or the 
combination. (B) 
Huh7.5 cells were 
treated with IFN-α 
(1000IU/ml), 5 µM JAK 
inhibitor I or their 
combination for 24 
hours before being 
subjected to qRT-PCR 
analysis of the relative abundances of the indicated mRNAs. (n = 3 independent experiments). (C) 
Caco2 cells were treated with 5 µM JAK inhibitor I for 24 hours before being subjected to qRT-PCR 
analysis of the relative abundances of the indicated mRNAs (n = 3 independent experiments). (D) 
Same as (C) for A549 cells (n = 3 independent experiments). 
Fig. S3. STAT1, STAT2, 
and IRF9 are required 
for constitutive ISG 
expression.  
(A) A549 and Caco2 cell 
lysates were 
fractionated into 
cytoplasmic (Cy) and 
nuclear (Nu) fractions 
and then were analyzed 
by Western blotting with 
antibodies against the 
indicated proteins. 
Cyclophilin A and Lamin 
A/C were used as 
cytosolic and nuclear 
markers, respectively. 
Western blots are 
representative of three 
independent 
experiments. (B) Confocal laser electroscope analysis of endogenous STAT1 localization in Caco2 
cells. STAT1 is shown in green. Nuclei were visualized by DAPI (blue). Images are representative of 
multiple cells from three independent experiments.. (C) Caco2 cells transduced with control 
lentivirus or with lentivirus expressing IRF9 were subjected to qRT-PCR analysis of the relative 
abundances of the indicated mRNAs.  (n = 3 independent experiments). (D) Rotavirus positive Caco2 
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cells transduced with control lentivirus or with lentivirus expressing IRF9 were subjected to qRT-PCR 
analysis of the relative abundances of the indicated mRNAs. (n = 3 independent experiments). *P < 
0.05; **P < 0.01; ns, not significant. 
 
Fig. S4. The overexpression of U-ISGF3 leads to increased ISG expression.  
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(A) STAT1 mutant cells (U3A) were transduced with control lentivirus or with lentivirus expressing 
STAT1, STAT2 and IRF9 before being subjected to Western blotting analysis with antibodies against 
the indicated proteins. Western blots are representative of three independent experiments.Western 
blotting (B) U3A cells were transduced with control lentivirus or with lentiviruses expressing the 
indicated proteins before being subjected to qRT-PCR analysis of the relative abundances of the 
indicated mRNAs. Data are means ± SEM of three independent experiments. (C) Same as (A) for U6A 
cells. (D) Same as (B) for U6A cells. (E) Representative immunohistochemical analysis of pSTAT1-
Tyr701 in mouse liver tissue samples. As negative control, primary antibody against pSTAT1-Tyr701 was 
replaced with PBS plus Tween 0.05%. (F and G) Confocal laser electroscope analysis (F) and Western 
blotting analysis (G) of pSTAT1-Tyr701 in human intestinal organoids (from three experiments). 
Human intestinal organoids treated with IFN-α for 30 min served as the corresponding positive 
control. (H) Confocal laser electroscope analysis of pSTAT2-Tyr690) in human intestinal organoids. 
Human intestinal organoids treated with IFN-α for 30 min served as the positive control. Images are 
representative of multiple organoids from three individual experiments. (I) RT-PCR confirmed the 
successful over-expression of STAT1, Y701F-STAT1, STAT2 or IRF9 in U3A cells (n = 3 independent 
experiments). (J) In U3A cells, over-expression of Y701F-STAT1 together with STAT2 and IRF9 led to a 
comparable ISG induction compared with its wild type (n = 3 independent experiments). (K) 
Representative Western blotting analysis (from three experiments) of pSTAT1 (Ser727) in Huh7 cells 
under the homeostatic condition. Huh7 cells treated with IFN-α, IFN-β (100IU/ml, 16 hours) served as 
positive controls. (L) Representative immunohistochemical staining (from three experiments) 
analysis of pSTAT1 (Ser727) in human liver tissue samples from two individuals. Neither of them was 
detected. As negative control, primary antibody against pSTAT1 (Ser727) was replaced with PBS plus 
Tween 0.05%. *P < 0.05; **P < 0.01; ns, not significant. 
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Fig. S5. U-ISGF3 stimulates ISG expression independently of IFN production.  
(A) The regulation of phosphorylation process of STAT1/2 was illustrated. Upon stimulations (e.g. by 
IFNs), STAT1/2 get phosphorylated by specific kinases. Importantly, phosphorylated STAT1/2 
undergo dephosphorylation process. Thus, the phosphorylation and dephosphorylation process 
coordinate to maintain the phosphorylation level at a balanced state, which balances its beneficial 
antiviral versus detrimental proinflammatory effects. Consequently, the inhibition of phosphatases 
will alter the balanced state, leading to higher levels of phosphorylated STAT1/2 and a much stronger 
induction of ISGs. (B) Caco2 cells were left untreated (CTR) or were treated with 5 μΜ NSC87877 
(phosphatase inhibitor) before the cells were subjected to qRT-PCR analysis of the relative 
abundances of the indicated mRNAs. (n = 3 independent experiments). (C) and (D) Huh7.5 cells 
transduced with control lentivirus or with lentivirus expressing Y701F-STAT1, STAT2 and IRF9 were 
subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. (n = 3 
independent experiments). (E) The basal expression levels of several interferons, including IFNA, 
IFNB1, IFNG, IL29, IL28A, and the reference gene (GAPDH) were evaluated by qRT-PCR. (F) Schematic 
illustration of the production of conditioned medium (supernatant). (G) Huh7.5 cells were treated 
with conditioned medium from Huh7.5 cells with over-expression of STAT1, STAT2, IRF9 or their 
combination were subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. 
IFN-α (10 IU/ml) serves as positive control (n = 3 independent experiments). 
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Fig. S6. IPCs produce IFNs to activate the JAK-STAT pathway, thus stimulating ISG expression and 
antiviral activity.  
(A) HEV viral replication-related firefly luciferase activity was measured upon the treatment of 
conditioned medium from pDC, mDC and T cells for 48 hours Data are means ± SEM of two or three 
replicates from three independent experiments. (B) HCV viral replication-related firefly luciferase 
activity was measured at 3 different time points (12 hours, 24 hours and 48 hours) upon the 
treatment of conditioned medium from pDC, mDC and T cells Data are means ± SEM of two or three 
replicates from three independent experiments. (C) ISRE luciferase value was measured at 2 different 
time points (12 hours and 24 hours) after the treatment of conditioned medium from pDC, mDC and 
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T cells Data are means ± SEM of two or three replicates from three independent experiments. (D) 
Huh7.5-ISRE-luc cells were treated with conditioned medium from pDC, mDC and T cells without (-) 
or with  JAK inhibitor I (5 μΜ) for 24 hours ISRE luciferase values were then measured and the fold-
increase in activity relative to that of untreated cells was determined. Data are means ± SEM of two 
or three replicates from three independent experiments. (E) Representative Western blotting 
analysis (from three experiments) of total STAT1 and pSTAT1(Tyr701) in Huh7.5 cells treated with 
conditioned medium (from pDC, mDC and T cells). (F) Huh7.5 cells were treated with conditioned 
medium (from pDC) without or with JAK inhibitor I (5 μM) for 24 hours before subjected to qRT-PCR 
analysis of the relative abundances of the indicated mRNAs. (n = 3 independent experiments). (G and 
H) Same as (F) for conditioned medium from mDC (G) and T (H) cells. *P < 0.05; **P < 0.01; ***P < 
0.001; ns, not significant. 
 
Fig. S7. U-ISGF3 stimulates ISG expression independently of upstream elements of the IFN signaling 
pathway.  
(A) Illustration of type I and III IFN signaling pathways. (B and C) Caco2 cells transduced with 
lentiviruses expressing control or JAK1-specific shRNAs were analyzed by qRT-PCR to determine the 
extent of knockdown of JAK1 mRNA (B) or by Western blotting with antibodies against the indicated 
proteins (C). Data in (B) are means ± SEM of three independent experiments. Western blots are 
representative of three independent experiments. (D) Caco2 cells transduced with lentiviruses 
expressing control or JAK1-specific shRNAs were analyzed by qRT-PCR to determine the relative 
abundances of the indicated mRNAs. Data are means ± SEM of three independent experiments. (n = 
3 independent experiments). *P < 0.05; **P < 0.01; ns, not significant. 
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Abstract  
Hepatitis E virus (HEV) infection, one of the foremost causes of acute hepatitis, is becoming a 
health problem of increasing magnitude. As other viruses, HEV exploits elements from host 
cell biochemistry, but we understand little as to which components of the human 
hepatocellular machinery are perverted for HEV multiplication. It is, however, known that 
the eukaryotic translation initiation factors 4F (eIF4F) complex, the key regulator of the 
mRNA-ribosome recruitment phase of translation initiation, serves as an important 
component for the translation and replication of many viruses. Here we aim to investigate 
the role of three subunits of the eIF4F complex: eukaryotic translation initiation factor 4A 
(eIF4A), eukaryotic translation initiation factor 4G (eIF4G) and eukaryotic translation 
initiation factor 4E (eIF4E) in HEV replication. We found that efficient replication of HEV 
requires eIF4A, eIF4G and eIF4E. Consistently, the negative regulatory factors of this 
complex: programmed cell death 4 (PDCD4) and eIF4E-binding protein 1 (4E-BP1) exert anti-
HEV activities, which further illustrates the requirement for eIF4A and eIF4E in supporting 
HEV replication. Notably, phosphorylation of eIF4E induced by MNK1/2 activation is not 
involved in HEV replication. Although ribavirin and interferon-α (IFN-α), the most often-used 
off-label drugs for treating hepatitis E, interact with this complex, their antiviral activities are 
independent of eIF4E. In contrast, eIF4E silencing provokes enhanced anti-HEV activity of 
these compounds. Thus, HEV replication requires eIF4F complex and targeting essential 
elements of this complex provides important clues for the development of novel antiviral 
therapy against HEV. 
Keywords: Eukaryotic translation initiation factor 4F complex; Hepatitis E virus; IFN-α; 
Ribavirin; eIF4E-binding protein 1 
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Introduction 
Hepatitis E virus (HEV), a single-strand-positive RNA virus classified within the genus 
Hepevirus in the family Hepeviridae, represents the most common cause of acute viral 
hepatitis [1]. Like all viruses, HEV is completely dependent on the translational machinery of 
host cells to synthesize the viral proteins essential for its productive infection [2]. The host 
protein synthesis machinery commandeered by viruses has major impact on viral protein 
synthesis and genome replication [3], but little is known regarding how HEV uses host 
translational machinery for its life-cycle. 
As a heterotrimeric protein complex, eukaryotic translation initiation factor 4F (eIF4F) 
mediates recruitment of ribosomes to mRNA and is the rate-limiting step for cap-dependent 
translation in viruses and cells under most circumstances. Functions of the constituent 
proteins of eIF4F include delivery of an RNA helicase eukaryotic initiation translation factor 
4A (eIF4A) to the 5’ region, bridging mRNA and ribosome by eukaryotic initiation translation 
factor 4G (eIF4G) scaffolding protein and recognition of the mRNA 5’ cap structure by 
eukaryotic initiation translation factor 4E (eIF4E) cap-binding protein [4]. Not surprisingly, all 
these translation initiation factors are required for various types of viruses during their 
translation and replication [2, 5-7]. In addition, eIF4E phosphorylation is induced by the eIF4G-
associated kinase MNK1 to facilitate eIF4F assembly [8]. This process of translational control 
has been reported to be critical for the efficient viral infection [2, 9, 10]. Furthermore, other 
cellular regulatory proteins of eIF4F complex such as eukaryotic translation initiation factor 
4B (eIF4B) [11], programmed cell death 4 (PDCD4) [12] and eIF4E-binding protein 1 (4E-BP1) 
have been reported vital for viral protein synthesis [13-15]. HEV, however, has not been 
investigated in this context and it is currently unknown whether the virus requires eIF4F 
complex for efficient replication. 
Interestingly, the eIF4F complex can interact with antiviral regimens, such as ribavirin 
or interferon-α (IFN-α), which are the classical standard therapy of chronic hepatitis C but 
also as off-label drugs for treating individual HEV cases or small case series [16, 17]. Ribavirin 
can directly bind to eIF4E and compete for 5’ cap mRNA binding [18, 19], whereas some 
regulatory factors of eIF4F complex are involved in interferon mediated antiviral immune 
response [20, 21]. In absence, however, of information as to requirement of HEV for elements 
of the host translational machinery it is impossible to make statements whether ribavirin 
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exerts its anti-HEV action through inhibition of the eIF4F complex or whether alternative 
mechanisms are involved. 
The lack of knowledge as to the requirements made by HEV on the hepatocellular 
host cell machinery with respect to translation of viral gene products represents a major gap 
in our understanding of the biology of this virus and hampers design of rational treatment. 
Therefore, this study has investigated the role of the eIF4F complex and its regulatory 
factors in HEV replication, as well as their potential involvements in the anti-HEV actions of 
ribavirin and IFN-α. 
Materials and methods 
Reagents 
Compound GCP57380 as Mnk1 inhibitor (> 98% purity) was purchased from Abcam 
Biochemicals (UK). Ribavirin was purchased from Sigma-Aldrich (St Louis, MO). Human IFN-α 
(Thermo Scientific, the Netherlands) was dissolved in PBS. Doxycycline hyclate ( ≥ 98% TLC) 
was purchased from Sigma-Aldrich (St Louis, MO). Stocks of Jak inhibitor I (Santa Cruz 
Biotech, Santa Cruz, CA) was dissolved in DMSO (Sigma-Aldrich, St Louis, MO) with a final 
concentration of 5 mg/mL. Antibodies including total-eIF4E, phosphor-eIF4E, total-4E-BP1 
(Cell Signaling Technology, Netherlands) and β-actin (Santa Cruz Biotech, Santa Cruz, CA); 
anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies (Stressgen, Glandford Ave, 
Victoria, BC, Canada) were also used. 
Cell culture and cell models 
Naïve or vector transduced Huh7 cells was established from a hepatocellular carcinoma, 
immortalized mouse embryonic fibroblasts (MEFs) derived from wild-type and 4E-BP1 
knock-out (4E-BP1-/-) mice (kind gifts from E.N. Fish’s lab), eIF4E-S209A MEFs containing an 
eIF4E mutation in which eIF4E cannot be phosphorylated (kind gift from Dr. Sonenberg's lab, 
McGill University) were cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen-
Gibco, Breda, the Netherlands) complemented with 10% v/v fetal calf serum (Hyclone, 
Lonan, Utah), 100 IU/mL penicillin, 100 mg/mL streptomycin and 2 mM L-glutamine 
(Invitrogen-Gibco). Authentication of cell line was performed at the Department of 
Pathology, Erasmus MC and regular testing for mycoplasma contamination was performed 
at the Laboratory of Gastroenterology and Hepatology, Erasmus MC. 
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HEV genomic RNA was generated from a plasmid construct containing the full-length 
HEV genome (Kernow-C1 p6 clone, GenBank Accession Number JQ679013) or a construct 
containing subgenomic HEV sequence coupled with a Gaussia luciferase reporter gene (p6-
Luc), using the Ambion MESSAGE MACHINE in vitro RNA transcription Kit (Life Technologies 
Corporation) [22, 23]. The human hepatoma 7 (Huh7) cells were collected and centrifuged for 5 
min, 1500 rpm, 4 °C. Supernatant was removed and washed with 4 mL Opti-MEM by 
centrifuging for 5 min, 1500 rpm, 4 °C. The cell pellet was re-suspended in 100 μL Opti-MEM 
and mixed with p6 full-length HEV RNA or p6-Luc subgenomic RNA. Electroporation was 
performed with the Bio-Rad’s electroporation systems using the protocol of a designed 
program (240 V, pulse length 0.5, number 1 and cuvette 4 mm) [22]. All cells were grown at 
37 °C, 5% CO2, and 100% humidity. 
Gene knockdown and overexpression by lentiviral vector 
Lentiviral vectors of shRNA (Sigma-Aldrich) targeting eIF4A, eIF4G, eIF4B, PDCD4, eIF4E, 4E-
BP1 and controls were obtained from the Erasmus Center for Biomics and produced in HEK 
293T cells as previously described [24]. Three types of control vectors have been tested on 
HEV replication (CTR1: Control that will not activate the RNAi pathway because the vector 
does not contain an shRNA insert, CTR2: Control that will activate RISC and the RNAi 
pathway, but does not target any human or mouse genes. The short hairpin sequence 
contains 5 bp mismatches and scrambled sequences to any known human or mouse gene, 
CTR3: Control contains shRNA sequence that targets GFP reporter that is not expressed in 
our cell lines. Since no off-target effect was observed (Supplementary Figure 1), the most 
advanced shRNA control vector targeting GFP (GFP is not expressed in our cell lines) was 
used in this study as control (shCTR). After a pilot study, the shRNA vectors exerting optimal 
gene knockdown were selected. To generate gene knockdown cells, Huh7 cells were 
transduced with lentiviral vectors. Since the knockdown vectors also express a puromycin 
resistance gene, transduced cells were subsequently selected by adding 3 μg/mL puromycin 
to the cell culture medium. Overexpression of 4E-BP1 lentivector (AddGene) was a kind gift 
from Dr. Sonenberg's lab, McGill University. To generate overexpression cells, Huh7 cells 
were transduced with lentiviral vectors and doxycycline was used to add in the 4E-BP1 
overexpression cell lines as the stimulation factor. 
Quantitative real-time polymerase chain reaction 
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RNA was isolated with a Machery-Nucleo Spin RNA II kit (Bioke, Leiden, Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total 
RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA was quantified with a SYBR 
Green-based real-time PCR (MJ Research Opticon, Hercules, CA, USA) according to the 
manufacturer’s instructions. GAPDH or β-actin was considered as reference gene to 
normalize gene expression. The HEV primer sequences were 5’-
ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’-CCGTGGCTATAATTGTGGTCT-3’ (antisense). 
Western blot assay 
Proteins in cell lysates were heated 5 min at 95 °C followed by loading onto a 10 - 15% 
sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) and separated by electrophoresis. 
After 90 min running at 100 V, proteins were electrophoretically transferred onto a 
polyvinylidenedifluoride (PVDF) membrane (Invitrogen) for 1.5 hrs with an electric current of 
250 mA. Subsequently, the membrane was blocked with blocking buffer. It was followed by 
incubation with rabbit t-eIF4E, p-eIF4E, t-4E-BP1 (1: 1 000) antibodies overnight at 4 °C. The 
membrane was washed 3 times followed by incubation for 1 hrs with anti-rabbit or anti-
mouse IRDye-conjugated secondary antibodies (LI-COR Biosciences, Lincoln, USA) (1: 5 000) 
at room temperature. Blots were assayed for β-actin content as standardization of sample 
loading, scanned, and quantified by Odyssey infrared imaging (Li-COR Biosciences, Lincoln, 
NE, USA). Results were visualized and quantitated with Odyssey 3.0 software. 
Measurement of luciferase activity 
For Gaussia luciferase, the activity of secreted luciferase in the cell culture medium was 
measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). For firefly 
luciferase, luciferin potassium salt (100 mM, Sigma) was added to cells and incubated for 30 
min at 37 °C. Both Gaussia and firefly Luciferase activity was quantified with a LumiStar 
Optima luminescence counter (BMG LabTech, Offenburg, Germany). 
Statistical analysis 
All results were presented as mean ± SEM. Comparisons between groups were performed 
with Mann-Whitney test. Differences were considered significant at a p value less than 0.05 
*or 0.01 **. 
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Results 
Requirements of eIF4A and eIF4G for efficient HEV replication 
Most of cellular and viral mRNAs rely on cap-dependent mRNA translation. The canonical 
mechanism of initiation commences with recognition of 5’ end m7GpppN cap structure by 
the eIF4F complex formed by the DEAD-box helicase eIF4A, the scaffolding protein eIF4G 
and the cap recognition factor eIF4E [25]. Among these initiation factors, eIF4A is a subunit in 
charge of unwinding of secondary structure within the leader sequence of mRNA, while large 
scaffolding subunit eIF4G is associated with many other translation initiation factors [7]. 
Because of the important roles of both eIF4A and eIF4G subunits reported in translation and 
replication of many viruses, we investigated their roles in HEV replication. 
Firstly, we evaluated the role of the DEAD-box RNA helicase eIF4A by using RNAi-
based gene loss-of-function approach. Two out of four (sheIF4A-1 and sheIF4A-2) shRNAs 
targeting eIF4A showed significant reduction of its mRNA level in Huh7 cells, compared with 
a control shRNA targeting GFP (shCTR) (Figure 1A). Consistently, their protein levels were 
also down-regulated without affecting the expression of eIF4G and eIF4E, which suggested a 
successful knockdown of eIF4A (Figure 1B). No cytotoxicity has been observed in these cells 
as measured by MTT assay (Supplementary Figure 2A). Silencing of eIF4A resulted in 
significant decrease of cellular HEV RNA level by 63.1% ± 8.6% and 57.6% ± 13.8% (mean ± 
SEM, n = 4, P < 0.05) after three days inoculation of HEV particles, respectively (Figure 1C). 
Next, knockdown of scaffold protein eIF4G by four shRNAs were also performed in Huh7 
cells. Two clones (sheIF4G-1 and sheIF4G-4) showed efficient down-regulation of eIF4G at 
both mRNA level and protein level, but did not influence the protein level of eIF4A or eIF4E 
(Figure 1D and 1E). No cytotoxicity was observed in these knockdown cells (Supplementary 
Figure 2B). Correspondingly, HEV RNA levels was significantly reduced by 36.1% ± 10.6% and 
33.8% ± 11.0% (mean ± SEM, n = 4, P < 0.05) in both eIF4G knockdown cells, respectively, 
compared to shCTR cells (Figure 1F). These results demonstrate that both eIF4A and eIF4G 
are required for efficient HEV replication.  
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Figure 1. Requirements of eIF4A and eIF4G for HEV replication. 
Knockdown of eIF4A and eIF4G by lentiviral shRNA vectors were performed in Huh7 cells. Compared 
with the control vector transduced cells, the sheIF4A clone 1 and 2 (A and B) or the sheIF4G clone 1 
and 4 (D and E) showed potent gene silencing at mRNA level and protein level. Correspondingly, 
knockdown of eIF4A (C) and eIF4G (F) resulted in significant increase of cellular HEV RNA level (Mean 
± SEM, n = 4). * P < 0.05. 
PDCD4, the negative regulatory factor of eIF4A, restricts HEV replication 
Given the fact that the function of eIF4A is regulated by multiple cellular factors, we first 
investigated the effect of its activator eIF4B that can increase the helicase activity of eIF4A. 
Knockdown of eIF4B by two out of four shRNA clones (sheIF4B-2 and sheIF4B-3) resulted in 
significant down-regulation of eIF4B expression (Figure 2A), but has no significant influence 
on cellular HEV RNA level (Figure 2B).  
We next examined a negative regulatory factor of eIF4A, PDCD4, which prevents the 
binding of eIF4A to eIF4G and thereby inhibits the initiation of translation [26], To assess the 
effect of PDCD4 on HEV replication, lentiviral shRNA vectors were used to stably knockdown 
its expression in Huh7 cells. Potent down-regulation of PDCD4 mRNA and protein expression 
of two clones (shPDCD4-1 and shPDCD4-3) (Figure 2C and 2D) resulted in a significant 
increase of HEV RNA after inoculation of HEV particles for three days (Figure 2E). No 
cytotoxicity was observed in knockdown cells (Supplementary Figure 2C). These results are 
Chapter 9 
226 | P a g e  
 
consistent with the finding that eIF4A supports HEV replication and inhibiting the function of 
eIF4A by PDCD4 in turn suppresses HEV replication. 
 
Figure 2. The regulatory factors of eIF4A, PDCD4 but not eIF4B, restricted HEV replication.  
(A) Clone 2 and 3 Knockdown of eIF4B by lentiviral shRNA vectors exerted significant down-
regulation of eIF4B at mRNA level. (B) Silencing of eIF4B did not influence HEV replication during 72 
hrs inoculation of viral particles. mRNA level (C) and protein level (D) of PDCD4 were significantly 
reduced in clone 1 and 3. (E) HEV RNA level were dramatically increased when silencing PDCD4 in 
clone 1 and 3. (Mean ± SEM, n = 4). * P < 0.05. 
eIF4E is also required for efficient HEV replication 
eIF4E, the least abundant component of the eIF4F complex, is a rate-limiting factor for 
translation [27], To investigate the role of eIF4E in HEV replication, its expression was silenced 
by RNAi. Two out of five shRNAs targeting eIF4E exerted potent knockdown at both protein 
(Figure 3A) and mRNA levels (Figure 3B). No off-target effect was observed on protein 
expression of eIF4G or eIF4A (Figure 3A), or on genes such as CyA, CyB, 4E-BP1 and mTOR, 
which are known to affect HEV replication as previously shown [28, 29] (Supplementary Figure 
3). MTT assay showed no cytotoxicity of eIF4E silencing in cells (Supplementary Figure 2D). 
Accordingly, inoculation of HEV led to reduction by 44% ± 12% and 41% ± 25% (mean ± SEM, 
n = 5, P < 0.05) in viral RNA level in these two knockdown cells compared to shCTR cells 
(Figure 3C). We observed similar effect in MEFs (Figure 3D and 3E), further confirming that 
eIF4E plays an important role in HEV replication.  
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Figure 3. eIF4E supports HEV replication.  
Knockdown of human eIF4E by five lentiviral 
shRNA vectors were performed in Huh7 cells. 
Clone 1 and 2 exhibited a potent down-regulation 
of eIF4E at protein (A) and mRNA (B) levels. β-
actin served as an internal reference. (C) 
Correspondingly, these two clones of eIF4E 
knockdown inhibited HEV replication. (D) 
Knockdown of mouse eIF4E by lentiviral shRNA 
vector was applied in MEFs showed a significant 
decrease at eIF4E mRNA level. (E) HEV RNA level 
was significantly reduced with eIF4E silencing in 
MEFs. (Mean ± SEM, n = 4). * P < 0.05. 
 
 
 
 
 
Phosphorylation is not required for eIF4E to support HEV replication 
Ser209 phosphorylation has been shown to be required for the oncogenic potential of eIF4E 
[30]. To examine whether this is also important in the context of HEV infection, Huh7 cells 
harboring the HEV subgenomic replicon or the full-length genome were treated with 10-100 
µM CGP57380, a well-characterized inhibitor of MNK. MNK is the only known physiologic 
kinase that phosphorylates eIF4E (Ser209 site) [31]. This compound potently inhibited eIF4E-
S209 phosphorylation without effect on total eIF4E protein level (Figure 4A). However, 
CGP57380 had no effect on HEV replication in both luciferase replicon model (Figure 4B) and 
infectious model (Figure 4C). To further confirm the function of phosphorylation of eIF4E, 
MEFs cultured from mice with S209A mutation were used. This mutation targeting the 
conserved phosphorylation site for MNK1/2 kinase with serine-to-alanine completely 
abolished phosphorylation of eIF4E at Ser209 without effect on total eIF4E (Figure 4D). 
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Consistently, no significant effect was observed on HEV replication between mutated and 
wild type MEFs (Figure 4E). These data suggest that phosphorylation of eIF4E is dispensable 
for HEV replication. 
 
Fig. 4. eIF4E phosphorylation did not significantly affect HEV replication.  
(A) Treatment with MNK1/2 inhibitor CGP57380 of 100 μM dramatically decreased the 
phosphorylation of eIF4E, but not total eIF4E protein shown by Western blot assay. β-actin served as 
an internal reference. 10 - 100 μM CGP57380 did not significantly affected viral replication-related 
luciferase activity during the three days (B) and viral RNA level in Huh7-p6 infectious model for 48 hrs 
(C). (D) MEFs of S209A mutation abolished phosphorylation of eIF4E at Ser209 shown by Western 
blot assay. β-actin served as an internal reference. (E) Inhibition of phosphorylation in S209A MEFs 
did not significantly influence HEV replication. (Mean ± SEM, n = 4). 
HEV replication is inhibited by the eIF4E suppressor, 4E-BP1 
eIF4E can be released by 4E-BP1 hyperphosphorylation with elimination of translational 
repression [21]. For a more detailed characterization of the role of eIF4E suppressor 4E-BP1 in 
HEV infection, we employed both loss- and gain-of-function approaches in Huh7 cells. Using 
lentiviral RNAi technique, 4E-BP1 was dramatically down-regulated at both protein and 
mRNA levels (Figure 5A). Accordingly, 48 hrs inoculation of HEV resulted in 2.6 ± 1.2 fold 
(mean ± SEM, n = 4, P < 0.05) increase of viral RNA in 4E-BP1 knockdown Huh7 cells, 
compared with the mock knockdown cells (Figure 5A). In contrast, using an inducible 
overexpression lentiviral vector, 4E-BP1 expression was drastically up-regulated at both 
protein and mRNA levels with treatment of dose dependent doxycycline, which resulted in 
significant reduction of HEV RNA by 59% ± 17% (mean ± SEM, n = 4, P < 0.05) (Figure 5B). 
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Figure 5. The eIF4E suppressor, 4E-BP1, limited HEV replication.  
(A) Efficient silencing of 4E-BP1 at protein level was detected by Western blot assay. β-actin served 
as an internal reference. Similarly, 4E-BP1 was significantly down-regulated at mRNA level (Mean ± 
SEM, n = 7). Correspondingly, inoculation of HEV resulted in significant increase of viral RNA in 4E-
BP1 knockdown Huh7 cells, compared with the mock knockdown cells (Mean ± SEM, n = 4). (B) 4E-
BP1 was drastically up-regulated at protein level when the overexpression cell lines were treated 
with different concentrations of doxycycline for 24 hrs. β-actin served as an internal reference. 
Similarly, mRNA levels of 4E-BP1 was dramatically increased after treatment of 4 μg/mL doxycycline 
for 24 hrs. (Mean ± SEM, n = 5). Correspondingly, 4E-BP1 overexpression cell line with treatment of 4 
μg/mL doxycycline for 24 hrs resulted in significant reduction of HEV RNA level (Mean ± SEM, n = 4). 
(C). MEFs derived from 4E-BP1 knockout (4E-BP1-/-) mice presented an efficient silencing of 4E-BP1 at 
protein level compared to WT MEFs, leading to significant increase of HEV RNA level (Mean ± SEM, n 
= 4). * P < 0.05. 
To further validate 4E-BP1 function in HEV infection, MEFs cultured from 4E-BP1 
knockout mice were studied. Western blot assay showed a complete knockout of 4E-BP1 at 
protein level (Figure 5C). Accordingly, 48 hrs inoculation of HEV led to 3.9 ± 0.8 fold (mean ± 
SEM, n = 4, P < 0.05) increase of cellular HEV RNA level in 4E-BP1 knockout MEFs (4E-BP1-/-) 
compared to wild type MEFs (4E-BP1+/+) (Figure 5C). Hence, these data supported a role of 
4E-BP1 in constraining HEV replication. 
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The anti-HEV activities of ribavirin and IFN-α are independent of eIF4E  
Ribavirin is a well-known inhibitor of eIF4E [18]. To evaluate whether the anti-HEV activity of 
ribavirin is mediated by the inhibition of eIF4E, both shCTR and sheIF4E-1 cells with HEV 
inoculation were used for the treatments of 6.25, 12.5, 25, 50, 100 μM ribavirin for 48 hrs. 
Comparable IC50 in shCTR and sheIF4E cells were found with the range between 12.5-25 μM 
(Figure 6A).  
 
Figure 6. The anti-HEV activities of ribavirin and IFN-α is independent of eIF4E. 
(A) IC50 of RBV was with the range between 12.5 - 25 μM: 15.67 μM in shCTR cells and 17.24 μM in 
sheIF4E cells and (B) IFN-α was with the range between 10 - 50 IU/mL: 14.55 IU/mL in shCTR cells and 
47.75 IU/mL in sheIF4E cells). (C) 25 μM ribavirin and 1000 IU/mL IFN-α were treated in shCTR and 
sheIF4E cells. HEV RNA level was detected by qRT-PCR after 72 hrs inoculation of viral particle. (Mean 
± SEM, n = 4 - 8). * P < 0.05. ** P < 0.01. 
The antiviral activity of IFN-α has also been associated to the regulation of translation 
initiation factors in particular circumstances [20, 21]. To further assess whether eIF4E could 
mediate the anti-HEV activity of IFN-α, treatments of 1, 10, 100, 1000, 10000 IU/mL IFN-α on 
HEV in both shCTR and sheIF4E-1 cells for 48 hrs has been performed. Comparable IC50 of 
IFN-α were observed with the range between 10-50 IU/mL in shCTR and sheIF4E cells (Figure 
6B). Furthermore, as expected, HEV replication were significantly inhibited with treatment of 
25 μM ribavirin and 1000 IU/mL IFN-α for 48 hrs. However, the anti-HEV effects of ribavirin 
and IFN-α were further enhanced by eIF4E knockdown (Figure 6C). In addition, no clear 
cytotoxicity was observed in both shCTR and sheIF4E cells (Supplementary Figure 4A and 
4B). These results indicated that the antiviral effects of ribavirin and IFN-α are independent 
of eIF4E, although silencing of eIF4E could already inhibit HEV replication. 
Discussion 
Most of the viruses can only encode restricted numbers of proteins and therefore they 
heavily rely on the host cellular machinery and their ingredients to accomplish the virus life-
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cycles [3]. Recent studies show that translation initiation mechanisms especially eIF4F 
complex is employed by many viruses as a primary target for cap-dependent translational 
control to confer advantages to generate progeny [32]. Three proteins: RNA helicase eIF4A, 
scaffolding protein eIF4G and cap binding protein eIF4E, which are components of the eIF4F 
complex, are related to the efficient translation and replication of various viruses [2, 5, 7]. It is, 
however, unknown to what extent HEV requires elements from the translation initiation 
complex. Our study was aimed to provide more insight in this area of HEV biology, also with 
the explicit goal to provide directions for the development of rational treatment of HEV-
related disease. Our study demonstrated a requirement of the eIF4F complex for efficient 
HEV replication (Figure 1 and 3). 
Among all three subunits of the eIF4F complex, eIF4E is the main regulatory nexus 
involved in the complex formation and has impact on many types of viral infections [3], 
including on HEV as we showed in this study. One of the mechanisms by which eIF4E takes 
control of complex formation and translation initiation process is via phosphorylation on 
serine 209 carried out by MNK1/2 [3]. Stimulation of eIF4E phosphorylation is correlated with 
facilitated translation and replication of some viruses [2, 9, 30]. In contrast, we found that S209 
phosphorylation is not required for eIF4E to support HEV replication (Figure 4). Another 
regulatory mechanism of eIF4E is exerted via 4E-BP1, a small-molecular-weight repressor of 
5’ capped mRNA translation, which has also been implicated in host defense against viral 
infection [15]. In apparent agreement, we show that 4E-BP1 can inhibit HEV replication 
(Figure 5). 4E-BP1 is a phosphoprotein that binds to eIF4E depending on its phosphorylation 
status. 4E-BP1 hyperphosphorylation results in releasing eIF4E to form the functional eIF4F 
complex. Conversely, 4E-BP1 hypophosphorylation allows binding of this protein to eIF4E 
and counteracts the formation of eIF4F complex [3]. Therefore, without this hijacking of eIF4E 
in a 4E-BP1-deficient context, eIF4E can still exert its pro-HEV activity (as we have shown in 
Supplementary Figure 5). Similarly, the eIF4A suppressor PDCD4 can also restrict HEV 
replication (Figure 2). PDCD4 sequesters eIF4A from the eIF4E-eIF4G complex, resulting in 
repressed translation of mRNAs [12] and thus modulates replication of various viruses [13, 14]. 
Apparently this notion also holds true in the biology of HEV infection. 
Despite the absence of proven medications for treating HEV, ribavirin, IFN-α, or the 
combination have been use as off-label antiviral drugs to treat individual HEV cases or small 
case series [16]. The antiviral effect of interferons and their signaling pathways have been 
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attributed to effects in the 4E-BP1 cascade [15, 20]. However, loss- or gain-function of 4E-BP1 
had no significant effects on the expression of IFN-α and -β (Supplementary Figure 6A) and 
no effect on phosphorylation of STAT1, the key element of interferon signaling transduction 
(Supplementary Figure 6B). Furthermore, the effect of 4E-BP1 on HEV is independent of JAK-
STAT cascades (Supplementary Figure 6C). Conversely, the anti-HEV effect of IFN-α is also 
independent of 4E-BP1 (Supplementary Figure 6D). Although ribavirin directly binds to eIF4E 
and competes for 5’ cap mRNA binding [18, 19], the anti-HEV activity of ribavirin is also 
independent of eIF4E in our experimental system (Figure 6). Instead, loss of eIF4E exerts 
additive anti-HEV effect of IFN-α or ribavirin and suggests that treatments aimed at targeting 
the translation initiation complex in conjunction with IFN-α or ribavirin have significant 
promise. 
In conclusion, we revealed that cap dependent translation machinery plays a critical 
role in help with efficient HEV replication. The translational suppressors PDCD4 and 4E-BP1 
are important antiviral factors in restraining HEV infection (Figure 7). Thus, these results 
have shed new light on virus-host interactions and provided new avenue for potential 
antiviral drug development against HEV infection.  
 
Figure 7. Schematic illustration of the involvement of the eIF4F complex in HEV replication.  
Three subunits of eIF4F complex: eIF4A, eIF4G and eIF4E play important roles in efficient HEV 
replication. Furthermore, HEV replication is limited by the cap dependent translational suppressors, 
PDCD4 and 4E-BP1, but is not influenced by eIF4E phosphorylation induced by MNK1/2 kinase 
activation. 
  
Chapter 9 
233 | P a g e  
 
Supplementary Figures and Tables 
 
Supplementary Figure 1.  
eIF4E knockdown did not significant affect off-target genes expression in Huh7 cells. CyA, CyB, 4E-
BP1 and mTOR mRNA levels were not influenced in sheIF4E-1 (A) and sheIF4E-2 cells (B). (Mean ± 
SEM, n = 3). 
 
Supplementary Figure 2.  
eIF4E is required for efficient HEV replication in 4E-BP1-/- knockout MEFs. Clone sheIF4E-2 of mouse 
eIF4E knockdown showed a potent eIF4E silencing at protein (A) and mRNA levels (B). β-actin served 
as an internal reference in Western blot assay. (C) HEV RNA level was significantly reduced in 
sheIF4E-2 MEFs deficient of 4E-BP1. (Mean ± SEM, n = 4). * P < 0.05. 
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Supplementary Figure 3. 
(A) IFN-α and -β production were not influenced by 4E-BP1 expression in Huh7 cells and MEFs. (B) 
IFN-α induced phosphorylation of STAT1, which represents key elements in antiviral JAK-STAT1 
cascades, showed no difference in 4E-BP1 overexpression Huh7 cells and 4E-BP1 knockout MEFs by 
Western blot assay. β-actin served as an internal reference. 4E-BP1 did not mediate the pro-HEV 
effects of Jak inhibitor I (C) and anti-HEV effects of IFN-α (D) for 48 hrs. (Mean ± SD, n = 4). 
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Abstract  
The ubiquitin proteasome system plays important role in virus infection. A previous study 
showed that the proteasome inhibitor MG132 could potentially affect hepatitis E virus (HEV) 
replication. In this study, we found that MG132 could inhibit HEV and hepatitis C virus (HCV) 
replication-related luciferase activity in subgenomic models. Furthermore, treatment with 
MG132 in a HEV infectious model resulted in a dramatic reduction in the intracellular level of 
HEV RNA. Surprisingly, MG132 concurrently inhibited the expression of a luciferase gene 
used as a control as well as a wide range of host genes. Consistently, the total cellular RNA 
and protein content was concurrently reduced by MG132 treatment, suggesting a 
nonspecific antiviral effect.  
Keywords: Ubiquitin proteasome system; MG132; Hepatitis E virus  
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Introduction  
The ubiquitin proteasome system (UPS), which serves as a major pathway for protein 
degradation and modification in eukaryotic cells, can be utilized by many types of viruses [1-3]. 
Previous studies have demonstrated that UPS can regulate viral RNA-dependent RNA 
polymerase (RdRp), which mediates viral RNA synthesis [1, 4-6]. In addition, UPS can also 
regulate ubiquitylation and degradation of some viral structural proteins [7-9] and thus 
represents a potential antiviral target.  
Hepatitis E virus (HEV) is a single-strand positive-sense RNA virus that belongs to the 
family Hepeviridae. It is a small non-enveloped virus with a 7.2-kb RNA genome, which is 
capped at the 5’ termini and polyadenylated at the 3’ termini [10]. Outbreaks of hepatitis E 
occur periodically throughout the developing world. It typically causes an acute and self-
limiting infection, but fulminant hepatitis and high mortality (reaching 25 %) have been 
described in cases of pregnant women. In the western world, HEV mainly affects 
immunocompromised patients with a high risk of developing chronic hepatitis [11]. However, 
no proven medication is available to treat hepatitis E. A recent study reported potent 
antiviral effects of a well-known proteasome inhibitor, MG132, against HEV [12]. In a Renilla-
luciferase-coupled HEV replication model, the authors showed that treatment with MG132 
resulted in dramatic reduction of HEV-related luciferase activity [12]. These important 
findings have inspired us to further evaluate the effects of MG132 in two HEV cell culture 
models.  
Materials and methods  
In this study, two human hepatoma cell line (Huh7)-based HEV cell culture models were 
employed: a subgenomic HEV replicon containing Gaussia luciferase reporter (p6- Luc) in 
which the accumulation of secreted luciferase serves as a reporter for HEV replication, and a 
full-length infectious model (p6) in which Huh7 cells were electroporated with full-length 
HEV genomic RNA (Kernow-C1 p6 clone, GenBank accession number JQ679013) [13]. Two 
firefly luciferase cell models were also used: a cell line for normalization in which stable 
expression of luciferase is driven by a phosphoglycerate kinase (PGK) promoter (Huh7-PGK) 
and a hepatitis C virus (HCV, also a single-strand positive-sense RNA virus) subgenomic cell 
culture model (Huh7-ET) [14]. The Gaussia luciferase and firefly luciferase activity were 
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measured as described previously [13] using a LumiStar Optima luminescence counter (BMG 
Lab Tech, Offenburg, Germany). MTT assays were performed as described previously [15]. 
The absorbance of each well was read using a microplate absorbance reader (Bio-Rad) at a 
wavelength of 490 nm. RNA was isolated using a Macherey-Nagel NucleoSpin RNA II Kit 
(Bioke, Leiden, The Netherlands) and quantified using a NanoDrop ND-1000 (Thermo, DE, 
USA). cDNA was prepared from total RNA using a cDNA Synthesis Kit (Takara Bio Inc.). HEV, 
GAPDH, RP2 (human retinitis pigmentosa 2), CyA (cyclophilin A), CyB (cyclophilin B), CD81 
(cluster of differentiation 81) and IMPDH2 (inosine-5’-monophosphate dehydrogenase 2) 
were quantified by SYBR-Green-based real-time PCR. The HEV primer sequences were 5’-
ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’ -CCGTGGCTATAATTGTGGTCT-3’(anti- 
sense), the primer sequences for the housekeeping gene GAPDH were 5’ -
TGTCCCCACCCCCAATGTATC-3’ (sense) and 5’ -CTCCGATGCCTGCTTCACTACCTT-3’(antisense), 
and the primers for the housekeeping gene RP2 were 5’-CCCATTAAACTCCAAGGCAA-3’ 
(sense) and 5’- AAGCTGAGGATGCTCAAAGG-3’ (antisense). The primer sequences for CyA 
were 5’-GGCAAATGCTGGACCCAACACA-3’(antisense) and 5’-TGCTGGTCTTGCCATTCCTGGA-3’ 
(sense), and the primers for CyB were 5’- AACGCAGGCAAAGACACCAACG-3’ (antisense) and 
5’- TCTGTCTTGGTGCTCTCCACCT-3’ (sense). The primers for CD81 were 5’ -
CTGCTTTGACCACCTCAGTGCT-3’ (antisense) and 5’-TGGCAGCAATGCCGATGAGGTA-3’ (sense), 
and the primers for IMPDH2 were 5’ -AGTGGCTCCATCTGCATTACGC-3’ (antisense) and 5’ - 
GGATTCCTCCATCAGCAATGACC-3’ (sense). For Western blot, 100,000 cells were seeded in a 
6-well plate and treated with MG132 for 48 h. Cell lysates (300 µL) were heated for 5 
minutes at 95 °C followed by loading 30 µL of sample onto a 10 % sodium dodecyl sulfate 
polyacrylamide gel and separating by electrophoresis. Mouse β-actin antibody (1: 1000) was 
used as primary antibody. For SDS-PAGE, after electrophoresis for 90 min at 120 V, the gel 
was stained in Coomassie brilliant blue solution and distained.  
Results  
Consistent with a previous study [12], treatment with 1 µM and 10 µM MG132 did not 
significantly impair cellular metabolic activity or viability as determined by MTT assay after 
24 h (Fig. 1A) and 48 h (Fig. 1B), although a minor inhibitory effect was observed when cells 
were treated with 10 µM MG132 for 48 h. As expected, treatment with 1 µM MG132 
potently inhibited HEV-replication-related Gaussia luciferase activity in the p6-Luc model (Fig. 
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1) after 24 h and 48 h. Furthermore, we tested this proteasome inhibitor in the Huh7-based 
hepatitis C virus subgenomic model (Huh7-ET). Consistently, MG132 inhibited HCV-coupled 
firefly luciferase activity (Fig. 1). Surprisingly, when Huh7-PGK cells were treated with MG132, 
the control firefly luciferase activity driven by the PGK promoter was also potently inhibited 
(Fig. 1). These results raised concerns regarding the specificity of the effect of MG132 on 
viral replication.  
 
Fig. 1 Nonspecific effects of 
the proteasome inhibitor 
MG132 on luciferase activity.  
Treatment with MG132 after 
24 h (A) and 48 h (B) resulted 
in dramatic reduction of 
luciferase activity in 
subgenomic HEV replicon 
(p6-Luc) (mean ± SD, n = 12), 
HCV replicon (Huh7- ET) 
(mean ± SD, n = 4) and Huh7 
cells constantly expressing a 
control luciferase gene under 
the control of the PGK 
promoter (Huh7- PGK) (mean 
± SD, n = 4). MG132 
treatment did not strongly 
affect cellular metabolic 
activity or viability, as 
determined by MTT assay 
(OD490 value) (mean ± SD, n 
= 4), although a minor 
inhibitory effect was 
observed after treatment at 
10 µM for 48 h  
To investigate further, the HEV infectious model (p6) was treated with MG132 for 48 
h. The relative levels of HEV viral RNA and two host reference genes (GAPDH and RP2) were 
quantified by SYBR-based qRT-PCR. As shown in Fig. 2A, treatment with 1 or 10 µM MG132 
resulted in a significant decrease in intracellular HEV RNA by 32 ± 19% and 76 ± 24% (mean ± 
SD, n=6, p < 0.01), respectively. Strikingly, the expression levels of two references genes, 
GAPDH and RP2 were concurrently decreased. In addition, the expression of four other host 
genes that we tested, CyA, CyB, CD81 and IMPDH2, also decreased simultaneously (Fig. 2B). 
These results confirm that the effect of MG132 is nonspecific. 
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Fig. 2 Significantly decrease in HEV viral RNA levels after MG132 treatment. 
(A) and (B) The expression of two reference genes (GAPDH, RP2) and four host genes (CyA, CyB, CD81 
and IMPDH2) were concurrently inhibited by treatment with MG132. Relative gene expression was 
quantified by qRT-PCR. Data are presented as 2-Ct and normalized to the untreated control (mean ± 
SD, n = 6). **P < 0.01  
Next, we measured the RNA concentration and total protein content of the cells after 
MG132 treatment and we found that MG132 treatment (1 µM and 10 µM) drastically 
reduced the total cellular RNA content (Fig. 3A). Furthermore, cells that were treated with 
MG132 and lysed showed reduced cellular protein expression. As shown in Fig. 3B, the 
protein level of internal reference b-actin was decreased after treatment with 1 µM and 10 
µM MG132, and the total protein content was also reduced (Fig. 3C). However, the effects of 
MG132 at the protein level were less profound than that at the RNA level. These results 
suggest that MG132 inhibits expression and translation of a broad range of genes rather 
than having a specific effect on viral infection.  
 
Fig. 3 Decrease in cellular RNA and protein content after MG132 treatment. 
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Total intracellular RNA in cells was dramatically reduced by MG132 treatment after 48 h. RNA 
concentration was determined using a NanoDrop 2000 spectrophotometer (mean ± SD, n = 7). (B) 
Protein expression of internal reference β-actin was inhibited by MG132 (in particular with 10 µM) 
treatment after 48 h. The same volumes of cell lysates were loaded, and the protein level was 
determined by Western blot. (C) Total intracellular protein was reduced by MG132 treatment (in 
particular with 10 µM) after 48 h. The same volumes of cell lysate were loaded, and the gel was 
stained in Coomassie brilliant blue solution and distained. **P < 0.01 ***P < 0.001  
Discussion  
There is substantial evidence suggesting that the cellular UPS is associated with viral 
infection. RdRp, the essential enzyme for viral replication, can be regulated by UPS in turnip 
yellow mosaic virus (TYMV) [1], Sindbis virus [4], hepatitis A virus (HAV) [5] and HCV [6] 
infections. Virus-encoded proteases cleave viral polyprotein proteolytically but can also 
mediate the processing of many host proteins [16]. Mature 3C proteases of HAV and 
encephalomyocarditis virus (EMCV) have been shown to be subject to rapid, ubiquitin-
mediated protein degradation [17, 18]. As a combat strategy, some viral proteases have been 
shown to contain de-ubiquitinating enzyme activity. Papain-like cysteine proteases of SARS 
coronavirus [19], HEV [20] and foot-and-mouth disease virus (FMDV) [21] have the ability to 
hydrolyze ubiquitinating substrates. Therefore, modulating the UPS represents as a potential 
antiviral strategy.  
Treatment with the proteasome inhibitor MG132 has been shown to decrease the 
titer of porcine circovirus type 2 (PCV2) at an early stage of infection [22]. Treatment with 
MG132 has also been shown to decrease the activity of Renilla luciferase expressed from an 
HEV replicon [12]. However, our study raised concerns regarding the specificity of the effect 
of MG132 on HEV replication. Although we confirmed the inhibitory effects on luciferase 
activity in both the HEV and HCV replicon models, MG132 also inhibited constitutively 
expressed luciferase in control cells. Furthermore, in the full-length HEV model, although 
MG132 treatment reduced HEV RNA levels, it also simultaneously inhibited the expression of 
reference genes and other host genes. We further demonstrated that MG132 dramatically 
decreases the levels of total intracellular RNA and protein, which explains its nonspecific 
effect on viral infection. 
It is not surprising that inhibition of this system could exert variety of effects on cell 
physiology, since the UPS plays an essential role in the processing of cellular proteins. 
Proteasomes promptly degrade ubiquitylated proteins [23], and some of these proteins are 
important mediators of cell-cycle progression and apoptosis [24]. MG132 has been shown to 
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induce the expression of death receptor 5 (DR5), a receptor for tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL), resulting in enhanced sensitivity to TRAIL-induced 
apoptosis in cancer cells [25, 26]. Thus, inhibition of this major intracellular protein 
degradation pathway could nonspecifically affect viral infection, but we do not fully exclude 
that UPS may also specifically modulate certain viruses [2]. 
In summary, this study demonstrated that inhibition of HEV infection by the 
proteasome inhibitor MG132 is nonspecific. Thus, we should be careful in interpreting data 
regarding the effects and mechanisms of proteasome inhibitors on viral infection. Although 
proteasome inhibitors are in the preclinical phase of testing as anticancer agents [24, 27], we 
would call for caution in developing proteasome-targeted antiviral therapies.  
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The interferon (IFN)-mediated cellular response is thought to be the first line of antiviral 
barrier [1-3]. The production of IFN is usually triggered by viral infection [4]. IFN exert its 
antiviral function by activating the expression a large number of IFN-stimulated genes (ISGs) 
[3, 5]. Generally, the transcription of these ISGs is provoked via the JAK-STAT pathway. 
However, recent studies demonstrated the other non-canonical mechanisms are also 
involved in the regulation of ISG transcription. In Chapter 2, we comprehensively reviewed 
the canonical and non-canonical regulation mechanisms of ISG transcription. In this review, 
we first reviewed the classical pathway that regulates ISG transcription. We also discussed 
non-canonical regulation of ISG expression that involved some unique pathways or complex, 
such as non-canonical ISGF3 complex, STAT5-CrkL complex and nucleotide synthesis 
pathway. We hope our review will expand our understanding of the ISG transcription 
regualtion and provide some clues for the development of new antiviral strategies. In our 
previous study, we have shown the inhibition of nucleotide synthesis leads to the expression 
of some ISGs independent of JAK-STAT pathway, although the exact mechanism is still 
unclear [6]. Interestingly, we now are conducting a large-scale screening of an FDA-approved 
drug library to identify molecular that have the ability to enhance IFN induced ISG 
transcription, several nucleotide synthesis inhibitors were identified (our unpublished data). 
This may have important clinical implication to develop new antiviral drugs. Host cells have 
the ability to sense the invasion of viruses through pattern recognition receptors (PRRs) to 
produce IFNs [3, 4]. Therefore, the innate antiviral immune response is largely mediated by 
IFN production. In Chapter 3, we highlighted the IFN-independent mechanisms of many ISGs. 
Many important antiviral ISGs have the ability to activate the ISG transcription without the 
involvement of IFN production. Some ISGs which are believed exert their antiviral function 
via the IFN production have direct antiviral abilites. Hence, we feel that although massive 
researches have been done in the ISG/IFN field, this is still a largely unknown area and 
further effects should be taken. 
Hepatitis E virus (HEV) infection is the leading cause of acute viral hepatitis 
worldwide [7]. Although its infection is usually a self-limiting disease for common people, gt1 
(genotype 1) HEV infection have severe outcomes in pregnant women and gt3 HEV infection 
could develop to chronic infection in certain patients [8-11]. The current anti-HEV therapy is 
mainly consistent by IFN-α and ribavirin, which is learned from anti-HCV or anti-HBV 
treatment [7, 12-14]. Both of IFN-α and ribavirin have proven their efficacy in vitro and in vivo 
Chapter 11 
252 | P a g e  
 
[15-19]. However, treatment failure was observed in some cases of chronic patients treated 
with ribavirin and this seems due to some mutations in the viral genome [20-23]. Hence, we 
moved focus on the natural antiviral regimen, IFNs. In Chapter 4, we first screened many 
human cytokines and chemokines for their anti-HEV potential and found most of them exert 
minor anti-HEV activity, expect for IFN-α. We further revealed that HEV replication level is 
much higher in cells that have a defected JAK-STAT pathway. This observation further 
highlighted the vital role of JAK-STAT cascade in defending HEV infection. We also noticed 
that the antiviral activity of IFN-α against HEV is much lower compare to HCV but the 
underlying mechanism remains unknown. IFN exerts its antiviral function via the activation 
of a large number of Interferon-stimulated genes (ISGs) [3, 5, 24]. The antiviral potential of 
each individual ISG against different viruses has been profiled in different studies [5, 24-27]. 
However, little is known about regarding HEV infection. 
In Chapter 5, by using the overexpression approach [5, 24], we profiled many important 
human ISGs for their anti-HEV ability. RIG-I, MDA5 and IRF1 were identified as potent anti-
HEV ISGs in two different HEV culture models. In this chapter, we main focus on the antiviral 
mechanism of RIG-I, which is a pattern recognition receptors (PRRs) that recognized viral 
RNA, especially viral RNA has a triphosphate signature at its 5’ end [28]. The antiviral potential 
of this ISG against HEV was further validated in different HEV culture systems. Interestingly, 
manually delivery the natural ligand of RIG-I 5’pppRNA into cytoplasm induced a strong 
antiviral immune response that inhibits HEV replication. This finding has a great clinical 
significance that provides an idea to develop new therapies for HEV treatment. Interestingly, 
we found RIG-I play important role in IFN induced ISG transcription. The lacking of RIG-I will 
attenuates IFN-initiated ISG expression while the overexpression of RIG-I enhances ISG 
expression. It is general believed that RIG-I exert its antiviral action by the induction of IFN 
production [4]. In this chapter, we revealed a non-canonical antiviral mechanism of RIG-I 
against HEV infection that independent IFN production. RIG-I overexpression causes the 
phosphorylation of STAT1 without triggering the IFN production. Furthermore, the RIG-I 
activated ISGs can be divided into 2 groups, one group totally depends on the JAK-STAT 
pathway and the other is not. However, some issues such as how STAT1 is phosphorylated 
by RIG-I without IFN production and how RIG-I activate ISGs independent of JAK-STAT 
pathways are not totally elucidated. In Chapter 6, we continue to investigate the antiviral 
mechanism of another identified anti-HEV ISG, IFN regulatory factor 1 (IRF1). IRF1 is an 
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important ISG that has been proved have broad antiviral ability against different kinds of 
DNA and RNA virus [5, 24]. IRF1 is also a transcription factor that leads to IFN-β expression [29]. 
However, in this study, we reveal that without triggering IFN expression, IRF1 still exert 
strong anti-HEV ability by activating the transcription of a wide range of ISGs. We further 
revealed that the antiviral and ISG induction ability of IRF1 is enhanced by ribavirin. Taken 
together, both studies demonstrated that many ISGs have non-canonical antiviral 
mechanisms. For instance, both IRF1 and RIG-I are known to exert their effect via IFN 
production, but our studies added new antiviral mechanisms to these genes, as we discussed 
in Chapter 3.  
As we reviewed in Chapter 2, the transcription of ISG is usually regulated by the 
classical JAK-STAT pathway, but many non-canonical pathways are also involved in the 
regulation of ISG transcription. Besides IFN-α, TNF-α (Tumor Necrosis Factor-alpha) is also an 
important antiviral cytokine and its downstream pathway NF-κB pathway plays essential 
roles in regulating the expression of inflammatory cytokines [30]. In Chapter 7, we 
investigated the antiviral ability of TNF-α against HEV infection and its role in regulating ISG 
transcription. We first demonstrated that TNF-α exerts potent antiviral ability against HEV 
and HCV. We also noticed that TNF-α have the ability to activate ISG transcription. With this 
interesting observation, we focused on the mechanism that how TNF-α induces ISG 
expression. We first rule out the possibility that TNF-α induces ISG expression through the 
production of IFN or JAK-STAT signaling. Next, we found the TNF-α activates ISG 
transcription via its canonical downstream pathway, NF-κB. Different kinds of techniques 
were employed to answer the question that how NF-κB pathway activate ISG transcription. 
We surprisingly demonstrated that RelA (P65), the subunit of NF-κB, have the ability to 
directly bind to the promoter region of many ISGs. Our following observation found that the 
combination of TNF-α and IFN-α exert additive effects in ISG induction and HCV/HEV 
inhibition. This further support the notion that TNF-α activates ISG transcription 
independent IFN-JAK-STAT pathway. Without the present of IFNs, many ISGs are constitutive 
expressed, which may confer a rapid and direct resistance to viral infection [31]. However, 
how the host cells maintaining this constitutive expression of ISGs is still not clear. In 
Chapter 8 we reported a novel mechanism that the unphosphorylated ISGF3 (U-ISGF3) 
complex drives the constitutive expression of ISGs in homeostatic condition. This novel U-
ISGF3 complex consists by unphosphorylated STAT1 and STAT2 together with IRF9. Deletion 
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any element of this U-ISGF3 complex leads the decreased expression of ISGs and increased 
HCV and HEV replication. In contrast, overexpression all these three parts together induced 
ISG expression and inhibited viral replication. Interestingly, overexpression any part alone 
cannot reproduce the induction of ISG or the inhibition of virus. Of note, overexpression all 
these three parts does not found any phosphorylation of STAT1 or STAT2, suggesting this U-
ISGF3 functions in a manner independent of phosphorylation. The study on this novel 
antiviral mechanism expands our knowledge in the mechanisms that regulate ISG 
transcription. As we reviewed in Chapter 2, more canonical and non-canonical regulatory 
mechanisms of the ISG expression will be studied in the future. All these canonical and non-
canonical mechanisms coordinately regulate the vast host antiviral web that centered at ISG. 
All viruses rely on the host translational machinery to complete their life cycles [32]. 
HEV is a positive single-stranded RNA virus, which means once HEV infects host cells, the 
viral RNA can be directly translated like mRNA. However, until now, little is now about how 
the host translational machinery involved in the replication of HEV. Most cellular mRNA and 
viral RNA use the cap-dependent mRNA translation system that initiated via the eIF4F 
complex. The eIF4F complex consists by eIF4A (Eukaryotic Translation Initiation Factor 4A), 
eIF4G and eIF4E [33]. In Chapter 9, we found all these three subunits are required for HEV 
replication. Meanwhile, after depleting the negative regulator of this pathway, a higher level 
of HEV replication was observed. This further support the notion the HEV replication 
required this eIF4F complex. Although ribavirin was reported has the ability bind to the eIF4E 
to act as an inhibitor of this complex [34], we observed that ribavirin inhibit HEV replication in 
an eIF4E independent manner. The inhibition of HEV translation may serve as a potential 
target for developing new treatments against HEV infection. In Chapter 9, we have 
demonstrated the host translation system has great an impact for HEV replication, it is 
reasonable to assume that protein degradation may also play important role in regulating 
HEV replication. The ubiquitin proteasome system (UPS) are the main pathway for protein 
degradation and also used by virus [35]. In a previous study, it was reported that the 
ubiquitin-proteasome system is necessary during HEV replication and proteasome inhibitor 
MG132 inhibits viral replication [36]. In line with this study, in Chapter 10, we also observed 
the inhibition effect of this MG132 against HEV replication. However, our following study 
revealed that HCV-couple luciferase activity, cellular RNA and protein content were also 
affected by this inhibitor, indicating the non-specific function of this proteasome inhibitor.   
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Samenvatting voor de leek 
Het hepatitis E virus (HEV) is één van de belangrijkste oorzaken van virale hepatitis. Het HEV 
komt het bloed binnen via het maag-darm kanaal en kan zich uitstekend vermenigvuldigen 
in de lever. Het beloop van een acute HEV-infectie wordt gekenschetst door een aantal 
stadia: van subklinisch, naar acuut en uiteindelijk naar fulminant. De ziekte hepatitis E wordt 
in steeds grotere mate gezien als een “public health concern”. Ofschoon de mortaliteit van 
0.2 – 1.0% relatief klein lijkt, kan deze bij zwangere vrouwen in het laatste trimester van de 
zwangerschap stijgen tot 20 - 25%. Daarnaast zijn er belangrijke zorgen over het risico van 
juist dit virus voor andere groepen patiënten en met name voor transplantatiepatiënten. 
Zulke patiënten krijgen immunosuppressieve medicijnen voorgeschreven die mogelijk de 
afweer tegen HEV zouden kunnen aantasten. Onfortuinlijker wijze is er weliswaar toch wel 
heel wat literatuur over de mechanismen waarmee het lichaam zichzelf verdedigt tegen HEV 
infectie, maar is deze goed samengevat noch afdoende geanalyseerd. Om deze deficiëntie te 
repareren voer ik in hoofdstuk 2 en hoofdstuk 3 een systematisch literatuuronderzoek uit, 
waar ik mij met name concentreer op de interferonen (inflammatoire hormonen belangrijk 
bij de virale afweer) alsook de zogenaamde ISGs (genproducten die van het DNA worden 
afgeschreven volgend op stimulatie van cellen door interferonen en die de uiteindelijke 
antivirale werking uitvoeren). Deze analyse vormt de basis van experimentele studies in de 
daarop volgende hoofdstuk ken. 
In hoofdstuk 4 begin ik eerst met het karakteriseren van verschillende immuun 
relevante hormonen met betrekking tot hun invloed op HEV infectie. Deze studie kreeg een 
extra dimensie door de resultaten te vergelijken met de werking van deze hormonen op 
infectie door het hepatitis C virus. Ik laat hier zien dat met name interferon alfa een krachtig 
anti-HEV effect heeft en deze studie steunt dan ook het gebruik van interferon alfa in HEV-
besmette patiënten.  
In hoofdstuk 5 concentreer ik mij met name op de ISGs en karakteriseer welke van 
deze ISGs belangrijk bij het bestrijden van HEV. Het blijkt dat specifiek het RIG-I ISG hier 
belangrijk is (samen met andere) en ik besteed aandacht aan het moleculaire mechanisme 
van dit ISG in haar gevecht met het HEV. De hoop is dat zulke fundamentele studies van hulp 
kunnen zijn bij het ontwikkelen van nieuwe rationele therapie om het HEV te bestrijden. 
Omdat in mijn studies beschreven in hoofdstuk 5 ook bleek dat IRF1 een krachtige ISG is met 
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betrekking tot HEV infectie, besloot ik in hoofdstuk 6 ook op basaal niveau de werking van 
dit ISG te onderzoeken. Ook omdat ik een veelheid van modelsystemen gebruik in dit 
hoofdstuk geeft het resultaat een goed beeld van de betrokken moleculaire mechanismen. 
Bovendien onderzoek ik de interactie van IRF1 met ribivarine therapie (een belangrijk wapen 
van de geneesheer in het gevecht met het HEV), wat van belang kan zijn voor artsen die 
dergelijke therapie voor HEV-besmette patiënten willen inzetten. Gelijkaardig ga ik in 
hoofdstuk 7 het proinflammatoire hormoon TNF-alfa onderzoeken. Dit hormoon wordt 
meer geassocieerd met het bestrijden van bacteriële infectie, ik laat echter zien dat het ook 
de anti-virale afweer ondersteunt. Het mechanisme is nieuw: TNF alfa werkt door het 
stimuleren van de productie van ISGs. Een belangrijke implicatie is dat patiënten die anti-
TNF alfa therapie krijgen verdacht moeten zijn op HEV infectie. 
Ook zonder interferonen kan het lichaam het gevecht aan met het HEV virus. De 
mechanismen vragen weer productie van ISGs. In hoofdstuk 8 karakteriseer ik het 
moleculaire mechanisme die deze constitutieve afweer onderligt, verder inzicht 
verschaffend. 
Een venster op verbeterde behandeling van hepatitis E in de toekomt wordt geopend 
in hoofdstuk 9. Hier bestudeer ik de importantie van de zogenaamde cellulaire proteïnet-
vertalendemachinerie voor de infectie metn HEV. Ik laat zien dat het afremmen van 
elementen uit deze processen een sterke antivirale werking heeft, met name het inhiberen 
van eIF4E remt virale replicatie in sterke mate. Omdat deze remming onafhankelijk is van 
interferon alfa en ribavirine, zou het eIF4E dus een belangrijk nieuw doelwit kunnen zijn voor 
nieuwe antivirale therapie. Onfortuinlijker wijze lijkt dit niet het geval voor de proteosoom 
inhibitor MG132. Anderen hadden reeds gerapporteerd dat deze remmer effectief was was 
voor het bestrijden van HEV infectie. In hoofdstuk 10 helaas, laat ik zien dat deze 
observaties waarschijnlijk niet specifiek zijn en dat proteosoominhibitoren geen toekomst 
hebben in de behandeling van hepatitis E. 
In het laatste hoofdstuk (hoofdstuk 11) van dit proefschrift tenslottega ik alle kennis 
die ik heb verzameld gedurende mijn promotieonderzoek duiden en integreren en inkaderen 
in de reeds beschikbare biomedische literatuur. Ik doe daar uitspraken over de 
mechanismen die worden aangezwengeld door het lichaam om het virus bestrijden. Samen 
hoop ik dat mijn studies een nieuwe bijdrage hebben in de strijd der mensheid tegen 
hepatitis E. 
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